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‘Basal Cell Carcinoma’ provides an insight into the recent developments and on going 
research into molecular biology and pathogenesis of basal cell carcinomas. This book 
also includes a chapter on metastatic basal cell carcinoma, an underreported clinical 
entity and sheds light on a custom made mold brachytherapy technique for certain 
basal cell carcinoma subtypes. A detailed account of the genomics of basal cell 
carcinoma compliments other chapters focusing on the pathogenic mechanisms. It is 
hoped that this book will offer the readers a greater understanding of the role of 
cytokines and chemokines and unfold the molecular pathways leading to 
development of basal cell carcinomas. Understanding of such mechanisms is central to 
development of targeted therapy which is of much interest to the clinicians and it is 
hoped that this book will help to facilitate further research into this field.  
 
Dr Vishal Madan MD, MRCP 
Consultant Dermatologist, Laser and Dermatological Surgeon 








Custom Made Mold Brachytherapy 
Bahadir Ersu 
Hacettepe University Department of Prosthodontics, Ankara 
Turkey 
1. Introduction 
Radiotherapy (RT) can be effective for primary BCC, recurrent BCC or as adjuvant for 
incompletely excised BCC in patients where further surgery is neither possible nor 
appropriate. Radiotherapy is a mixture of superficial, electron beam, and brachytherapy for 
curved surfaces. Treatment in fractions over several visits may produce better cosmetic 
outcomes than a single fraction treatment.1 Radiotherapy is contraindicated in radiotherapy 
recurrent BCC, genetic syndromes predisposing to skin cancer and connective tissue 
disease. Significant side effects are radionecrosis, atrophy, and telangiectasia. Skin cancers 
can arise from radiotherapy field scars and should be avoided in younger age groups. 
Brachytherapy has been widely used for the treatment of head and neck cancers. Mold 
therapy is excellent for the treatment of superficial carcinomas because it allows the 
planning of an adequate dose distribution before treatment and provides highly 
reproducible irradiation.2,3 However, therapists and members of the nursing staff can be 
exposed to radiation if remote afterloading units are not used. Although the combination of 
mold and remote afterloading units has been used in the head and neck region, including 
the oral cavity,4-6 its use as a method of radical radiotherapy has been extremely limited 
because of the low flexibility of the connection catheters. Recently developed units with 192-
Ir microsources have more flexible catheters and molds that are better suited to uneven 
regions such as the oral cavity. The first case of superficial carcinoma of the nasal vestibule 
that was successfully treated by a technique combining a mold and a remote afterloading 
unit with a 192-Ir microsource was reported in 1992.7 However, no well-controlled case of 
treatment of an oral carcinoma through use of this combined technique has yet been 
reported, although trials of interstitial use are now in progress.8-11 Details on construction of 
molds used in this type of therapy have been described in the literature.12 Because of the 
favorable reports concerning the combined technique, we planned to use it for primary oral 
carcinomas as a part of radical radiotherapy. 
Basal cell carcinoma (BCC) is an epithelial tumor of the skin.13 It arises from the basal cells of 
the surface epidermis and can exhibit various clinical manifestations. It predominantly 
occurs on exposed areas of the skin. Actinic radiation is considered a major etiologic factor. 
It appears to be directly proportional to the amount of exposure of the skin to sunlight and 
is inversely proportional to the degree of skin pigmentation. Chronic arsenic exposure and 
genetic factors may also play a role in the development of BCCs. BCCs are highly variable 
and several different clinical types are recognized.13,14 
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Various methods have been used for treatment of BCC. These techniques have included 
electrocoagulation followed by curettage, electrosurgery, chemosurgery, chemotherapy, and 
radiation therapy.13,14 Radiation therapy can be delivered either by external beam radiation 
or by brachytherapy. Brachytherapy is usually applied in the form of interstitial therapy, 
which involves the implantation of radioactive sources into the tissues or the application of 
radioactive molds to the skin surface.15 Mold brachytherapy is usually delivered in specially 
constructed carriers. Surface radiation carriers primarily indicated for the treatment of 
superficial lesions. They are helpful where external radiation can be used as a boost dose.13 
Such carriers can vary in design from the simple to complex, according to treatment needs.14 
The radiation carrier should be easy to fabricate and be readily usable by the radiation 
oncologist. Carriers that will be worn for extended periods must be carefully constructed to 
provide maximal patient comfort and to ensure at the same time correct dose delivery to the 
treatment area and reproducibility of the treatment at repeated sessions. An irreversible 
hydrocolloid is used for making impression. The carrier can be constructed from 
autopolymerizing acrylic resin rather than heat-curing acrylic resin. Cerrobend alloy is 
chosen for shielding purposes.16 
2. Mold production procedure 
It consisted of a mold of polymethyl methacrylate (PMMA) of 5 mm thickness, built over a 
plaster mold obtained as an individual impression of the region of the face to be treated. The 
construction of this PMMA mold was very similar to the construction of dental prostheses. 
First, an impression of the region of the patient to be treated was obtained with 
condensation silicones of putty texture (Optosil, Bayer), carefully adapted to the surface of 
the skin with gentle pressure. Over this impression a plaster model was obtained, with the 
same surface characteristics as the patient’s face. Over this plaster model, the contours of the 
tumor were carefully drawn, requiring generally the presence of the patient. Over this 
plaster model, successive thin layers of acrylic material with catalyzer were deposited, until 
a minimum thickness of 5 mm was obtained, taking care to avoid sharp surfaces. This first 
layer of PMMA had to act as a bolus material and as a first support for the brachytherapy 
catheters. On it, the appropriate number of plastic tubes, covering the area to be treated, 
were fixed with an instant contact glue. Usually 3 to 7 parallel and equidistant tubes were 
placed, following the contour of the zone to treat, parallel to the skin’s surface and avoiding 
sharp turns. The distance between the catheters ranged between 5 to 10 mm. The next step 
was to check that the radioactive source ran without interruption along the entire length of 
the catheters, by connecting the tubes to the microselectron and running the check cable. In 
case of curvatures of a diameter smaller than that required to pass the microselectron source 
through the tube, the plastic tube was replaced and glued in a new position, checking again 
the pass of the source through the catheters. Only when the source passed through all 
channels without any problem, was the custom mold completed by adding the necessary 
quantity of PMMA acrylic material and catalyzer to cover all the catheters and to give 
solidity to the mold. To harden the assembly, it was heated to 70°C for 5 minutes with a hair 
dryer, taking care to avoid deformations of the guide tubes. In the sides of the applicator 
were built some, usually two, buttonholes in which an elastic tape was fixed to maintain the 
mold in the correct position during the entire treatment time and facilitating the reposition 
of the assembly for daily treatment. Treatment parameters were calculated by the 3D 
treatment planning software (Plato, Nucletron Int. BV). Each source dwell position was 
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weighted individually to ensure the best isodose distribution. Geometrical optimization in 
volume and distance was done. Isodoses at skin surface and at 5-mm depth were plotted 
and the dose to 5 easily identifiable dose points calculated. The treatment parameters were 
chosen, with the best fit of isodoses to the target volume. Before treatment, a test run 
without the patient was done: the mold was attached to the plaster model with 5 
thermoluminescent dosimeters (TLD) placed in the dose points and guide tubes connected 
to the microselectron. The results of the TLD were read and compared with the calculated 
values. A verification autoradiograph of the applicator was obtained modifying the 
prescribed dose to 50 cGy to the film but maintaining the same weight to each dwell time. In 
the cases of tumors close to the eye, a lead sheet 5 mm thick was placed in the corresponding 
zone of the mold in order to reduce the dose to the eye. The procedure of construction, 
dosimetry, and verification of the custom-made mold required 3 working days, requiring 2 
visits of the patient before beginning the treatment, one to take the impression of the face and 
the second to draw the tumor and treatment volume on the plaster model. The custom-made 
applicators were used to treat tumors of more than 2 cm diameter, or those of smaller size but 
seated in a non-flat region or a difficult-to-fix area with the Brock’s applicators. In one patient 
it was necessary to built a second mold at the halfway point of the treatment, due to changes in 
the surface of the skin resulting from tumor regression.  
2.1 Tolerance of custom-made molds 
All patients tolerated treatment without difficulties. Patients helped the nurses to fit the 
custom-made mold in place. Treatment time took 3 to 8 minutes in each session. The 
custom-made molds were very ease to use, and the patients felt comfortable during 
treatment. There were no cases of interruption of treatment resulting from break of the 
applicator or constriction of the plastic tubes preventing the radioactive source from 
traveling properly to the treatment dwell positions. 
2.2 Conclusions 
Radiotherapy is a highly effective treatment of skin carcinomas of the face and head. The 
use of HDR brachytherapy with custom-made external molds permits one to obtain a 
uniform dose distribution with a sharp gradient in the edges of the applicator. The custom-
made molds are easily used and permit a highly accurate daily treatment reproduction. 
They enable one to obtain excellent local control with minimum treatment-related sequelae 
or late complications. Given the excellent results, HDR brachytherapy with external custom-
made molds is a reasonable alternative to other radiation therapy techniques for the 
treatment of skin carcinomas of the head and face. 
3. Clinical reports 
3.1 Case report 1: A hinged flange radiation carrier for the scalp 
The purpose of this cases was to describe fabrication of a hinged flange radiation carrier for 
a patient with BCC of the scalp. 
A 63-year-old man with the chief complaint of scalp lesions of 15 years duration was 
examined at the Hacettepe University hospital. These lesions were biopsied and diagnosed 
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as BCC (Fig. 1). Radiation treatment of 4 days duration (details could not be obtained) to the 
scalp performed 45 years ago was noted in the patient’s history. Total scalp excision was 
suggested as the treatment of choice. However, the patient refused the surgical intervention 
because of cosmetic problems and was accordingly referred to the department of radiation 
oncology. The treatment that was selected was a specially constructed mold suitable for 
remotely controlled after-loading brachytherapy. The patient was referred to the 
department of prosthodontics for fabrication of the radiation carrier 
3.1.1 Procedure 
The catheter radiation carrier was fabricated to ensure the fixation of the after-loading 
catheters in the required orientation to make the treatment reproducible. For fractionated 
treatment, it was decided to fabricate a catheter carrier mold. The patient’s head was 
shaved, and the border of the shaved area was outlined on the skin with indelible pencil. 
The patient’s head was lubricated with petroleum jelly (Aafes). The moulage impression of 
his head was made with irreversible hydrocolloid impression material (Blueprint Cremix, 
Dentsply, DeTrey, England) supported with gypsum (Kristal Alçi Sanayi Ltd., Ankara, 
Turkey). The surface was outlined with a pencil and boxed with wax. The impression was 
then poured in dental stone. One layer of baseplate wax (1 mm in thickness) was adapted 
over the cast. The catheters were placed parallel to each other at spaces of 10 mm (Fig. 2). 
The spacing was determined by the radiation oncologist and the radiation physicist in 
accordance with dosimetry for the target volumes to avoid creating cold or hot spot areas in 
the treatment region. Autopolymerizing methyl methacrylate (Meliodent, Bayer Dental, 
Bayer UK Limited Bayer House, Newbury, U.K.) was prepared, poured, and spread over the 
surface. The device was designed to be two pieces from frontal to cervical border. An acrylic 
resin hinge was fabricated and embedded into the two pieces (Fig. 3, A and B). This 
approach was necessary because undercuts over the head prevented placement of the 
carrier as a single unit. After polymerization and trimming, the device was tried on the 
patient’s head and adjusted (Fig. 4). Remote control after-loading technique was used to 
provide radiation and to distribute the active sources in the mold. High dose rate (HDR) 
microselection equipment with Ir-192 source and 1.77 ´ 1011 Bq activity was used. A total 
dose of 4050 cGy at 0.5 cm skin depth was given over a period of 3 weeks. 
3.1.2 Discussion 
Radiation prostheses have assisted the delivery of radiotherapy for carcinomas. These 
prostheses are used to protect or displace vital structures from the radiation field, locate 
diseased tissues in a repeatable position during radiation treatment, position the radiation 
beam, carry radioactive material or dosimetric devices to the tumor site, recontour tissues to 
simplify the therapy, or shield tissues from radiation. Radiotherapy has been used in the 
management of the head and neck region for many years. It has been shown to be effective 
in the treatment of superficial lesions. 15,16 Superficial lesions usually have a higher cure rate 
with radiation than do deeply infiltrating lesions. Radiation treatment of BCC is reported to 
be 96.4% with radiation therapy.17 Small BCCs that occur in essential cosmetic area can be 
successfully treated with a short treatment course14 (Fig. 5). Surgery is indicated, especially 
when the lesions have arisen in damaged skin or have invaded cartilage.18 Modern 
brachytherapy is delivered by remote controlled after-loading systems where the 
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radioactive sources are delivered to the prepositioned treatment catheters HDR remote 
control after-loading brachytherapy is used in the treatment of patients with curative 
intent.19 There are several advantages in using HDR remotely controlled after-loading 
systems. Radiation exposure of treating and nursing staff is virtually eliminated. Patient 
immobilization time is short; therefore complications that result from prolonged bed rest, 
such as pulmonary emboli and patient discomfort, is decreased. Treatment planning and 
dosimetry are more exact. Radioactive sources can be accurately positioned to a specific 
region. The sources have been arranged for loading according to the results of calculations 
by the radiation physicist to determine dose distribution. This ensures delivery of the 
calculated degree of radiation. If a change in dosage is required, it can be adjusted 
accordingly. Treatment can be performed on an outpatient basis, reducing healthcare cost. 
The use of external carrier fixation devices allows more constant and reproducible geometry 
for source positioning. Surface radiation carriers are being used more frequently with high 
dose remote after-loading devices.19 
3.1.3 Conclusions 
A hinged flange cranial radiation carrier was fabricated for a patient with basal cell 
carcinoma of the scalp. This method allowed for accurate and repeatable positioning of the 
carrier to facilitate radiation therapy. The use of the after-loading principles of 
brachytherapy allowed for the delivery of an accurate dose of radiation while minimizing 
radiation exposure to the radiation oncologist and nursing staff. The patient is in complete 
remission 15 months after treatment. 
 
Fig. 1. View of patient with lesions on scalp. 
 





Fig. 2. Catheters were embedded within wax plates and placed parallel to each other at 






Fig. 3. A, Outer view of carrier on cast. B, Inner view of carrier. 
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Fig. 4. Radiation carrier is placed and fixed on patient’s head. 
 
 
Fig. 5. View of patient’s scalp 15 months after radiation treatment. 
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3.2 Case report 2: Periauricular mold brachytherapy 
A 42-year-old male was referred to the Otorhinolaryngology Department of Hacettepe 
University with the clinical diagnosis of recurrent BCCA of the right pinna (Fig. 6). The 
patient was treated in 1992 for a lesion in the periauricular area that was totally excised and 
pathologically diagnosed as BCCA. In 1995, a recurrent BCCA lesion infiltrating into the 
parotid gland was excised; and in October 1995, a retroauricular recurrent BCCA was 
excised and the patient treated with electron beam radiotherapy at the dose of 5000 Gy 
using fraction size of 250 Gy in 1996. In October 1996, a recurrent BCCA in the fronto-
parietal area was excised; and in 2000, a recurrent BCCA in the remaining right auricle 
infiltrating to the mastoid process was excised. A recurrent tumor was then diagnosed in the 
mastoid cavity in September 2001 and a final attempt at excision of the tumor was made 
with known microscopic residual disease. It was then decided to treat the patient with 
brachytherapy. The patient was informed about possible severe side effects of the treatment, 
and the patient was referred to the Department of Prosthodontics for fabrication of a 
radiation carrier. The patient was reclined in dental chair; the head positioned allowing the 
patient to rest in a relaxed position with easy application of impression material to the lesion 
area. The neighboring area with hair was isolated with petroleum jelly, and the orifice of the 
outer auricular canal was filled with moist gauze. The external border of the area that was 
intended to be included in impression was outlined with utility wax (Moldwax; Sankay 
Ltd., Izmir, Turkey). An irreversible hydrocolloid impression material (Kromopan; Lascod 
Sp.H., Firenze, Italy) was mixed and poured over the target area and slightly pushed and 
directed to the desired areas with a brush. Then, a simple wrought wire metal mesh was 
applied over the impression material for eliminating possible distortions that may occur 
during the removal of the impression and subsequent setting of the cast. The impression 
was poured with a Type III dental stone (Amberok, Ankara, Turkey). A 0.5-mm thick layer 
of pink modeling wax plate (Multiwax; B.D.P Industry, Ankara, Turkey) was heated slightly 
and adapted onto the model to act as a spacer preventing the direct contact of catheters to 
the tissues, extending through the borders of the target area (Fig. 7). To avoid developing 
hot or cold spots, the spaces between the plastic carrier tubes (Nucletron; Veenendaal, 
Netherlands) and the space between tubes and tissues were standardized by the use of wax 
sheets of uniform thickness. The catheters were placed parallel to each other with 8 mm 
distance. As the surface of the target tissue was not perfectly smooth, the adaptation of 
catheters to the superficial contours of these areas was impossible; two catheters were 
superimposed in these areas where needed (Fig. 8). The mold was prepared with clear 
autopolymerizing acrylic resin (Akribel; Atlas- Enta, Izmir, Turkey) overextending 2 mm 
from the treatment area. The wax spacer was removed, and this area was filled with a soft-
lining material (Visco-Gel; Dentsply De Trey, Konstanz, Germany) to provide an excellent 
adaptation of the radiation mold to the target area (Figs. 9 and 10). A remote-controlled 
high-dose-rate (HDR) after-loading unit (microselectron; Nucletron) was used for the 
treatment. Q4The CTV defined as 5-mm tissue starting from the surface Q5 of the mold and 
therefore encompassing microscopically residual tumor volume. Dose calculations were 
performed using Plato brachytherapy treatment planning system (Nucletron). The dose was 
specified at the reference dose-rate curve encompassing the CTV. A total radiation dose 
prescribed to the reference isodose was 2500 cGy in 10 fractions in an overall treatment time 
of 5 days. The patient did well during and after the treatment. The patient was lost to 
followup, after followed in complete remission for 2 years. 
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3.2.1 Discussion 
Radiotherapy has been used in the adjunctive management of the head and neck region for 
many years. It has been shown to be effective in the treatment of superficial lesions 20,21. 
Superficial lesions usually have a higher cure rate with radiation than do deeply infiltrating 
lesions 20. Successful radiation treatment of BCCA is reported to be 96.4% with radiation 
therapy 28. Small BCCAs that ocur in critical cosmetic areas may be successfully treated with 
a short treatment course 21. Radiation delivery devices are important for delivery of 
radiotherapy and are used to protect or displace vital structures from the radiation field, 
locate diseased tissues in a repeatable position during succeeding radiation treatment 
sequences, position the radiation beam, carry radioactive material or dosimetric devices to 
the tumor site, recontour tissues to simplify the therapy, or shield tissues from radiation 20,21. 
However, the technique of implanting radioactive materials into target tissues may have 
potential disadvantages. The major concern is the potential for nonuniformity of the dose 
delivered throughout the implanted volume. This can occur if the radioactive sources are 
spaced too closely together (thereby producing a hot spot) or too far apart (leading to a cold 
spot). Therefore, brachytherapy (and particularly interstitial implantation therapy) requires 
the radiotherapist to have adequate technical and conceptual skills to achieve good radiation 
dose distribution 29. Some clinicians have stated that most patients who have had radiation 
treatment for malignancies will, in time, develop new cancers in the irradiated area. 
Experienced radiotherapists who carefully followed their patients for many years find this 
to be an extremely rare possibility and irradiation should never be withheld from the patient 
for this reason. The best local control results for patients with previously irradiated 
recurrent head and neck cancers were reported to be with brachytherapy 30. The reason for 
better local control was argued in the literature and reported that tumors with good 
prognostic factors (smaller tumors and oral cavity locations) were suitable for treatment 
with brachytherapy. Moreover, higher radiation dose could be delivered by brachytherapy 
30. Our patient was previously received high-dose external beam radiation, tumor and we 
decided to deliver reirradiation with brachytherapy. Q7 We delivered 25 Gy in 5 days, 
divided in 10 fractions. Most authors used similar fractionation; however, most used higher 
doses. Narayana et al. 31 also delivered HDR brachytherapy, a total dose of 34 Gy in 10 
fraction, twice daily, and reported 2-year local control rate of 71% for recurrent squamous 
cell carcinoma of the head and neck. Martinez-Monge et al. 32 also delivered HDR 
brachytherapy for previously irradiated recurrent head and neck carcinomas, the authors 
used 40 Gy in 10 fractions and achieved 4-year local control rate of 85.6%. We have only one 
case and unfortunately we could not report long-term followup. Because of basal carcinoma 
histopathology and prior external beam radiotherapy, we think that 25 Gy would be enough 
to achieve local control. There are many advantages of using HDR remotely controlled after-
loading radiation delivery systems that cannot be overlooked. This method takes advantage 
of the rapid decrease in dose with distance from a radiation source (inverse square law). The 
intensity of radiation is inversely proportional to the square of the distance from the source. 
Thus, a high radiation dose can be given to the tumor while sparing the surrounding normal 
tissues. Patient immobilization time is short; therefore, complications that result from 
prolonged bed rest, such as pulmonary emboli and patient discomfort, are decreased. 
Treatment planning and dosimetry are more exact. Radioactive sources can be accurately 
positioned to a specific region. The sources have been arranged for loading according to the 
results of calculations by the radiation physicist to determine dose distribution. This ensures 
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accurate delivery of the calculated magnitude of radiation. If a change in dosage is required, 
it can be adjusted accordingly. The use of external carrier fixation devices allows more 
constant and reproducible geometry for source positioning. Surface radiation carriers are 
being used more frequently with highdose remote after-loading devices 23. 
3.2.2 Conclusion 
This method allowed accurate and repeatable positioning of the radiation carrier to facilitate 
therapy. Carriers that will be worn for extended periods must be carefully constructed to 
provide maximal patient comfort and to ensure, at the same time, correct dose delivery to the 
treatment area and reproducibility of the treatment at repeated sessions. Mold brachytherapy 
is an option for reirradiation of recurrent head and neck tumors in selected group of patients. 
 
Fig. 6. Patient with recurrent basal cell carcinomas of right periauricular area. 
 
Fig. 7. Wax spacer and placement of catheters. 
 













Fig. 9. Wax spacer removed and replaced with soft-lining material. 
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Fig. 10. Adaptation of brachytherapy appliance to target tissues. 
3.3 Case report 3: High dose rate mold brachytherapy of early gingival carcinoma 
The purpose of this clinical report is to present the use of mold brachytherapy in the 
management in gingival cancer.  
Gingival carcinomas are rare, constituting less than 2% of all head and neck tumors.33 
Surgery with intraoral resection of the tumor or wide excision with the underlying bony 
structures is the most preferred treatment approach.33 Radiation therapy is used as an 
adjunct to surgery and is the primary treatment modality in inoperable patients.33,34 
Radiotherapy can be applied either through external beam or by brachytherapy. However, 
mold brachytherapy is rarely used in the management of the head and neck tumors, it is a 
promising method with encouraging results.35 It has the advantages of low acute radiation 
morbidity and shortened treatment period compared with the external beam technique.  
3.3.1 Patient 1 
A 70-year-old edentulous woman was seen by her dentist with the complaint of ill-fitting 
dentures, which had been experienced for 2 months. A tumoral lesion that measured 25 × 15 
mm was detected in the left maxillary gingiva. A biopsy was performed on the lesion (Fig. 
11); histopathologic examination of the specimen was consistent with well-differentiated 
squamous cell carcinoma. She denied use of alcohol or tobacco, and it was learned that she 
had been wearing dentures for more than 30 years. The computerized tomography (CT) of 
the primary tumor and neck region showed no abnormality. The patient was staged as 
T2NOMO cancer of the maxillary gingiva and referred for primary radiation therapy. High 
dose rate (HDR) mold brachytherapy was applied, considering the size, site, stage and 
differentiation of the tumor, and age of the patient (Fig. 12). 
Brachytherapy was well tolerated without any acute side effects. Grade IV mucositis was 
observed immediately after the treatment and healed completely in 1 month. Complete 
regression of the tumor was observed 1 month after the treatment (Fig. 13). The patient is 
alive and disease-free 36 months after the treatment. 
 
Custom Made Mold Brachytherapy 13 
 
 
Fig. 11. Tumoral lesion at left side of maxillary gingiva before brachytherapy. 
 
 




Fig. 13. Lesion from Figure 2, 1 month after brachytherapy, shows complete response. 
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3.3.2 Patient 2 
A 84-year-old edentulous woman with a 6-week history of an ill-fitting denture was 
admitted to the hospital at Hacettepe University. Physical examination revealed a tumoral 
mass that measured 30 × 15 mm on the maxillary left gingiva and leukoplakia on the 
neighboring mucosa. A biopsy specimen of the lesion disclosed moderately differentiated 
squamous cell carcinoma. There was no pathologic lymph node on physical examination 
and CT scan. The patient had a history of using dentures for the last 26 years and no history 
of alcohol or tobacco consumption. The patient was staged as T2NOMO carcinoma of the 
maxillary gingiva and referred to radiation therapy. Brachytherapy by customized dental 
mold was planned. No acute side effects were observed. However, grade III mucositis 
developed after the completion of treatment. Although complete resolution of tumor was 
achieved, the patient experienced dyspnea due to pleural effusion at the sixth month of 
follow-up. Her condition gradually deteriorated and she died of intercurrent disease with 
pleural metastases 6 months after the brachytherapy. 
3.3.3 Procedures 
3.3.3.1 Dental mold 
Irreversible hydrocolloid impressions of the maxillae were made for both patients and 
custom trays were fabricated onto the obtained cast. Final impressions were made with a 
medium viscosity additional cure silicone material (Coltene/Whaledent Inc, Mahwah, N.J.) 
and were poured in type III dental stone (Amberok, Ankara, Turkey). After trimming the 
post-dam area, 2 layers of modeling wax were heated and adapted onto the cast to obtain a 
uniform thickness denture base. The cast was then flasked, the elimination of wax was 
accomplished with hot water, and heat-cured acrylic resin (Meliodent Bayer, Newbury, 
Berkshire, U. K.) was used to process the stent. After deflasking and trimming away excess 
material, the tubes that would transport the radioactive source to the target site were placed 
into the resin base preserving approximately 10 mm distance between each other. Two 
plastic tubes of 6F diameter for the first patient (Fig. 14) and 4 tubes of the same types were 
used for the second patient (Fig. 15). Grooves were formed on the base to allow the tubes to 
closely contact the mucosa at the target site. The tubes were ending at the border of the 
target site and secured with clear autocuring acrylic resin. 
 
Fig. 14. Impression of maxillary gingiva and tumor using irreversible hydrocolloid paste 
(right) and acrylic resin dental mold with 2 6F plastic catheters incorporated within it, 
parallel to gingiva (left). 
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Fig. 15. Impression of maxillary gingiva and tumor of second patient (right) and acrylic resin 
dental mold with 4 6F plastic catheters incorporated (left). 
3.3.3.2 Brachytherapy 
Position of the dummy sources within the tubes were verified by simulation. Dosimetric 
calculations were performed by using the Plato Nucletron planning system (module BPS, 
Nucletron B.V., Veenendaal, The Netherlands). Irradiation was delivered by an Ir-192 HDR 
micro Selectron Afterloading unit. A total of 40 Gy was administered in 4 Gy fractions twice 
daily in 10 fractions and overall treatment time of 5 days for both patients. Special intraoral 
shielding lead blocks were used to shield buccal mucosa and tongue. Biologically equivalent 
doses for both patients were calculated to be 56 Gy10 for the tumor and 120 Gy2 for the late 
reacting tissues. Reference dose rate was 264.6 cGy/min and total air kerma was 0.06 cGy at 
1 m for the first patient and 162.7 cGy/min and 0.12 cGy at 1 m for the second patient. The 
active length of both sources were 2.5 cm and the dimensions of the specified reference dose 
volume was 3.5 × 2.5 × 1.5 cm for the first patient. Active length of the sources were 4.25 cm 
for 1 source and 4.75 cm for the remaining 2 sources of the second patient. The specified 
reference dose volume was 4 × 4.5 × 3.5 cm for the second patient.  
3.3.4 Discussion 
Gingival carcinomas are rare tumors and optimal treatment modality is not settled yet. Early 
lesions are mostly treated with surgery, the role of definitive radiotherapy in these cases is 
unclear. External beam radiotherapy is generally used postoperatively or rarely as a primary 
treatment in advanced lesions.33,34 Mold brachytherapy experience in oral cavity carcinomas 
is mostly with low dose rate brachytherapy.35-37 There are few reports in the literature on the 
use of HDR mold brachytherapy combined with or without external beam therapy and the 
optimal time; dose and fractionation for HDR brachytherapy has not yet been determined.38-
40 In 1 of these reports, an early carcinoma of the nasal vestibule was treated with HDR mold 
brachytherapy and treatment parameters of this patient were similar to our patients.7 After 
an extensive literature review, only 1 report was found on the use of dental molds with 
HDR remote brachytherapy.41 Eliminating the morbidity of surgery, preserving the function 
of major salivary glands, being an outpatient treatment procedure, and allowing simple 
repeated noninvasive treatments are the advantages of HDR mold brachytherapy. 
Inadequate previous experience is the major disadvantage of this technique. Although the 
follow-up period is relatively short, these patients seemed to indicate that HDR mold 
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brachytherapy alone may be used in the management of small volume cancers of the 
gingiva with satisfactory local control. It was presumed that brachytherapy may be used as 
a boost method after external beam radiation for larger lesions. Because there is not enough 
experience and data in oral cavity cancers of HDR brachytherapy, more patients should be 
treated to determine the optimal dose and fractionation. 
3.3.5 Summary 
Two elderly edentulous patients with the diagnosis of early stage cancer of the upper 
gingiva were treated by customized dental mold brachytherapy. Locoregional tumor control 
was achieved in both patients. One patient is alive without any evidence of disease 36 
months after treatment, the other patient died of distant metastasis shortly after 
brachytherapy. Brachytherapy, being easy to apply with short treatment time and good 
acute tolerance, is a good choice and effective modality for the management of early stage 
gingival cancer, particularly in elderly patients. 
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1. Introduction 
Basal cell carcinoma is the most frequently occurring skin tumor. Most cases are not life 
threatening. Only a very small proportion of BCCs metastasize. A high tendency to 
recurrence makes characterizing BCCs and tumor margin areas obligatory. It will assist in 
better understanding their pathogenesis and in more effective treatment through prevention 
of recurrence and second primary disease. In addition to histopathological assessment, the 
spread of the primary tumor according to TNM classification is crucial for estimating the 
further development of the disease. 
1.1 Molecular alterations involved in the emergence and development of basal cell 
carcinomas (BCC) 
While it has not been fully clarified which primary cell gives rise to basal cell carcinomas it 
is supposed that BCCs arise from interfollicular basal cells, keratinous cells of hair follicles 
or sebaceous glands (1 to 6). Chemically induced BCCs were produced in the pilosebaceous 
structures of rats (3, 7). Solar ultraviolet radiation (UVR), in particular ultraviolet B (UVB, 
waveband 280-315 nm), is a major and significant factor (8 to 23) in many of the carcinogenic 
steps leading to basal cell carcinomas. Additional risk factors are predisposing syndromes 
and genetic predisposition (3, 11 to 14, 16, 19, 24 to 41), such as skin-type (13, 42, 43), viral 
infections, above all human papilloma viruses (HPV) and / or immunosuppression (3, 13, 
17, 20, 35, 39, 41, 44 to 46). The influence of UVB is evident from the fact that BCC incidence 
is lowest in Finland (47, 48) and highest in Australia (13, 47 to 51). Incidence increases with 
advancing age through the accumulation of UV-radiation (52, 53). UVB exposure and 
chronic oxidative stress (54) effect direct DNA damage, mutations and chromosome 
aberrations in the skin (41, 55 to 57), all of which are found in basal cell carcinomas. They are 
comparable with squamous cell carcinomas (58) insofar as field cancerization can be shown 
in the environment of the BCC (59 to 63). The BCC can be characterized by certain markers 
such as proof of p53. Figure 1 illustrates UVB damage with regard to the mutation and 
inactivation of tumor suppressor gene p53 as well as activation of telomerase during 
cancerization, particularly in basal cell carcinomas (64).  
The inactivation of tumor suppressor activity is a universal step in the development of 
human cancers (65, 66). With  inactivation p53 looses its function as the “guardian of the 
genome” (66) thanks to which it normally controls, among other things, the normal cell 
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cycle, arresting irregularly growing cells via G1 / G2 transition of the cell cycle and 
compelling them to programmed suicide, apoptosis (67 to 76). bcl-2 can block and control 
p53-dependent apoptosis and loss of bcl-2 stimulates apoptosis (67 to 71, 73, 77, 78). While 
wild-type p53 suppresses cell growth, p53 mutations reduce DNA repair, for example after 
UVB radiation, and stop apoptosis. That can explain the increased incidence of skin tumors 
such as basal cell carcinoma through UVB radiation (13, 79 to 82).  
 
Fig. 1. Carcinogenesis of basal cell carcinomas. Concept for the course of molecular changes 
in the cancerogenesis of basal cell carcinomas: adapted and reprinted by permission of the 
American Association for Cancer Research: Ueda et al. (64) (Tel+ = telomerase activation). 
1.2 Molecular markers for differentiation of BCC and SCC of the skin 
Basal cell carcinomas and squamous cell carcinomas of the skin are differentiated by means 
of histopathological staining, mostly with hemalaun-eosin staining. This can lead to 
difficulty, as seen for instance in cytology. Vega-Memije et al. (83) introduced Papanicolaou 
staining to successfully distinguish between the two carcinoma types, and this was also 
used by Christensen et al. (84) along with May-Grünwald-Giemsa staining for the 
cytological differentiation of BCCs and actinic keratosis. Tellechea et al. (85) used 
immunohistochemical anti-Ber-EP4 monoclonal antibody. The total of 22 BCCs showed 
positive reactions, while in 21 SCCs the reaction was negative, proving this monoclonal 
antibody suitable for differentiating between the two nonmelanomatous skin-tumors. It was 
confirmed by Beer et al. (86) who verified expression of Ber-EP4 in all of 39 BCCs and in 
none of 23 SCCs tested. Swanson et al. (87) were able to distinguish BCCs both from SCCs of 
the skin and from trichoepitheliomas (TE) with proven expression of Ber-EP4 (also of bcl-2 
and CD34): The reaction of Ber-EP4 was positive in all of 44 BCCs, in 81% (29/36) of TEs and 
in none of 22 SCCs. According to the same procedure, Tope et al. (88) differentiated between 
BCC, actinic keratosis (AK) and SCCs: All of 5 superficial BCCs were Ber-EP4 positive, while 
all of 10 AKs and of 8 SCCs were negative. To differentiate between BCCs and SCCs the Ber-
EP4 marker is the most suited. Swanson et al. (87) differentiated with CD34 BCCs, SCCs and 
TEs: CD34 was positive in 16% (7/43) of BCCs, in 25% (5/20) of SCCs and in 8% (3/36) of 
TEs. Likewise, Yada et al. (89) and Aiad and Hanout (90) were able to discriminate BCC 
from SCC immunohistochemically with CD10. In the study by Yada et al. (89) BCCs 
expressed CD10 1+ to 2+ in 86% (44/51) and in all 9 SCCs CD10 was negative. According to 
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Aiad and Hanout (90) CD10 expression was significantly higher in BCCs than in SCCs: 
10/21 (48%) and 0/16 SCC (p=0.002). 
Guttinger et al. (91), Seelentag et al. (92), Dietrich et al. (93) and Seiter et al. (94) used 
immunohistochemical methods with monoclonal anti-CD44s and various anti-CD44 splice 
variant antibodies to differentiate BCCs and SCCs. Guttinger et al. (91) obtained distinct 
marking of tumor cells (++) in all SCCs with anti-CD44s, CD44v4, CD44v6 and CD44v9 
antibodies. The nodular BCCs showed no expression and the sklerodermiform BCCs (+) a 
weaker expression. This result was congruent with studies by Seelentag et al. (92). 
Seelentag et al. observed the expression of CD44s, CD44v3, CD44v4, CD44v6 and CD44v9 
in immunohistochemical paraffin sections. They (92) achieved higher or distinctly higher 
expression of CD44v3, CD44v5, CD44v6 and CD44v9 in SCCs of the skin (n=37) than in 
BCCs (n=10). In BCCs the expression was low (CD44s, CD44v3) or absent (CD44v4). 
Higher expression in BCCs was found with the splice variants CD44v5, CD44v6 and 
CD44v9. In squamous cell carcinomas Seelentag et al. (92) found CD44v3, CD44v5, 
CD44v6 and CD44v9 expression comparable with that in keratoacanthomas (n=12). CD44s 
and CD44v4 expression was lower in SCCs than in keratoacanthomas. This contradicted 
the findings by Dietrich et al., (93) who demonstrated CD44v4, CD44v5 and CD44v6 both 
in BCCs (n=7) and in SCCs (n=6). Indeed, using immunohistochemical methods Dietrich 
et al (93) demonstrated expression of CD44v7/8 and CD44v10 in all BCCs but in none of 
the SCCs tested. Forming groups according to the estimated percentage of staining cells, 
Seiter et al. (94) assessed expression of CD44s, CD44v5, CD44v6, CD44v7, CD44v7/8 and 
CD44v10 semiquantitatively. In the BCCs and SCCs they investigated, CD44s was 
expressed in the same degree, while all splice variants tested showed higher expression in 
SCCs. Simon et al. (95) checked the suitibility of immunohistochemistry for definite 
distinction between BCCs and SCCs with splice variants CD44v3, CD44v4, CD44v5, 
CD44v6, CD44v7/8 or  CD44v10. All splice variants stained the tumor center of BCCs, 
while in SCCs only tumor periphery was marked.  12/17 BCCs (71%) were positive with 
CD44v3 and 13/17 (77%) with CD44v5. The remaining CD44-splice variants marked all 
BCCs, and all of 16 SCCs were marked with all CD44-splice variants. In an 
immunohistochemical study by Son et al. (96), 49% of BCCs and only 35% of SCCs 
showed CD44v6 marking.  
Al-Sader et al. (97) sought to differentiate immunohistochemically the proliferative 
indices between BCCs and SCCs. The median scores of the mitotic index were 5 for BCCs 
and 4 for  SCCs (p=0.621), but the authors (97) observed that the median scores of Ki-67 
were significantly different, amounting to 271 (per 1000 cells) in BCCs and 340 (per 1000 
cells) in SCCs (p=0.029). To differentiate BCCs from skin-SCCs, Park et al. (98) used 
immunohistochemical proof of p53, p63 and survivin. With p53 the authors were unable 
to differentiate between the two, which were malignant in differing degrees: 90% 2+ to 3+ 
vs. 100% 2+ to 3+. Proof of p63 made this distinction possible: BCC 90% 2+ to 3+, SCC 
40% 2+, as did proof of survivin (BCC 40% 2+, SCC 80% 2+ to 3+). However, Bäckvall et 
al. (99) succeeded in demonstrating a significant difference between normal skin adjacent 
to BCC and that adjacent to SCC (p<0.05) with regard to the number of p53 clones. Chang 
et al. (100) found significantly less Ki-67 in 10 BCCs investigated (mean score value 12±7) 
than in 8 SCCs (mean score value 47±21), (p<0.05), and detected clearly different 
expression of p53 (mean score value BCC 50±17 vs. SCC 61±15). Son et al. (96) used 
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immunohistochemical findings of Ki-67 and p53 to differentiate BCCs (n=108) from SCCs 
(n=94). Ki-67 expression was low in 90% of BCCs and high in 10%, while Ki-67 showed 
high expression in 27% of SCCs and low expression in 73%. p53 was demonstrated in 15% 
of BCCs and in 46% of SCCs. Bolshakov et al. (101) succeeded in establishing clear 
differences between aggressive SCCs / nonaggressive SCCs and also aggressive BCCs / 
nonaggressive BCCs through mutation frequency of p53 with single-strand conformation 
polymorphism and sequencing: frequency of p53 mutations amounted to 35% (28/80) of 
aggressive SCCs vs. 50% (28/56) of nonaggressive SCCs as opposed to 66% (35/50) of 
aggressive BCCs vs. 38% (37/98) of nonaggressive BCCs. Chang et al. (100) also 
demonstrated a clear differentiation between BCC and SCC by immunohistochemical bcl-
2 detection: All of 10 BCCs displayed positive marking that was absent in all of 8 SCCs. In 
consonance with this, Delehedde et al. (80) found immunohistochemically distinct bcl-2 
expression (+++) in 17 BCCs examined, which was missing in all of 14 SCCs (p<0.05). 
Likewise, Swanson et al. (87) found positive bcl-2 reaction in 91% (41/45) of BCCs and in 
18% (4/22) of SCCs. Contrary to these results Al-Sader et al. (97) observed no difference 
between the median scores of the apoptotic index in BCCs (10.5 apoptotic cells / 1000 
cells) and in SCCs (10 apoptotic cells / 1000 cells). 
In our studies we introduced proof of telomerase activity to differentiate BCCs from SCCs 
(102 to 104), cf. 2.4.1: the proportion of BCCs with activation of telomerase amounted to 87% 
(26/30) and was barely higher than in SCCs of the skin with 75% (9/12). This result is in 
approximate conformity with synoptic references: activation of telomerase in 87% (177/203) 
of BCCs examined altogether and in 77% (58/75) of SCCs of the skin (103, 104). However, 
our studies demonstrated that the score values of immunohistochemical proof with APAAP 
(105) of the telomerase subunit hTERT cannot be used to differentiate between BCCs (n=24) 
and SCCs (n=7) of the skin (106, 107): BCC mean score value 9.4±4.9 (Ab 1: anti-hTERT 
antibody Calbiochem, USA, code 582005) and 9.0±4.0 (Ab 2: anti-hTERT antibody code 
NCL-hTERT Novocastra, UK, clone 44F12,) vs. SCC mean score value 9.9±2.4 (Ab 1) and  
9.1±3.8 (Ab 2), cf. 2.4.2. 
2. Molecular markers for basal cell carcinomas and tumor-free margin tissues 
Adequate resection of BCCs is of utmost importance in preventing recurrence (108 to 114). 
Other authors are therefore searching for markers which discriminate between basal cell 
carcinoma and histopathologically tumor-free margin. In addition to histopathological 
assessment, assessing the spread of the primary tumor (T1<2cm, T2 2cm) according to the 
TNM classification (115) is crucial for assessing further development of the disease. The risk 
of recurrence of each tumor is defined as closely as possible to enable choice and application 
of the most appropriate clinical procedure (51, 116, 117). Tumor size is important for 
prognosis of the disease, as is shown by comparison in Kaplan-Meier curves. With all due 
precaution given the many censored cases, we ascertain that patients with primary T2 
tumors relapse much earlier than those with T1 tumors (Log-rank p=0.003): after 14±2 
months (T2) vs. 65±16 months (T1), Figure 2. 
The classification in nonaggressive basal cell carcinomas and aggressive BCCs is 
predominantly determined by the clinical course of BCCs and by the tendency to recurrence: 
nonaggressive nodular, micronodular or superficial BCCs and aggressive infiltrative or 
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morphea BCCs (20, 81, 118 to 121). Additional markers will help to characterize and are 
essential for distinctly determining the spread of BCCs (19). 
 
Fig. 2. Up-to-date outcome in patients with BCCs and the spread of the tumor (T1 < 2cm, T2 
 2cm) in Kaplan-Meier curves. 
2.1 Different markers classifying nonaggressive and aggressive BCCs 
Staibano and colleagues classified between nonaggressive BCC1 without relapse and 
aggressive BCC2 with local recurrence during metaphylaxis. For this differentiation they 
introduced various markers. They detected high expression of p53 in 60% of 30 BCC2 
tumors and low expression in 10% of BCC1 tumors (122), or in 0/21 BCC1 tumors and in 
82% (18/22) of BCC2 tumors, respectively (123). Bolshakov et al. (101) were also able to 
discriminate clearly between aggressive BCCs and nonaggressive BCCs through 
determination of p53 mutations by single-strand conformation polymorphism and 
nucleotide sequencing: the frequency of p53 mutations was 66% (33/55) with aggressive 
BCCs and only 38% (37/98) with nonaggressive BCCs. In 11 aggressive BCCs Ansarin et al. 
(121) found significant immunohistochemical nuclear staining of p53 in more than 50% of 
tumor cells and in 33 nonaggressive BCCs in less than 50% of tumor cells (p<0.01).    
In BCC1 tumors the AgNOR scores were 6.56±1.98 and in BCC2-tumors 9.48±2.12: De 
Rosa et al. (119). When Staibano et al. (124) ascertained the apoptotic index, they found a 
marked difference: BCC1 5.98±2.52% vs. BCC2 39.82±8.32%. BCC1 tumors examined 
showed a distinct cytoplasmic staining of bcl-2. This marker was missing in all of the 30 
BCC2 tumors examined by Staibano et al. (122). In agreement with these investigations 
Ramdial et al. (81) detected a distinctly higher bcl-2 expression in  immunohistochemical 
assays in nonaggressive BCCs than in aggressive BCCs: 45/50 (90%) nonaggressive BCCs 
expressed bcl-2 2+ to 4+ and 22/25 (88%) aggressive BCCs maximally 2+. High expression 
of cyclin D1 was not found in any BCC1 tumors but in all of 30 BCC2 tumors (125). By 
determining DNA ploidy Staibano et al. (125) were also able to differentiate between 
BCC1 and BCC2: All BCC2 tumors were aneuploid as against 77% of BCC1 tumors. After 
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immunohistochemical staining for monoclonal antibody against factor VIII (von 
Willebrand factor), microscopic counts of microvessels revealed a statistically significant 
difference: mean score value BCC1 25.76±2.21 vs. BCC2 46.76±2.54 (126). 
Histopathological diagnostics using these markers can be supplementary evidence for the 
surgeon deciding on the surgical procedure for therapy. 
2.2 Examination of BCC spread by means of anti-CD44 antibodies and anti-splice 
variant antibodies, by anti-E48 and anti-U36 antibodies 
Cell adhesion molecules such as CD44 splice variants can be used as selective markers for 
different tumors and are important both for the diagnosis and prognosis of some tumors 
(127 to 129). Squamous cell carcinomas with poor differentiation display downregulation of 
CD44v6 expression in comparison with squamous cell carcinomas with high differentiation. 
Hyckel et al. (130) planimetered the immunohistochemical reaction of oral SCCs by anti-
CD44 monoclonal antibodies and confirmed an inverse relation to carcinoma grading. Our 
immunohistochemical findings in frozen sections with APAAP (105) in regard to squamous 
cell carcinomas of the head-and-neck region (131 to 133) are comparable with the 
downregulation of isoforms containing CD44v6 that  Salmi et al. (134) observed with 
CD44v3 and CD44v6 in SCCs in the head-and-neck area.  
Guttinger et al. (91), Baum et al. (135), Seelentag et al. (92), Seiter et al. (94), Simon et al. (95), 
Kooy et al. (136), Dingemans et al. (137, 138) and Son et al. (96) used immunohistochemical 
marking on BCCs with CD44v6 and found it better than hemalaun-eosin staining for 
identifying their local spread. In 20 BCCs, Seelentag et al. (92) found  low or no expression of 
CD44s or CD44v4, contrary to SCCs with low expression of CD44v3. The authors found 
high expression of CD44v5, CD44v6 and CD44v9 in BCCs, but the expression was lower 
than in SCCs. 
We had previously achieved better results discriminating squamous cell carcinomas of the 
head and neck from their surroundings with immunohistochemical APAAP (105) in small 
frozen sections by using adhesion molecules CD44v6 (also its chimera U36) and E48 (131 
to 133). This method was now confirmed in BCCs.  We accomplished APAAP (105, cf. 131, 
132) with a monoclonal antibody against the adhesion molecule CD44v6 (clone VRR-18, 
Bender, Austria) and with two monoclonal antibodies against adhesion molecules E48 
(Centocor B.V., Netherlands) and U36 (Centocor B.V., Netherlands). Antibody E48 has 
been developed to recognize normal squamous epithelium and squamous cell carcinomas 
(139). It is well suited for differentiating carcinomas from negative adenocarcinomas and 
small cell carcinomas (140). Monoclonal anti-U36 antibody is an anti-CD44v6-chimeric 
(mouse/human) antibody for marking normal human squamous epithelia and squamous 
cell carcinomas (141 to 143). The quantitative presentation of antigen expression (CD44v6, 
E48, U36) in frozen sections was evaluated in our study by means of an immunoreactive 
score (IRS) according to Remmele et al. (144) and Remmele and Stegner (145). Our 
evaluation was performed three times by an independent examiner. The membrane 
staining intensities (SI) were divided into 5 levels: negative, 1+ (weak expression) to 5+ 
(very strong expression). The percentage of positive stained cells (PP) was classified into 4 
groups according to percentage of stained cells: 0-<10%=score 1; 10-<50%=score 2; 50-
<75%=score 3; 75-100%=score 4. The IRS was calculated by multiplication of SI and PP. To 
identifying the spread of BCCs in small frozen sections we applied immunohistochemical 
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staining with APAAP (105) to membrane marking of CD44v6, E48 and U36. We found it 
better than hemalaun-eosin staining.  
In our study the immunoreactive scores (IRS) in BCC tumor center vs. tumor-free margin 
were demonstrated and are illustrated in Figure 3. Only the expression of CD44v6 was 
significantly higher in tumor center (mean score value 12.5±3.2) than in squamous 
epithelia in the tumor margin (mean score value 8.4±4.0, p=0.006), and was comparable to 
the expression of Ki-67 (p<0.001). Microscopic representation with the three monoclonal 
antibodies, particularly CD44v6, distinguished BCCs clearly from their surroundings: 
Figure 4. 
The ample expression of  CD44v6 and U36 (if necessary E48) adhesion molecules might 
make them useful both for the diagnostics and adjuvant therapy of BCCs. Radionuclide-
labeled purified monoclonal antibodies were successfully developed in VU University 
Medical Center (Amsterdam/Netherlands). They have proven themselves in this capacity 
for years in the diagnostics (146 to 152) and therapy (142, 147, 153 to 156) of squamous cell 







Fig. 3. Immunoreactive scores (IRS, cf. 144, 145) of expression of CD44v6, E48 and U36 in 
basal cell carcinomas (mean values). 
 











Fig. 4. Comparison of expression of CD44v6 (a), E48 (b) and U36 (c) in small frozen sections 
of BCCs, magnification 200x. 
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2.3 Markers p53 and Ki-67 in BCCs and BCC-free tumor margin tissue 
Molecular alterations can be found during carcinogenesis and tumor growth. As illustrated 
schematically in Figure 1 (cf. 1.1), the inactivation of tumor suppressor gene p53 is an 
important step towards carcinogenesis. During inactivation and mutation of p53 mutated 
p53 protein is formed. Mutated and wildtype p53 protein can be detected 
immunohistochemically by different or identical antibodies, for instance in tissues with field 
cancerization after intensive solar irradiation (60, 62) as well as in tumor-free margin 
surrounding of BCCs (98, 157 to 161). Authors are therefore searching for markers such as 
p53 which discriminate between basal cell carcinoma and histologically tumor-free margin 
surrounding the tumor.   
2.3.1 Marker p53 in BCCs and BCC-free tumor margin tissues 
Urano et al. (157) applied immunohistochemistry using anti-p53 antibody clone Do-7, which 
recognizes both wildtype p53 protein and mutated p53 protein. The authors found 
significantly lower p53 expression in tumor margin than in tumor center (p<0.05): 7/17 
tissues of tumor margin (41%) and 11/17 (65%) of tumor center were p53 positive. Barrett et 
al. (158) were able to detect p53 in 20/27 (74%)  BCCs. They also investigated adjacent 
actinic keratosis in the tumor margin of 4 tumors and found increased p53 staining. 
Demirkan et al. (159) detected significantly less p53 in BCC-free  tumor margin than in the 
tumor center: 26% (11/42) p53 positive tumor-free margins vs. 44% (8/18) tumor center 
tissues (p=0.034), the same was found with monoclonal antibody Do-7 (DAKO/Denmark). 
According to investigations by Rajabi et al. (160), p53 expression in 96/123 BCC tumor 
tissues (82%) was not significantly higher than in 84/117 tumor-free margin tissues (78%), 
p=0.38. The relatively high p53 expression of the tumor margin could be related to strong 
sun exposure of uncovered skin with patients in southern latitudes. Bäckvall et al. (99) and 
Koseoglu et al. (161) were also unable to find a significantly decreased expression of p53 in 
adjacent tissues surrounding the BCCs. Koseoglu et al. (161) detected p53 clones in 10/43 
tumor center tissues (23%) and in 9/21 tumor margin tissues (42%).  
In our study we employed an antibody from Oncogene (USA) to ascertain p53 scores in 
small frozen sections: a monoclonal antibody against mutated p53 Ab-3 (OP 29-1) (103, 106, 
107). Before performing the APAAP (105), slides with frozen sections were fixed in 
methanol and acetone and pretreated in a steamer (95 to 99°C). This was non-essential  for 
p53 and Ki-67 but for hTERT and retinoic acid receptors nuclear staining in frozen sections 
essential (106, 107, 162). We determined p53 scores as described in 2.2. In quantitative 
presentation of antigen expression (p53, Ki-67, hTERT and retinoid receptors) by means of 
an immunoreactive score (IRS) we refer exclusively to the nuclear and / or nucleolar 
staining. We evaluated staining intensity (SI) and number of positive stained cells (PP) in the 
BCCs and in squamous cell epithelia of the tumor margin. The IRS was calculated by 
multiplication of SI and PP. In our immunohistochemical investigations the difference 
between IRS of p53 in tumor center (mean score value 7.9±3.4) was not significantly higher 
than in tumor margin (mean score value 5.8±4.2), p=0.095:  Figure 5 and illustrated in Figure 
6a (tumor center) and Figure 6c (tumor margin), cf. 2.3.2. p53 scores in T2-BCCs (8 primary 
tumors 2cm) were not higher than in T1-BCCs (17 primary tumors <2cm): mean score 
value 6.3±4.3 (T2) vs. 7.9±3.3 (T1), p=0.328. We tested the role of p53 scores investigated for 
prognosis in Kaplan-Meier curves (cf. 2.3.2). We divided all p53 scores (also Ki-67 scores and 
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hTERT scores) into two groups (group 1: scores < mean value, group 2: scores  mean value) 
and used the patients’ up-to-date outcome as documented in our hospital. With all due 
reservation due to the many censored cases, we ascertain that BCCs of patients with higher 
p53 scores in tumor center tissues recurred later, almost significantly later, than BCCs of 
patients with lower scores in tumor center tissues (65±16 months vs. 23±6 months): Log-rank 
p=0.059, Figure 7a. However, patients with higher p53 scores in BCC tumor margin tissues 
did not relapse significantly but nevertheless earlier than patients with lower p53 scores in 
tumor margin tissues (36±6 months vs. 40±11 months): Log-rank p=0.622, Figure 7c. 
 
Fig. 5. IRS (immunoreactive scores, cf. 144,  145) mean values of expression of mutated p53 
and of Ki-67 in basal cell  carcinomas. 
2.3.2 Marker Ki-67 in BCCs and BCC-free tumor margin tissues in comparison with 
p53  
Some authors compared proof of p53 with expression of the proliferation marker Ki-67. 
Healy et al. (163) proved 71 BCC tissues immunohistochemically with p53 and Ki-67, 17 
BCCs group 1 (patients without recurrence), 17 BCCs group 2-0 (patients who relapsed 
some time later) and 17 BCC relapses (group 2-R). p53 was demonstrated in 95% of each 
group. However, the authors (163) revealed significantly lower values of Ki-67 expression in 
BCCs in group 1 (mean value 12%) than in group 2-0 (mean value 25%) or group 2-R (mean 
value 22.5%): p=0.009. Barrett et al. (158) examined expression of p53, Ki-67 and PCNA in 27 
basal cell carcinomas and compared them to histopathological BCC types. Expression of p53 
and PCNA was higher in aggressive BCCs than in nonaggressive BCCs, and PCNA was 
higher than Ki-67.  Chang et al. (100) tested 10 BCCs and detected both p53 and Ki-67 in all 
of them. The labeling index with Ki-67 was significantly lower than with p53: 12±7 vs. 50±17 
(p <0.05). By contrast, in 20 BCCs Abdelsayed et al. (164) demonstrated higher marking with 
Ki-67 (mean value 51.25±6.06) and PCNA (mean value 52.25±7.57) than with p53 (mean 
value 31.75±9.02). Koseoglu et al. (161) also investigated the p53 level of 50 BCCs 
immunohistochemically in comparison with Ki-67 expression (anti-Ki-67 antibody clone Ki-
88). They found significantly higher Ki-67 expression in p53 positive tissues (Ki-67 mean 
value 14.66) than in p53 negative tissues (Ki-67 mean value 8.37): p=0.019. 
 








Fig. 6. Comparison of expression of p53 (a, c) and Ki-67 (b, d) in small frozen sections of 
BCCs (a, b) and in tumor  margin tissues (c, d), magnification 400x. 
We also compared Ki-67 scores with p53 scores in tumor center tissues and tumor-free 
margin tissues. To prove Ki-67 in small frozen sections we used a monoclonal mouse anti-
human Ki-67 antibody (clone MIB-1) from DAKO (Denmark) (106, 107). As described under 
2.2 and 2.3.1, nuclear staining scores were achieved with immunohistochemical APAAP 
(105). The Ki-67 mean score value in tumor center (10.9±2.5) was significantly higher than 
that in tumor margin (7.4±1.8), p<0.05: Figure 5, cf. 2.3.1. Our results with p53 and Ki-67 
expression of tumor center and tumor margin tissues are displayed in Figure 6.  
We tested the prognostic prediction of Ki-67 status (107) detected in our patients’ tissues 
with BCCs in Kaplan-Meier curves. With all due reservation in view of the number of 
censored cases, patients with higher Ki-67 scores in tumor center tissues suffered BCC 
recurrence (not significantly) later (Log-rank p=0.560) than patients with lower Ki-67 scores 
(56±16 months, higher scores, vs. 27±7 months, lower scores): Figure 7b. In contrast, patients 
with higher Ki-67-scores in tumor margin tissues did not relapse significantly earlier (Log-
rank p=0.321) than patients with lower Ki-67-scores (35±5 months, higher scores, vs. 48±13 
months, lower scores): Figure 7d. 
 






Fig. 7. Kaplan-Meier curves for p53 expression (a, c) and Ki-67 expression (b, d) in BCC 
tumor center tissues (a, b) and in tumor margin tissues (c, d). 
2.4 The biology of telomerase 
In 1984 Blackburn and Greider discovered telomerase in a single-celled ciliate Tetrahymena 
(165, 166), a ribonucleoprotein enzyme. The enzyme is of universal importance for cell 
proliferation. Telomerase replaces the mitotic loss of telomeres at chromosome ends with 
telomeric substitutes. This abrogates the limited cell division potential (the Hayflick limit). 
Hayflick and Moorhead (167) observed limited cell division in fibroblast cultures. Activation 
of telomerase occurs during embryogenesis (168, 169). In normal somatic tissues with a 
limited replicative potential telomerase activity can be demonstrated only in traces or not at 
all (170 to 172). Activation of telomerase can be found inside cells with proliferative 
potential such as stem cells, in strongly regenerative cells, and in dermal cells of hair follicles 
(169, 171 to 175). Telomerase can be activated by UVB in seriously sun-exposed skin (10, 64). 
It may also be detected in benign proliferative lesions (174) or after activation in cells of 
inflammatory reactions (170, 172, 174, 176 to 178). Reactivation of telomerase also occurs in 
carcinogenesis (179, 180), as was illustrated by Ueda et al. (64) (Figure 1, 1.1). It is an 
essential step for cancer immortalization and cancer progression (172, 180).  
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However not until Kim et al. (168) developed the polymerase chain reaction based telomeric 
repeat amplification protocol in 1994 (TRAP assay) was it possible to detect telomerase in 
greater numbers in unfixed tissues. Since then, a great number of tissues, particularly from 
cancer, have been investigated for telomerase activity as the reviews by Shay and Bacchetti 
(181) and Dhaene et al. (182) demonstrate.  
2.4.1 Activation of  telomerase in tumor center and tumor margin tissues of BCCs 
The results of telomerase activity in BCCs and tumor-free adjacent tissues have been 
summarized. The portion of 203 specimens with evidence of telomerase detected with the 
TRAP assay (168) amounted to an average of 87%, varying between 20 and 100% (64, 103, 
104, 183 to 189). Table 1 sums up telomerase activity of BCCs and tumor-free adjacent 
tissues. To discriminate between BCC center tissue and tumor-free margin tissue Taylor et 
al. (183) and Ueda et al. (64) introduced proof of telomerase activity. They found clearly less 
telomerase activity in tumor margin tissue than in the tumor center: BCC margin tissues 
with 67% and 39% vs. 95% and 85% of BCC center tissues. 
 
 
Table 1. The frequency of telomerase activity (detected with the TRAP assay) in basal cell 
carcinomas and their tumor-free margin tissues. 
Like Taylor et al. (183) and Ueda et al. (64), we found significantly higher telomerase activity 
in 26/30 (87%) of BCC tumor center tissues (mean value 661±388 mOD) than in 9/25 (36%) 
histopathologically tumor-free tumor margin tissues (mean value 187±233 mOD) (103, 104). 
As we proved telomerase activity semiquantitatively with a PCR-ELISA (Telo TAGGG 
Telomerase PCR and PCR-ELISA plus, Roche Diagnostics, Germany) we were able to be 
somewhat more precise:  the mean value of telomerase activation in BCC tumor tissues was 
significantly higher than in tumor margin tissues: p<0.001. In contrast, telomerase activation 
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in T2 tumors (mean value 564±225 mOD) did not differ significantly from telomerase 
activation in T1 tumors (mean value 709±446 mOD): p=0.783. In Figure 8, our study on 
telomerase activation in tumor center and tumor margin has been compiled according to 
extinction values. 
We tested whether the telomerase examined in BCCs or tumor margin tissues has 
prognostic relevance (103, 104). We divided all measured values of telomerase (PCR-ELISA) 
and divided the patients into two groups, group 1: < mean value and group 2:  mean value, 
and used the patients’ up-to-date outcome as documented in our hospital. In Kaplan-Meier 
curves of tumors and tumor margin tissues, patients with higher telomerase activity 
suffered recurrence earlier than patients with lower telomerase activity but not significantly: 
tumor center: 36±9 vs. 97±0 months (Log-rank: p=0.100), tumor margin: 19±1 vs. 42±6 
months (Log-rank: p=0.141): Figure 9. 
 
    
 
Fig. 9. Comparison of Kaplan-Meier curve for telomerase activity in BCCs (a) and tumor-free 
margin tissues (b). 
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Detection of telomerase activity in unfixed BCC tissues and tumor margin tissues can 
corroborate, with due reservation in view of the censored cases, histopathological and 
clinical assessment of risk of recurrence. 
2.4.2 Expression of hTERT in tumor center and tumor margin tissues of BCCs  
hTERT (human telomerase reverse transcriptase) is a catalytic subunit and a component of 
telomerase (171, 190, 191). Proof of hTERT protein can be carried out both in unfixed and in 
fixed tissue and facilitates the localization of telomerase activity. The detectable evidence of 
the hTERT protein or hTERT mRNA might, however, not always mirror detectable 
telomerase activity (171).  
Saleh et al. (189) used proof of hTERT to differentiate between BCCs of differing size and 
histopathological type. They determined hTERT in all of 12 BCCs, with no significant 
difference between mRNA hTERT by RTq-PCR in BCCs of different size: mean value BCCs 
<9 mm 0.458 vs. mean value BCCs 9 mm 0.478. In tumor-free margin tissues of larger BCCs 
the authors (189) found a somewhat lower, non-significant expression of hTERT mRNA 
(BCC <9 mm mean value 0.160, BCC 9 mm 0.119).  hTERT expression of superficial BCCs 
(n=5), however, was significantly lower (p<0.05) than that of nodular BCCs (n=7): tumor 
center mean value 0.305 vs. 0.525 and tumor-free margin 0.094 vs. 0.172. With senior patients 
(65 years of age, n=6) Saleh et al. (189) succeeded in determining non-significant hTERT 
expression in tumors and tumor-free margin tissues that was lower than that in younger 
patients (<65 years of age, n=6): tumor center mean value 0.343 vs. 0.593 and tumor margin 
0.104 vs. 0.175. Proof of hTERT was also established by Hu et al. (192) and Park et al. (98) for 
evaluating BCCs. Hu et al. (192) examined 62 fresh skin tissues in RT-PCR.  They compared 
hTERT with TPI (another protein component of telomerase) and with hTR, an RNA 
component of telomerase (171). Part of their study (192) was the investigation of 4 BCCs, all 
of which expressed hTERT, TPI and 3 / 4 hTR. Park et al. (98) demonstrated hTERT 2+ to 3+ 
in 8 / 10 BCCs in paraffin sections with anti-hTERT antibody from Calbiochem (USA, Ab-2). 
Ogoshi et al. (193) used in situ hybridization to prove hTERT and confirmed its occurrence 
in 93% (14/15) of BCCs.  
Attia et al. (194) introduced the anti-hTERT antibody code NCL-hTERT (clone 44F12, 
Novocastra, UK) for evidence of immunohistochemical hTERT in normal tissues such as in 
photo-exposed skin. The authors succeeded in proving hTERT (1+ to 3+) in 80% of the 
epidermis of photo-aged subjects. hTERT was expressed in normal skin in the basal layer 
and in some supra-basal layers, as well as in hair follicles (cf. telomerase activity in hair 
follicles: 173 to 175). 
In our study with small frozen sections we used eleven anti-hTERT antibodies to detect 
and localize hTERT expression in 25 BCC tumor tissues and 25 tumor margin tissues 
(107). Previously we had employed the same antibodies to examine squamous cell 
carcinomas and SCC tumor margin tissues (106). Before performing APAAP (105), slides 
were fixed in methanol and acetone and pretreated in a steamer (95 to 99°C). As described 
in detail in our first study (106), this pretreatment was essential for hTERT nuclear 
staining in frozen sections. The most prominent immunohistochemical effects were 
achieved with anti-hTERT antibody code NCL-hTERT (clone 44F12, Novocastra, UK), 
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which was also used by Attia et al. (194) for hTERT detection in sun exposed skin. This 
antibody was classified later in the paper by Wu et al. (195) as an antibody against 
nucleolin. We expanded our investigation and incorporated an anti-nucleolin antibody to 
clarify this issue (106, 107). On the basis of our peptide absorption studies (106) and in 
agreement with many authors we think that this antibody clone 44F12 Novocastra 
identifies hTERT. We compared the results of BCCs (107) with antibody Calbiochem, 
USA, code 582005 and others, and determined the hTERT scores as described in 2.2 and 
2.3.1. In the quantitative presentation of antigen expression we refer exclusively to the 
nuclear and / or nucleolar staining. We evaluated staining intensity (SI) and the number 
of positive stained cells (PP) in the BCCs and in squamous cell epithelia of the tumor 
margin. The IRS was calculated by multiplication of SI and PP (144, 145).  
Our immunohistochemical proof of hTERT is predominantly localized in tumor and in 
squamous cell epithelia of BCCs and BCC tumor-free margin tissues. hTERT scores with a 
polyclonal antibody (Calbiochem/USA, code 582005, Ab 1) and with a monoclonal antibody 
(Novocastra/UK, code NCL-hTERT, clone 44F12, Ab 2) are significantly lower in the tumor 
margin (mean score values Ab 1  5.4±3.3 and Ab 2  7.0±2.9) than in tumor center (mean score 
values Ab 1  9.4±4.9 and Ab 2 9.0±3.9): p=0.002 and p=0.011 (107). In Figures 10 and 11, 
hTERT expression is demonstrated with two antibodies. Proof of hTERT expression now 







Fig. 10. Mean values of immunoreactive score (cf. 144, 145) with two anti-hTERT antibodies 
(Calbiochem/USA and Novocastra/UK). 
 




Fig. 11. Comparison of hTERT expression with two anti-hTERT antibodies: polyclonal 
antibody code 582005, Ab 1 ( a, c and e)  and monoclonal antibody code NCL-hTERT, clone 
44F12, Ab 2 (b, d and f), magnification 400x. 
Kaplan-Meier curves indicate that proof of hTERT does not reveal the further course of the 
disease. We divided all hTERT scores into two groups (group 1: < mean value, group 2:  
mean value) and related them with the patients’ up-to-date outcome as documented in our 
hospital.  With the caveat that there were many censored cases, it can be said that patients 
with higher hTERT scores in tumor center tissues relapsed earlier than patients with lower 
hTERT scores in tumor center tissues: antibody code 582005 (Ab 1): 43±8 months vs. 70±31 
months, Log-rank p=0.539, Figure 12a; antibody code NCL-hTERT (Ab 2): 42±9 months vs. 
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77±25 months, Log-rank p=0.387, Figure 12b. However, patients with higher hTERT scores 
in BCC tumor-free margin tissues did not relapse earlier than those with lower hTERT 
scores in tumor-free margin tissues: antibody code 582005 (Ab 1): 43±9 months vs. 30±9 
months, Log-rank p=0.230, Figure 12c; antibody code NCL-hTERT (Ab 2): 39±5 months vs. 
32±5 months, Log-rank p=0.686, Figure 12d. 
 
Fig. 12. Kaplan-Meier curves of hTERT expression in BCCs (a and b) and tumor-free margin 
tissues (c and d): Ab 1 = polyclonal antibody code 582005, Ab 2 = monoclonal antibody code 
NCL-hTERT. 
Our hTERT results in tissues from patients with basal cell carcinoma (107) verify the value 
of hTERT in localizing the cells in which telomerase is activated (2.4.1). Although we 
identified differences between eleven antibodies (106, 107), we succeeded in detecting 
hTERT expression primarily in tumor cells and in squamous epithelia cells (Figure 11) after 
pretreatment of frozen sections in the steamer. We applied the same unfixed tissues for 
proof of telomerase activity and for hTERT expression. As McKenzie et al. (171) had already 
discovered, our detection of hTERT might not always mirror detectable telomerase activity 
(Figure 11, a to f). Kyo et al. (196) arrived at the same conclusion that hTERT did not always 
correlate with telomerase activity of the various cell types. 
Given our previous observations, we decided to evaluate only nuclear or nucleolar 
expression of hTERT although some antibodies also displayed cytoplasmic staining (106, 
107). It must be mentioned, however, that investigations of gynaecologic carcinomatous 
tissues by Kyo et al. (196) established proof of both hTERT and high levels of telomerase 
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after the isolation of cytoplasms, so further evaluation for immunohistochemical proof of 
hTERT is warranted. Taken together, both telomerase and hTERT may be useful as 
biomarkers in predicting chemotherapeutic effects (197).  
3. Biomarkers for chemoprevention of basal cell carcinomas 
Given frequent BCC recurrence and field cancerization in tumor-free margin tissues, several 
studies were launched to investigate the efficacy of chemoprevention in patients with a 
basal cell carcinoma. The best and primary prevention of basal cell carcinomas is reduction 
of the most important risk factor, exposure to strong sunlight from childhood (11, 12, 15, 18, 
21, 23, 39, 52, 198).  The use of agents that inhibit the noxious influence of UV light (199) 
could therefore be the most effective preventive method. In addition, there have been many 
studies applying retinoids (topical and oral / systemic) to suppress the emergence of basal 
cell carcinomas (200 to 207) and thus influence field cancerization of skin and tumor 
surroundings (59 to 63) to prevent new tumors and / or tumor recurrences. For 
immunosuppressed patients, chemoprevention is particularly important (63, 198, 208 to 
210). After chemoprevention proved to be unsuccessful in most studies, receptor-selective 
retinoids such as tazarotene were tried out (211 to 218). Tazarotene is selective for retinoic 
acid receptors RAR and RAR. Thus Bianchi et al. (217) successfully applied tazarotene-gel 
preoperatively for small superficial and nodular BCCs. This was not successful on keratotic 
BCCs with high p53 expression, and they were operated afterwards. Crucial for effective 
retinoic acid chemoprevention and / or therapy is the expression of RAR- and RXR-
receptors (218, 219), as was demonstrated by So et al. (220). So et al. consider tazarotene to 
be the most appropriate agent to date for chemoprevention of BCCs.  
In addition to synthesis of suitable agents it is essential to search for suitable biomarkers to 
improve prevention (19), and markers such as p53, Ki-67 or telomerase (2.3 and 2.4) merit 
consideration along with other genetic markers. Intermediate markers are needed in particular 
for chemoprevention trials (204). To determine a preliminary endpoint, genetic, cellular, 
biochemical and immunological surrogate biomarkers  - surrogate endpoint markers (SEBs)  -  
are being used and validated so that BCC chemoprevention can be evaluated before a 
recurrence becomes evident (204, 221 to 225). Orlandi et al. (225) employed the markers Ki-67, 
p53, apoptosis-index, RAR, RAR and RAR before and after tazarotene therapy of 30 BCCs. 
Expression of Ki-67 was significantly reduced after therapy compared with controls (11% vs. 
29%, p<0.001). Expression of p53 was unchanged after therapy. In comparison with controls, 
however, evidence of apoptotic cells was significantly higher after therapy (4.5% vs. 1%, 
p<0.001). While expression of RAR and RAR was not changed through therapy, expression 
of receptor RAR was distinctly higher. In our model investigations with cell cultures of oral 
squamous cell carcinomas, telomerase proved to be a suitable biomarker before and after 
retinoid therapy (162). Verification with BCCs is yet to follow.  
Examination of RAR receptors (retinoic acid receptors) and RXR receptors (retinoid X 
receptors) on BCCs might indicate why most studies do not show any differences between 
therapy and placebo groups. Using immunohistochemical methods, Kamradt and Reichrath 
(226) investigated expression of RAR receptors in frozen sections of 15 basal cell carcinomas: 
RAR was most evident (3 +), RAR a little weaker (2 +) and RAR scanty (0 to 1 +). This 
corroborates studies by Hartmann et al. (227). In comparison with SCCs of the skin, the 
authors determined RAR receptors of 28 BCCs by RTq-PCR. Measured values of this study 
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were also lowest for RAR-mRNA (7.91 x 10 –5) and distinctly higher for RAR (1.97 x 10 –3) 
and RAR (1.25 x 10 –2). 
Approximately comparable with regard to tumor-free margin tissues are 
immunohistochemical investigations by Reichrath et al. (228) on normal skin RAR- and RXR 
receptors of 12 male volunteers. Expression of RAR was most distinctly detectable, among 
other things, in epidermal keratinocytes (5 +) and in hair follicle keratinocytes (5 +). 
Expression of RAR was distinct in epidermal keratinocytes (2 +) and in hair follicles (3 +), 
but expression of RAR was found in traces only (0 to 1 +). All three RXR receptors RXR, 
RXR and RXR were distinctly expressed (2 +, mostly 3 +) in both of these cell types.  
We therefore tested as well for expression of RAR and RXR receptors in small frozen sections 
of BCCs with immunohistochemical APAAP (105). After fixing pretreatment in a steamer, 
which was essential in our study for clear and strong nuclear receptor detection in frozen 
sections (162, cf. 106, 107), we applied antibodies from Santa Cruz / USA (anti-RAR, code sc-
551; anti-RXR1, code sc-556 and anti-RXR, code sc-555), from Abcam / USA (anti-RAR, 
code ab15515) and from Abnova / USA (anti-RXR, code H00006256 M01). Other antibodies 
were less suitable for our frozen sections. In our study the anti-RAR antibody was 
inappropriate (162). Evaluation succeeded with immunoreactive scores (IRS) as described with 
p53, Ki-67 and hTERT (2.3.1, 2.3.2 and 2.4.2). For control we investigated tissues with 
comparable localization from BCC-free patients. Figure 13 summarizes mean score values for  
 
 
Fig. 13. Immunoreactive scores (IRS, cf. 144, 145) of expression for RAR  and RXR receptors 
in small frozen sections of BCCs and control tissues (mean values). 
expression of RAR and RXR receptors. In agreement with Kamradt and Reichrath (226) and 
with Hartmann (227) we were able to detect all receptors tested in BCCs in similar levels as in 
control tissues. RAR expression in BCCs had the lowest value (mean score value 4.92±1.81), 
followed by RXR (mean score value 5.83±1.76), RXR (mean score value 7.83±2.36), RARα 
(mean score value 10.17±2.02) and RXR (mean score value 10.38±2.14). Expression of RAR 
was almost significantly lower in BCCs than in control tissues (p=0.056). The expression of the 
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remaining receptors in BCCs and control tissues did not differ statistically: p=0.586 (RAR), 
p=0.862 (RXR), p=0.863 (RXR) and p= 0.871 (RXR). 
Our results suggest that the increase of RAR  in the context of a chemoprevention might 
give us valuable information as a surrogate end point biomarker for the success of therapy 
in chemoprevention, as was previously demonstrated by Orlandi et al. (225).  Figures 14a to 





Fig. 14. Expression of retinoic acid  receptors (RAR) and retinoid X receptors  (RXR) of a 
nodular BCC (frozen sections); bars 20 µm. 
e) RXR 
c) RXR                                                                  d) RXR 
a) RAR                                                                 b)RAR 
 




Immunohistochemical application of Ber-Ep4  (85 to 88) is particularly appropriate for 
histopathological differentiation between SCCs of the skin and basal cell carcinomas. When 
examined with immunohistochemical methods, adhesion molecules CD44v6 and U36 
(CD44v6-chimera) give clear evidence for spreading of BCCs (Figure 4) and for the absence 
of tumor in tumor margins (91 to 96, 134 to 138, cf. 131 to 133). Radionuclide-labeled 
antibodies developed against oral squamous cell carcinomas (146 to 156, 229, 230) might also 
be applied in the diagnosis and therapy of patients with BCC.  
It is important for prognostic purposes to make a clear distinction between smaller T1-BCCs 
and larger T2-BCCs (cf. 2. and Figure 2). Clinical classification into aggressive and less 
aggressive BCCs confirmed by histopathology can be supported, among other things, by 
markers p53 (101, 103, 121 to 124, 157 to 161), bcl-2 (81, 100, 122), Ki-67 (100, 106, 107, 158, 
161) and by the apoptotic index (124).  The markers Ki-67 and p53 can impart 
supplementary information and are important for histopathological diagnosis with regard 
to making a clinical judgement of the consequences of “tumor-free margin”. Representation 
of telomerase activity in unfixed tumor margin tissues (64, 103, 104, 183), and not so much 
immunohistochemical proof of hTERT, (98, 107, 189, 192) can contribute to a better 
diagnostic assessment of tumor-free margins and may indicate early recurrence.   
The high proportion of BCC recurrences is a challenge to develop better selective agents for 
chemoprevention and to support them with appropriate biomarkers such as Ki-67, apoptotic 
index, telomerase or by RAR (199, 214, 225, cf. 162). 
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1. Introduction 
The Hedgehog (Hh) signaling pathway is critical for growth control and patterning during 
embryonic development and adult homeostasis (Jiang and Hui 2008). The identification of 
loss-of-function mutations in PATCHED1 (PTCH1) as the underlying cause of nevoid basal 
cell carcinoma syndrome (Gorlin 2004), which predisposes patients to the development of 
neoplasms including basal cell carcinoma (BCC), first implicated the involvement of the Hh 
pathway in tumorigenesis (Johnson et al., 1996; Hahn et al., 1996). PTCH1 is a Hh-binding 
membrane receptor and functions as a major negative regulator of the pathway by 
inhibiting the signaling membrane protein SMOOTHENED (SMO). Inactivating mutations 
in PTCH1 as well as activating mutations in SMO are commonly found in BCC, and it is 
well established that abnormal Hh pathway activation is the underlying cause of BCC 
(Reifenberger et al., 2005; Ruiz i Altaba, 2006). However, how pathway activation disrupts 
normal skin homeostasis to promote BCC formation remains poorly understood.  
This chapter provides an overview of the Hh pathway and the role of Ptc receptors during 
normal skin homeostasis and tumorigenesis. The Patched mouse model provides an 
excellent tool to study BCC pathogenesis since these mice recapitulate many clinical features 
of human BCC. In addition, the mouse Ptc1 protein is 95% identical to its human 
counterpart PTCH1. Examples of how Patched mouse models have facilitated our 
understanding of the molecular genetic and cellular events of BCC biology will be 
discussed. In particular, we will focus on studies performed to tease out the biological 
function of the C-terminal domain of Ptc and its role not only in tumorigenesis but also stem 
cell biology and cell cycle progression.  
2. Patched: The link between BCC and Hh signaling 
BCC typically arises in sun-exposed skin and is the most commonly diagnosed cancer in the 
Caucasian population, with over one million people diagnosed every year in the United 
States. Despite the high incidence, mortality rate is low, as BCCs rarely metastasize and are 
generally locally invasive. The vast majority of BCCs arise sporadically, although some are 
attributed to a genetic predisposition syndrome. NBCCS (Nevoid basal cell carcinoma 
syndrome, also known as Basal-cell syndrome or Gorlin syndrome, OMIM#109400) is a rare 
autosomal dominant disease in which individuals display a spectrum of developmental 
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disorders including skeletal malformations, neural tube closure defects, and general 
overgrowth of the body (Gorlin 2004, Gorlin and Goltz 1960). These patients are highly 
susceptible to medulloblastoma (MB) of the cerebellum, rhabdomyosarcoma (RMS) of the 
soft tissue and more frequently BCC.  
A link between BCC and the Hh signaling pathway was discovered in 1996, when two 
independent groups used positional cloning to identify germline mutations in PTCH1 
(9q22.3) in patients with NBCCS and sporadic BCC (Johnson et al., 1996; Hahn et al., 1996). 
This discovery was seminal in understanding the genetic underpinnings of BCC and aided 
researchers in developing a suitable animal model. Transgenic mice that overexpress Sonic 
hedgehog (SHH), the ligand for PTCH1, in the skin develop many features of NBCCS 
including BCC (Oro et al., 1997). In subsequent years, activating mutations in SMO were 
reported in patients with sporadic BCC (Xie et al., 1998). These studies highlight the 
importance and close connection between Hh signaling and BCC biology.  
2.1 Hh signaling in the skin 
Vertebrate Hh signal transduction occurs in the primary cilium, a microtubule-rich 
organelle that protrudes from the cell surface of virtually all mammalian cells (reviewed in 
Goetz and Anderson 2010). Many key components of the Hh pathway are localized to the 
cilium and, in response to Hh stimulus, they dynamically shuttle in or out of this organelle 
(May et al., 2005). In vertebrates, there are three Hh ligands: Sonic hedgehog (Shh), Dessert 
Hh (Dhh) and Indian Hh (Ihh). While Shh is more broadly expressed in tissues, including 
the skin, neural tube and the limb, the action and expression of other ligands are more 
restricted: Dhh in the testis and Ihh in the bone. In the absence of the Hh ligand, Ptc is found 
at the base of the primary cilium and it acts to inhibit the activity of an obligatory 
transmembrane protein Smo, which normally resides in intracellular vesicles (Figure 1). The 
binding of Hh to Ptc promotes its migration out of the cilium, allowing the activation and 
translocation of Smo to the tip. Though the mechanism is unclear, Smo signals downstream 
to generate activator forms of Gli transcription factors that turn on the expression of Hh-
target genes, such as Ptc1 and Gli1 (Figure 1). Mutation in components of the intraflagellar 
transport (IFT) machinery, which is required for cilia production and maintenance, leads to 
patterning defects in Hh-dependent tissues such as the neural tube and the limb (Huangfu 
and Anderson 2005; Liu et al., 2005). Depending on the tissue, loss of IFT function during 
embryogenesis can result in low or high Hh activity as IFTs are required to generate both 
activator and repressor forms of Gli transcription factors (Huangfu and Anderson 2005; Liu 
et al., 2005; May et al., 2005). The dual function of cilia on Hh signaling is also revealed in 
adult tissue homeostasis since removal of cilia could promote as well as suppress Hh-driven 
BCC depending on the oncogenic context (Wong et al., 2009). This action is not tissue-
dependent as it is also observed in other Hh-driven tumors such as MB (Han et al., 2009). 
There are three Gli proteins in the mammalian Hh signaling pathway. Among them, Gli2 is 
the major mediator of Shh signaling during skin development and tumorigenesis (Mill et al., 
2003). Gli2-/- mice display hair follicle growth arrest similar to Shh-/- mutants and 
overexpression of Gli2 drives BCC development and supports tumor growth (Mill et al., 
2003; Hutchin et al., 2005; Grachtchouk et al., 2000). In addition, the level of Gli activity can 
determine tumor type and latency (Huntziker et al., 2006; Grachtchouk et al., 2001). How 
Gli2 is regulated in the skin is unclear, however recent studies have demonstrated that 
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Suppressor of fused (Sufu) and Kif7 are evolutionarily conserved regulators of Gli 
transcription factors. Sufu, like Ptc, acts as a major negative regulator of the Hh pathway 
and in vitro studies revealed that Sufu inhibits Gli-dependent transcription by anchoring 
Gli2 in the cytoplasm to prevent its access to the nucleus (Humke et al., 2010; Tukachinsky 
et al., 2010). Upon Hh stimulus, Gli dissociates from Sufu and translocates freely to the 
nucleus to activate Hh-target gene transcription (Humke et al., 2010; Tukachinsky et al., 
2010). SUFU mutations have been identified in patients with sporadic BCC; however, these 
are accompanied by additional mutations including PTCH and TRP53 (p53). Therefore, it is 
difficult to determine whether SUFU mutations are the driver or merely passenger 
mutations (Reifenberger et al., 2005). Complete ablation of Sufu in mice leads to embryonic 
lethality and there is conflicting data as to whether Sufu+/- mice are prone to skin tumors 
(Svard et al., 2006; Cooper et al., 2005; Lee et al., 2007). Analysis of Sufu deletion specifically 
in the skin will be useful to resolve this issue. Another regulator of Gli proteins is Kif7, a 
kinesin molecule that acts predominantly as a negative regulator of the Hh pathway 
(Cheung et al., 2009; Liem et al., 2009; Endoh-Yamagami et al., 2009). Kif7 is localized to the 
base of cilia when the pathway is inactive and it translocates to the cilia tip upon pathway 
activation (Endoh-Yamagami et al., 2009; Liem et al., 2009). Upon Hh stimulus, Kif7 is 
required for the accumulation of Gli2 and Gli3 to the cilia tip (Endoh-Yamagami et al., 2009; 
Liem et al., 2009), but the molecular significance of this action has yet to be determined, and 
whether Kif7 plays a role in the skin remains unknown. Since the activity of the Hh pathway 
ultimately culminates on the Gli proteins, studying how molecules regulate Gli2 is critical 
for our understanding of the molecular events of BCC pathogenesis. 
 
Fig. 1. Vertebrate Hh signal transduction. See text for details.  
3. Patched receptors and Patched animal models of BCC 
Human BCCs are difficult to culture and classical mouse models of skin tumors often 
develop other skin tumors and not BCC. This has in many ways hampered efforts to 
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understand BCC pathogenesis. It was not until the generation of the Ptc1+/- mice that BCC 
research truly began to advance. Ptc1+/- mice display many features of NBCCS and develop 
BCC (upon ionizing or ultraviolet (UV) radiation) that has many clinical and histochemical 
features of its human tumor counterparts: slow progression, local invasiveness, and lack of 
metastasis (Aszterbaum et al., 1999; Mancuso et al., 2004). This model facilitated the 
identification of both the genetic events and the molecular basis of BCC. Table 1 outlines the 
current models of BCC using Ptc mutant mice. Next, we will describe how the Ptc1 mutant 
mouse model revealed the temporal importance of proliferation for BCC formation as well 
as gave insight into the genetic control, molecular events and the cell of origin of BCC.  
3.1 The Patched family members: Patched1 and Patched2 
Ptc receptors contain 12 hydrophobic membrane-spanning domains, two large 
hydrophilic extracellular loops as well as intracellular amino- and carboxyl-terminal 
regions (Figure 2). The Ptc receptors have a sterol-sensing domain (SSD) and belong to a 
family of integral-membrane proteins (Kuwabara and Labouesse 2002). SSDs are 
implicated in vesicle trafficking and cholesterol homeostasis. In addition, the predicted 
transmembrane topology of Ptc is similar to the resistance nodulation division (RND) 
family of prototypic bacterial multidrug efflux pumps. RND proteins in bacteria typically 
transport substrates from the cytoplasm to the extracellular space. How Ptc inhibits Smo 
is not well understood but it is not likely through direct physical interactions since Ptc can 
inhibit a large stoichiometric excess of Smo (Taipale et al., 2002). One possibility is that Ptc 
could function as a molecular transporter for a small molecule that directly binds to or 
regulates Smo activity. In agreement with this notion, natural and synthetic molecules can 
modulate the ability of Smo to activate the Hh pathway (Chen et al, 2002).  
 
Fig. 2. Topological models of the mouse Ptc receptors. The two large extracellular loops of Ptc 
receptors bind to the Hh ligands. The CTD of Ptc1 is 273 amino acids in length while the CTD 
of Ptc2 only extends to 71 amino acids (blue). Green denotes the proposed cyclin B1 interacting 
domain of Ptc1 (amino acids 690-779) Amino acids 690-779 of Ptc1 is 51% identical to a similar 
region on Ptc2. Ptc1mes protein retains the first 53 amino acids (blue) of the C-terminal 
cytoplasmic domain and gains a missence mutation of 68 amino acids (red); therefore, lacks 
most of its CTD. Predicated caspase-cleavage site (asterisks). 
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Mutant Type of mutation Phenotype References 
Ptc1+/-  
Loss of function (in-frame 
fusion of lacZ reporter to 
exons 1 and 2) 
Features of NBCCS and increased 
susceptibility to spontanous tumor 
development (RMS and MB) 
Low frequency of spontanous 
trichoblastoma-like tumors 
Enhanced tirchoblastoma-like tumors 
and microscopic BCC-like lesions were 
observed after ultraviolet or ionizing 
radiation 
Goodrich  
et al., 1997; 
Aszterbaum 
et al., 1999;  
Ptc1neo67/+ Loss of function (deletion of exons 6 and 7) 
Features of NBCCS and increased 
susceptibiilty to spontanous tumor 
development (RMS and MB)  
Non-irradiated mice develop basaloid 
hyperproliferation in the skin 
Irradiated mice develop nodular and 
iniltrative BCC-like tumors 
Hahn  
et al., 1998; 
Mancuso  
et al., 2004 
Ptc1mes/mes 
Deletion of the most C-
terminal cytoplasmic 
domain 
Excess skin; basal cell layer hyperplasia 
and expansion of the epidermal stem 
cell compartment in adult skin 
Makino  
et al., 2001; 
Nieuwenhuis 
et al., 2007 
Ptc1flox/flox Conditional allele 
BCC develops when crossed to skin-
specific promoters of Cre (K6-Cre, K14-
Cre, K5-CrePR1, and Lgr5-CreERT2) 
Adolphe  
et al., 2006 
Villani  
et al., 2010  
Kasper  
et al., 2011 
Ptc1D11 
Weak allele, effect on gene 
and protein product is 
unknown 







terminus (T1267N) of Ptc1 
allele found in C57BL/6 
background mice 
compared to FVB/N mice  
C57BL/6 mice are resistant to 
squamouse cell carcinoma induced by 
activated Ras 
Wakabayashi 
et al., 2007 
Ptc2-/- 
Truncated Ptc2 mRNA 
(deletion of exons 5-17), 
effect on protein product is 
unknown 
No discernable skin defect; however, 
Ptc1 and Ptc2 compound mutants have 
increased tumor susceptiblity 
compared to Ptc1 mutants 
Lee  
et al., 2006 
Ptc2tm1/tm1 
Hypomorphic allele 
(disruption of exon 6), with 
several truncated Ptc2 
mRNA products produced, 
effect on protein product is 
unknown  
Male-specific alopecia, ulceration and 
epidermal hyperplasia with 
progressing age 
Nieuwenhuis 
et al., 2006 
Abbreviations: BCC, basal cell carcinoma; NBCCS, nevoid basal cell carcinoma syndrome; MB, 
medulloblastoma; RMS, rhabdomyosarcoma 
Table 1. Summary of Genetic Analyses of Ptc function in the mouse skin. 
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There are two Ptc genes in vertebrates: Ptc1 and Ptc2. PTCH2/Ptc2 encodes a protein with 
45% identity to PTCH1/Ptc1 and contains much shorter intracellular amino- and carboxy-
terminal regions than Ptc1 (Figure 2). They also differ in the hydrophilic loop between 
transmembrane domain 6 (TM6) and TM7. Hh ligands bind to the two extracellular loops of 
PTCH1 and PTCH2 with similar affinity (Carpenter et al., 1998; Marigo et al., 1996). Both 
Ptc1 and Ptc2 inhibit Hh pathway activity in the absence of ligand, however whether this 
inhibition is equivalent has not been determined. PTCH2 mutations were found in some 
cases of sporadic BCC, and a PTCH2 germline mutation was identified in a family with 
NBCCS (Fan et al., 2008; Smyth et al., 1999). This suggests that Ptc2 has a role in 
development and possibly tumor suppression. We found that Ptc2-deficient (Ptc2tm1/tm1) mice 
are viable, fertile and do not develop any obvious developmental defects in Hh-responding 
tissues, such as the hair follicle, limb, neural tube or testis (Nieuwenhuis et al., 2006). 
However, with age, adult male Ptc2tm1/tm1 mice develop epidermal hyperplasia and hair loss. 
Ptc2-deficient mice are not cancer prone but, in the Ptc1+/- background, Ptc2+/- and Ptc2-/- 
mice showed a higher incidence of tumors including BCC when compared to Ptc1+/- mice 
(Lee et al., 2006). These studies demonstrate that Ptc2 is required during adult skin 
homeostasis and possesses overlapping functions with Ptc1 in tumor suppression. The 
divergence of Ptc receptor expression patterns and levels may reflect their unique and 
overlapping roles during embryogenesis and in maintenance of adult tissues such as the 
skin (Carpenter et al., 1998; Motoyama et al., 1998; Nieuwenhuis et al., 2006). 
3.2 Insights gained from Patched animal models  
Ptc1+/- mice in many regards recapitulate the typical pathologies associated with NBCCS, 
including a higher sensitivity to spontaneous tumorigenesis (Aszterbaum et al., 1999; 
Goodrich et al., 1996). The vast majorities of these tumors are MB and RMB, and at a low 
frequency, skin tumors. When these mice are exposed to UV or ionizing radiation, BCC-like 
lesions form, suggesting that additional genetic alterations, possibly caused by DNA 
damage, are required to promote BCC progression. Consistent with this notion, human BCC 
typically occur in sun-exposed areas of the skin and BCC with PTCH1 mutation are 
frequently associated with mutations in p53, a tumor suppressor gene that is mutated in 
over 50% of all human tumors (Ponten et al., 1997; Zhang et al., 2001). Furthermore, BCC 
formation in Ptc1+/- mice was enhanced upon the ablation of p53 in the skin, suggesting that 
Ptc1 mutations synergize with the loss of p53 to promote BCC (Wang et al., 2011). 
Intriguingly, loss of p53 induces the expression of Smo, an obligatory signal transducer of 
the pathway in the interfollicular epidermis (IFE), where Smo expression is normally not 
detected (Wang et al., 2011). How p53 contributes to BCC development is unclear but this 
finding suggests that loss of p53 may promote BCC through its effects on the expression of 
Hh components. Another genetic signature found in BCC is the loss of heterozygosity (LOH) 
at the PTCH1 locus and NBCCS patients with BCC have the remaining somatic wild-type 
PTCH1 allele mutated or deleted (Teh et al., 2005). Similarly, LOH at the Ptc1 locus is observed 
in tumors of Ptc1+/- mice after exposure to UV or ionizing radiation, further illustrating that 
DNA damaging agents are a strong etiological factor in BCC (Aszterbaum et al., 1999). 
Whether inactivation of the second allele of PTCH1 is required for BCC formation could not be 
conclusively addressed using Ptc1+/- models. Using Ptc1 conditional knockout mice, it was 
reported that mice develop BCC only upon biallelic loss of Ptc1 whereas monoallelic 
inactivation of Ptc1 is not sufficient to induce tumorigenesis (Zibat et al., 2009; Kasper et al., 
 
BCC and the Secret Lives of Patched: Insights from Patched Mouse Models 
 
61 
2011). These studies have revealed that Ptc1 is a classical tumor suppressor gene and follows 
Knudson’s two hit hypothesis that germline mutation in the PTCH1 locus requires a “second 
hit” for tumorigenesis to occur (Knudson 1996).  
Interestingly, the frequency of BCC and histological BCC subtypes that develop in Ptc1+/- 
mice correlates with the phase of the hair follicle cycle at the time of irradiation. In the adult 
skin, the hair undergoes cyclic nature of active growth (anagen), regression (catagen) and 
rest (telogen) (Figure 3A). Hair follicle keratinocytes at anagen are highly proliferative since 
they are required to generate a new follicle at each hair cycle. Shh pathway activation acts as 
a biological switch for the transition from telogen to anagen. Shh is only detectable during 
anagen and is transcribed asymmetrically in the distal growing tip of the hair follicle, while 
in the IFE, little to no expression of Shh or Hh target genes is detected (Oro and Higgins 
2003). During anagen, Hh target genes are expressed in the hair matrix and dermal papilla 
suggesting that these cells represent Hh-responding cells (Oro and Higgins 2003). As the 
hair degenerates, Ptc1 and Gli1 expression decrease and becomes undetectable at telogen 
(Oro and Higgins 2003). Ptc1+/- mice irradiated at anagen exhibited more advance tumor 
growth and much earlier tumor onset than mice irradiated at telogen (Mancuso et al., 2006). 
This suggests that the hair cycle-induced differences in the proliferation capability of 
keratinocytes can regulate BCC latency and progression.  
Conditional deletion of Ptc1 in the skin has revealed possible molecular events and pathways 
involved in BCC. Inactivation of Ptc1 in the skin induces rapid skin tumor formation without 
disrupting the expression pattern of Notch signaling components and the nucleo-cytoplasmic 
distribution of β-catenin, key signaling molecules known to play a role in the skin (Adolphe et 
al., 2006). Loss of Ptc1 results in the nuclear accumulation of cell cycle regulators cyclin B1 and 
cyclin D1, suggesting that Ptc1 functions as a tumor suppressor in the skin in part through 
regulation of the G1-S and G2-M check points of the cell cycle (Adolphe et al., 2006). 
Consistent with this finding, Ptc1 has been shown to physically interact with cyclin B1, 
tethering it in the cytoplasm (Barnes et al., 2001). The authors tested the clinical significance of 
this interaction by generating a construct that contains a common PTCH1 mutation found in 
NBCCS/BCC patients, which lacks the cyclin B1-binding domain (Barnes et al., 2005). Cell 
culture experiments have shown that Ptc1Q688X, a mutant construct encoding a Ptc1 protein 
truncated at the large intracellular loop, enhances Gli1 activity, promotes proliferation and is 
non-responsive to Shh treatment (Barnes et al., 2005). Since Gli2 has been shown to promote 
the transcription of D-type cyclins, nuclear translocation of cyclin D1 is likely a consequence of 
activated Hh pathway rather than a direct interaction with Ptc1. 
Ptc1 has also been shown to inhibit basal cell progenitor expansion possibly through 
limiting the activity of Insulin-like growth factor binding protein 2 (Igfbp2) (Villani et al, 
2010). The function of Igfbp2 in the skin is unknown; however, there is a positive correlation 
between Igfbp2 expression and human BCC raising the possibility that Igfbp2 is associated 
with BCC (Villani et al, 2010). Whether the control on Igfbp2 activity is a Ptc1-specific 
function or a consequence of activated pathway activity remains unknown. 
The skin is composed of functionally and biologically distinct units: hair follicle, IFE and the 
sebaceous gland (Figure 3B). The basal cell layer in the IFE is continuous with the outer root 
sheath (ORS) of the hair follicle and contains progenitor keratinocytes. Two populations of 
stem cells are required to maintain skin homeostasis: one that resides in the hair follicle 
niche, the bulge and the other dispersed in the IFE (Levy et al., 2005). Genetic lineage 
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analysis demonstrated that bulge cells are capable of generating all lineages of the hair 
follicle to ensure proper tissue homeostasis but only contribute to IFE during wound healing 
(Levy et al., 2007; Ito et al., 2005). Given that the skin is composed of different cell 
populations, a key question that arises is what is the cell of origin of BCC? The development 
of molecular tools was critical to address this question. Using different cell type-specific 
promoters to drive Cre expression to conditionally express an activating mutation in Smo 
(SmoM2), Blainpain’s group elegantly showed that specifically activating Hh signaling in the 
long-lived K14+ progenitors of the IFE induces BCC formation (Youssef et al., 2010). In 
contrast, K15+ cell fate mapping analysis on irradiated Ptc+/- model of BCC revealed that the 
majority of BCC arose from K15 expressing hair follicle bulge stem cells (Wang et al., 2011). 
These studies would suggest that both hair follicle stem cells (K15+) and epidermal progenitor 
cells (K14+) are capable of tumor-initiation and that epidermal cell subpopulations are 
sensitive to different Hh-driven BCC mutations. Interestingly, cutaneous injury has been 
shown to influence the cell of origin of BCC. For example, overexpression of SmoM2 in the 
K15+ bulge cells does not lead to BCC; however, wounding can induce migration of oncogene-
expressing bulge cells to the sites of injury to promote BCC formation (Wong and Reiter 2011). 
Taken together, these studies illustrate that the cell of origin of BCC is context dependent, 
encompassing both the type of activating mutations and factors involved in wound healing.  
 
Fig. 3. Adult hair cycle. In the adult skin, the hair follicle constantly degenerates (catagen), 
rests (telogen) and grows (anagen). Only the non-permanent region of the hair follicle, 
below the bulge stem cells (SC) participates in these phases of hair cycle. Bulge SCs are 
located beneath the sebaceous gland (SG). Following telogen, when the dermal papilla (DP) 
is proximal to the permanent follicle segment, the bulge SC are activated (red arrows) to 
initiate a new round of hair growth by producing transiently amplifying cells/matrix cells 
(Mx). The matrix cells will give rise to all differentiated layers of the mature hair follicle.  
 
BCC and the Secret Lives of Patched: Insights from Patched Mouse Models 
 
63 
4. C-terminal domain of Ptc1: Cell survival, cell cycle progression and stem 
cell maintenance in the epidermis 
Besides its ability to inhibit Hh signaling, Ptc1 has been shown to act as a dependence receptor. 
Dependence receptors promote cell survival when bound to their ligands and induce 
programmed cell death in the absence of the ligand. Overexpression of Ptc1 results in 
apoptosis in both cell culture and the neural tube of chick embryos and this can be reversed 
through addition of Shh ligand (Thibert et al., 2003). The ability of Ptc1 to induce cell death is 
dependent on a caspase-cleavage site located at Asp 1392, 42 amino acids from the C-terminus 
of Ptc1 (Figure 2) (Thibert et al., 2003; Mille et al., 2009). Interestingly, Ptc-induced cell death is 
not affected through expression of Smo, suggesting that Ptc’s ability to induce apoptosis is 
independent of Ptc-Smo transduction. How Ptc transduces this survival signal downstream 
and whether this is dependent on the Gli transcription factors are unknown.  
Interestingly, the majority of PTCH1 mutations identified in BCC result in premature 
truncation of the protein (Daya-Grosjean and Couve-Privat 2005). These findings raise the 
tantalizing possibility that the C-terminal half of PTCH1 is crucial for tumor suppression. 
Little is known about the C-terminal domain (CTD) of Ptc1 in the context of skin 
development and homeostasis. Our group aimed to address these questions by analyzing 
Ptc1mes mice. A spontaneous recessive mutation in Ptc1, mesenchymal dysplasia (mes) was 
found in mice containing a missense mutation resulting in a 32bp deletion and a 152 amino 
acid truncation of the CTD (Figure 2) (Sweet et al., 1996; Makino et al., 2001). It was reported 
that Ptc1mes/mes mice possess excess skin, suggesting that the CTD of Ptc1 is involved in skin 
development and/or homeostasis (Makino et al., 2001). We found that adult Ptc1mes/mes mice 
have severe epidermal hyperplasia starting as early as postnatal day 12. These mice 
displayed hyperproliferation of the basal cell population, attributed to increased c-Myc 
expression, while stratification and apoptosis of the epidermis were not affected. Despite the 
fact that Ptc1 is a major negative regulator of Hh signaling, Ptc1mes/mes mice displayed normal 
pathway activity in the epidermis, and the Ptc1mes protein maintained similar Shh-binding 
abilities to wild-type Ptc1. These data suggest that the function of the CTD is independent of 
Shh pathway/Gli activity. Normally, epidermal stem cells rarely divide and reside in two 
functionally distinct locations in the skin: the bulge and the IFE. Using BrdU pulse-chase 
labeling, we found that Ptc1mes/mes epidermis exhibited an increase in the number of label-
retaining cells (i.e. quiescent stem cells) in the IFE, indicating that the CTD is required for 
epidermal stem cell maintenance (Figure 4). Despite the persistent hyperplasia phenotype, 
Ptc1mes/mes mice do not develop skin tumors even in response to the DNA damaging effects of 
radiation (unpublished data). It has been reported that the level of Hh pathway activity 
determines tumor outcome, ranging from epidermal hyperplasia to BCCs. Therefore we 
speculate that the lack of tumorigenesis may be attributed to normal Hh pathway activity 
observed in Ptc1mes/mes adult mice. As wounding can contribute to tumor outcome, it 
would be interesting to determine whether injury can promote tumorigenesis in the mes 
background. Given that Ptc1+/- mice are more susceptible to tumorigenesis, whether the 
mes mutation can modulate tumorigenesis of Ptc1+/- mice remains to be determined. 
Together, our study revealed a novel, unexpected role for the CTD of Ptc1 in the 
regulation of epidermal homeostasis. Furthermore, it highlights a non-canonical function 
of Ptc1, which appears to be independent of Gli activity.  
 




Fig. 4. Ptc1mes/mes epidermis exhibits an increase in the number of label-retaining cells. (A) 
Schematic diagram illustrating pulse-chase experiment. Ten-day-old wild-type and 
Ptc1mes/mes pups received four consecutive BrdU injections at 12-hour intervals to label all 
mitotic cells. Skin samples were collected 30 and 80 days post-labeling (dpl). (B–E) Basal 
cells were identified using K-14/BrdU double labelling and are considered to be label-
retaining interfollicular epidermal stem cells (B, D, E; arrowheads). Suprabasal cells were 
identified using K-10/BrdU double labeling. These cells were not considered to be 
interfollicular stem cells and were not counted (C; arrowhead). (D, E) BrdU/K-14-double 
positive cells could be detected at 30 (D) and 80 (E) dpl in wild-type and Ptc1mes/mes skin. (F) 
At 30 days, skin showed a 3.6-fold increase in BrdU/K14-double positive cells. A 3.3-fold 
increase was observed at 80 dpl. Data represent the mean ± SEM. Scale bars = 50 μm. 
Reprinted from Developmental Biology, E.N., P.C.B., S.M., C.-c. H., Epidermal hyperplasia 
and expansion of the interfollicular stem cell compartment in mutant mice with C-terminal 
truncation of Patched1, 308, 547-560, © 2007, with permission from Elsevier. 
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5. Conclusion and future prospective 
The establishment of Ptc mutant mouse models of BCC has given us critical insight into the 
genetic underpinnings and the molecular events that drive BCC formation. We described 
here that the tumor suppressor Ptc1 is a multifaceted protein that is not solely dedicated to 
repressing the Hh pathway. By attempting to understand BCC biology using the Ptc1 mouse 
model, researchers have serendipitously stumbled upon the non-canonical functions of Ptc1. 
In the neural tube, Shh can act as a chemical cue to guide commissural axons independent of 
Gli transcription factors, further illustrating that Gli activity is not always coupled to the 
Shh-Ptc module (Okada et al., 2006; Yam et al., 2009). Interestingly, the non-canonical 
actions of Ptc1 can be traced to its C-terminal domain, which is largely absent in Ptc2, 
suggesting a functional divergence between the Ptc family of receptors.  
Our group found that the CTD of Ptc1 is important in stem cell homeostasis of the IFE, 
identifying Ptc1 as a pivotal switch between quiescence or cell cycle progression 
(Nieuwenhuis et al., 2007). The molecular events mediating this outcome remain unclear. 
We speculate that the CTD of Ptc1 might act as a docking site for regulatory proteins 
required for stem cell maintenance. Determining these potential binding partners could 
help decipher the atypical functions of Ptc1. Mutations of the PTCH1 locus in BCC 
typically display a truncating mutation in one allele and a deletion on the other (Reichrath 
2006). Further analyses on the monoallelic loss of Ptc1 in conjunction with Ptc1 point 
mutations will be necessary to recapitulate the molecular events leading to BCC 
pathogenesis, which cannot be uncovered using current Ptc mouse models.  
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1. Introduction 
The immune system plays an important role in surveillance against tumor development, 
and it is widely known that cancer cells protect themselves against the host's anti-tumor 
immune defense. Cancer cells have several means of evading the antitumor immunity, one 
of which is the production of immune modulators such as cytokines and chemokines. These 
factors can either promote or block immune responses. Many of these molecules are used by 
cancer cells to promote tumor progression including cell proliferation, cell migration, matrix 
remodeling, immune suppression and angiogenesis. On the other hand, some molecules are 
involved in immunotherapeutics for the purpose of enhancing and modifying antitumor 
immune responses. 
In basal cell carcinoma (BCC), several cytokines and chemokines and their receptors are 
associated with the development of this cutaneous cancer. There are varying degrees of 
inflammation in BCC. The majority of peritumor inflammatory cells are lymphocytes and 
most are T cells (1). It has been proposed that the tumor microenvironment of BCC is 
generally Th2 dominant. T regulatory cells and immature dendritic cells mediated by Th2 
cytokines cause immunosuppression and decreased immunity to BCC (2). Tumor-associated 
macrophages (TAM), which are polarized to M2 type, are associated with tumor invasion 
and angiogenesis in BCC (3). In this chapter, we focus on cytokines and chemokines which 
may influence and enhance these immunosuppressive networks. 
2. IL-6 
Interleukin-6 (IL-6) is a pro-inflammatory cytokine, which can induce tumor progression by 
manipulating immune responses in the tumor microenvironment. IL-6 is directly related to 
epidermal hyperproliferation in psoriasis (4). There are many experimental evidences that 
IL-6 is associated with BCC. Overexpression of IL-6 in BCC cell lines increases anti-apoptotic 
activity and tumorigenic potency (5). The phosphotidyl inositol 3-kinase (PI3K)/Akt signal 
pathway is involved in such anti-apoptosis (6). On the other hand, IL-6 induces bFGF-
dependent angiogenesis in BCC cell line via JAK/STAT3 and PI3k/Akt pathways (7). IL-6 is 
also involved in CXCL-12 (SDF-1)-enhanced angiogenesis via activating ERK1/2 and NF-κB 
(8). IL-6 expression is associated with a significant increase of IL-8 (CXCL8) expression in 
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BCC (9, 10), one of which functions is tumor angiogenesis. The expression of these two 
cytokines shows a significant positive correlation (10).  
A single nucleotide polymorphism (SNP) in the promoter regions of IL-6 gene (IL6) is 
associated with the risk of BCC. The promoter region of IL6 contains several SNPs, 
including –634G>C, –597G>A and –174G>C. It has been reported that IL6 –597 G>A is 
significantly associated with BCC risk (11). However, others reported that there was no 
difference for genotype distributions of SNPs in the promoter region of IL6 between the 
BCC cases and controls, while linkage disequilibrium was observed between the –174 and 
–597 alleles in the IL6 (12). 
3. IL-10 
Interleukin-10 (IL-10) is a major immunosuppressive cytokine that plays a critical regulatory 
role in several areas of the immune system. It contributes to immunosuppression in the 
tumor microenvironment and may render it permissive for infiltration of cancer cells. IL-10 
is upregulated in both melanoma (13-15) and non-melanoma skin cancer including BCC (2, 
16, 17). The presence of IL-10 in BCC is associated with the lack of expression of HLA-DR, 
ICAM-1, CD40 and CD80 and the inconsistent expression of HLA-ABC in BCC (17). BCC is 
regarded as an indolent (slow growing) cancer with limited metastatic potential. While IL-10 
expression by melanoma cells correlates with melanoma progression and development of 
metastatic competence (18), there is no clear correlation between IL-10 expression and tumor 
invasiveness of BCC. IL-10 can be detected by both aggressive BCC and nonaggressive BCC 
such as superficial BCC. However, there are discrepant results regarding IL-10 expression in 
superficial BCC. Urosevic et al. found that superficial BCC cells were uniformly negative for 
IL-10 expression at baseline and showed little change after imiquimod treatment (19). 
 
Fig. 1. IL-10 mRNA is expressed by tumor cells in basal cell carcinoma (blue/purple color, 
RT in situ PCR). 
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SNP in the promoter regions of IL-10 gene (IL10) is associated with the risk of BCC. IL10 –
1082G>A is detected in BCC (12), and this polymorphism, as well as tumor necrosis 
factor-alpha (TNF-α) gene TNF –308G>A polymorphism, is more prevalent in aggressive 
BCC (20). However, others reported that there was no significant association between 
BCC and IL10 –1082 (11). 
4. CXCL12 and CXCR4 
CXCL12 (SDF-1) is a proinflammatory chemokine produced in response to inflammatory 
stimuli. This chemokine functions as a chemoattractant for lymphocytes. CXCL12 also plays 
an important role in tumor angiogenesis through binding to its receptor, CXCR4. CXCR4 
expression enhances tumorigenesis and angiogenesis in BCC. Such CXCL12-enhanced 
angiogenesis involves the ERK1/2 and NF-κB pathways mediated by IL-6 (8). CXCR4 is 
especially expressed in noduloulcerative and sclerosing types of BCC and is associated with 
more aggressive behavior (21). CXCL12 directs BCC invasion by upregulating gelatinase 
activity of matrix metalloproteinase-13 (MMP-13). The transcriptional regulation of MMP-13 
by CXCL12 is mediated by phosphorylation of ERK1/2 and c-Jun/AP-1 activation (22). 
CXCL12 also upregulates several angiogenesis-associated genes including interferon alpha-
inducible protein 27 (IFI27), bone morphogenetic protein 6 (BMP6) and cyclooxygenase 2 
(COX-2) (8).  
5. CXCL9, CXCL10, CXCL11 and CXCR3 
CXCL9 (MIG), CXCL10 (IP-10) and CXCL11 (I-TAC) are chemokines that are induced by 
interferon during inflammatory responses. These chemokines bind to a common receptor, 
CXCR3. They can promote chemotaxis of activated T cells and NK cells through binding to 
CXCR3. The most recent attention has been given to the role of these chemokines in 
tumorigenesis of BCC. It has been reported that CXCL9, CXCL10, CXCL11, and their receptor 
CXCR3 are significantly upregulated in BCC. CXCR3, CXCL10, and CXCL11, but not CXCL9, 
colocalize with keratin 17, which is a BCC keratinocyte marker. Exposure of BCC cells to 
CXCL11 in vitro enhances keratinocyte cell proliferation (23). CXCL9, CXCL10 and CXCL11 
promote expression of functional indoleamine 2,3-dioxygenase (IDO), which also colocalizes 
with keratin 17 (24). Thus, CXCR3 and its ligands may be important in tumorigenesis of BCC. 
6. IL-8 (CXCL8) 
Interleukin-8 (IL-8, CXCL8) is a chemokine produced by inflammatory cells and other cell 
types. This chemokine is one of the major mediators of the inflammatory response. It functions 
as a chemoattractant, but is also known as an angiogenic factor. IL-8 is associated with tumor 
angiogenesis in many solid tumors. It has been reported IL-8 is highly expressed in BCC (25). 
As described earlier in this chapter, IL-8 expression is associated with a significant increase of 
IL-6 expression in BCC (9, 10), and is positively correlated with IL-6 expression (10). However, 
the detailed mechanisms of IL-8 involved in the development of BCC are not fully understood. 
7. CCL27 
CCL27 is a chemokine that functions as a chemoattractant by interacting with its receptor, 
CCR10. This chemokine regulates T cell homing under homeostatic and inflammatory 
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conditions, and plays a role in T cell-mediated inflammation of the skin. In BCC, the 
downregulating of CCL27 expression is associated with tumor immune escape. A significant 
decrease in CCL27 expression is also observed in squamous cell carcinoma and actinic 
keratosis. These skin tumors may evade T cell-mediated antitumor immune responses by 
down-regulating the expression of CCL27 through the activation of epidermal growth factor 
receptor (EGFR)-Ras-MAPK-signaling pathways (26). 
8. IFN-γ 
Interferon-gamma (IFN-γ) is a cytokine that is critical for immune responses against cancer. 
IFN-γ binding to the receptor activates the JAK-STAT pathway. In BCC, The expression of 
IFN-γ receptor is significantly decreased on the cancer cells compared with the overlying 
epidermis. The absence or paucity of IFN-γ receptor and the absence of intercellular 
adhesion molecule-1 (ICAM-1) may explain the lack of tumor-infiltrating cells and the lack 
of an active cell-mediated immune response in BCC (27). 
On the other hand, Th1 cytokines including IFN-γ play a role in spontaneously regressing 
BCC. Some cases of BCC may show spontaneous regression in the absence of therapy. Such 
spontaneous regression is mediated by activated CD4+ T cells, and IFN-γ is elevated in 
actively regressing BCC (28). There is a significantly increased number of CD4+ T cells 
infiltrating regressing tumors, and the expression of IL-2 receptor, which is an early 
activation marker for T cells is also increased (29). Abundant CD8+ T cells and interferon 
signal transduction is associated with partial host antitumor response (2).  
Imiquimod has been shown to be efficacious as a topical treatment for BCC. Imiquimod is a 
Toll-like receptor 7 (TLR7) agonist, which induces interferon and other cytokines through 
the immune system and stimulates innate and adaptive cell-mediated immunity. Clinical 
studies have demonstrated clinical and histological clearance of superficial BCC after 
treatment with imiquimod 5% cream (30-32). Imiquimod treatment is associated with the 
early appearance of lymphocytes and macrophages. This early response tends to be a mixed 
cellular response of CD4 cells, activated dendritic cells and macrophages, with later 
infiltration by CD8 T cells (33). Application of imiquimod induces a cascade of Th1 
cytokines including IFN-α, TNF-α, IL-1α, IL-12, and IFN-γ, with profound effects on innate 
and adaptive immunity and on immunologic memory and antigen presentation. IFN-γ is 
produced by CD4 and CD8 T cells. IFN-γ is associated with the enhanced expression of 
ICAM-1, promoting the influx of immune cells. Imiquimod treatment also induces a massive 
increase in macrophage peritumoral and intratumoral infiltration (19). Thus, the TLR7-
agonist plays an important role in inducing a lymphocytic infiltrate by promoting specific 
Th1 cellular immune response capable of eliminating cancer cells (34). 
9. FasL (CD95L) and Fas (CD95) 
Fas ligand (FasL, CD95L) belongs to the tumor necrosis factor (TNF) family. FasL binds to 
its receptor, Fas (CD95), and induces apoptosis. Apoptosis via FasL/Fas pathway plays an 
important role in the regulation of the immune system. FasL expressed by cacncer cells 
induces apoptosis of infiltrating lymphocytes and they can evade immune surveillance, 
contributing to cancer progression. BCC has been reported to lack Fas expression (19, 35), 
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while they commonly retain the expression of FasL (36). In normal skin, Fas is expressed by 
keratinocytes in the basal layer. Fas expression is up-regulated in chronically sun-damaged 
skin. Actinic keratosis does not express Fas. Squamous cell carcinoma focally expresses Fas 
at the sites of contact with lymphocytes (35).  
It has been suggested that BCC can evade host immune surveillance by expressing FasL (37). 
However, different results were obtained for the FasL expression in BCC (19, 38, 39), and the 
issue of FasL expression in BCC is still debatable. After imiquimod treatment, the infiltrating 
cells demonstrate an increase in Fas/FasL expression, while Fas expression by BCC cells 
remains unaffected and FasL expression demonstrates either an increase or a decrease in 
different cases (19). After intralesional IFN-α treatment, BCC cells become Fas-positive with 
signs of tumor regression as a result of tumor cell apoptosis (36). Thus, Fas/FasL pathway 
may be associated with tumor regression by such treatments. 
 
Substance Alternative name Receptor Action 






IL-10  IL10RA (CDw210a); IL10RB (CDw210b) Immune suppression 
CXCL9 MIG CXCR3 (CD183) Tumorigenesis 
CXCL10 IP-10 CXCR3 (CD183) Tumorigenesis 
CXCL11 I-TAC CXCR3 (CD183) Tumorigenesis 
CXCL12   SDF-1 CXCR4 (CD184) Tumor angiogenesis; stromal invasion  
CCL27 CTACK, ILC,  ESKine CCR10 
Immune escape by down-
regulation of CCL27 
IFN-γ  IFNGR1 (CD119); IFNGR2 
Tumor regression; immune 
escape by down-regulation 
of IFN-γ receptor 
FasL CD95L Fas (CD95) Immune escape 
 
Table 1. Cytokines and chemokines in the pathogenesis of Basal Cell Carcinoma. 
 




There is much more work to be done in order to adequately characterize the clinical 
significance of cytokines, chemokines and related molecules in BCC. Studies thus far show 
that the factors described in this chapter play an integral role in BCC development and 
immunosuppression. A better understanding of these interactions may facilitate 
development of more potent immune-based treatment for BCC. 
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1. Introduction 
Basal cell carcinoma (BCC) is the most common skin malignancy, accounting for up to 80% 
of all cancers arising from the epidermis.1 The disease usually presents as a slow growing, 
non-healing raised lesion with rolled borders and telangiectasias. These cancers arise from 
cells lining the deepest layer of the epidermis. BCC affects approximately 1 million 
Americans each year, more than squamous cell carcinoma and melanoma combined.2 It is 
most commonly diagnosed in older, fair skinned individuals from ages 40-60.3 Large 
amounts of sun exposure and UV radiation are the most common cause of BCC. Other 
etiologies include arsenic and various genetic disorders such as Nevus Sebaceous of 
Jadassohn, Xeroderma Pigmentosum, Basal Cell Nevus syndrome, Bazex syndrome, and 
Rombo syndrome. 
An overwhelming majority of BCCs occur on the face or ear, but other likely sites include 
the neck, scalp, and upper trunk. Classically, it clinically presents as a pearly, non-healing, 
papulonodular lesion with rolled borders and telangiectasias, with or without ulcerations. 
These lesions are typically slow growing, minimally invasive, and thus have a very 
favorable prognosis. Surgical excision has long been considered the gold standard of 
treatment.4 
2. Incidence 
Since non-melanoma skin cancers are not reported in most cancer registries, it is hard to 
determine the exact yearly incidence of BCC. In a study by Miller et al.,5 the age-
                                                 
1Rubin, AI., Chen, EH., & Ratner, D. (2005). Basal-Cell Carcinoma. New England Journal of Medicine, Vol. 
353, No. 21, (November 2005), pp. 2262-2269. 
2Basal Cell Carinoma. n.d. In: Skin Cancer Foundation, May 2011, Available from: 
http://www.skincancer.org/basal-cell-carcinoma.html 
3Chuang, TY., Popescu, A., Su, WP., & Chute, CG. (1990). Basal cell carcinoma: a population-based 
incidence study in Rochester, Minnesota. Journal of the American Academy of Dermatology, Vol. 22, No. 3, 
(March 1990), pp. 413-417. 
4Bader, RS. (March 2011). Basal Cell Carcinoma, In: Medscape Reference, April 2011, Available from:  
http://emedicine.medscape.com/article/276624-overview 
5Miller, DL. & Weinstock, MA. (1994). Nonmelanoma skin cancer in the United States: incidence. Journal 
of the American Academy of Dermatology, Vol. 30, No. 5.1, (May 1994), pp. 774-778 
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standardized yearly rates in the United States have been estimated at up to 407 cases of BCC 
per 100,000 white men and 212 cases per 100,000 white women. The yearly incidence is 
estimated to range between 900,000 and 1,200,000 cases per year with the trend towards an 
increasing number of cases each year. The estimated lifetime risk of BCC in the white 
population is 33-39% in men and 23-28% in women. In a population study of people 
younger than 40 years, the incidence of BCC per 100,000 persons was 25.9 for women and 
20.9 for men.6  
While the lifetime risk of BCC is high, it is well known to physicians that metastasis is 
relatively rare.4 Using the criteria proposed by Lattes and Kessler in 1951, studies have 
indexed a metastasis rate of 0.0028-0.5%.7 The proposed criteria for the diagnosis of 
metastatic BCC include: 
1. The primary tumor must arise in the skin and not the mucous membranes 
2. Metastases must be demonstrated at a site distant to the primary and must not be 
related to simple extension. 
3. Histologic similarity between the primary tumor and the metastasis must exist. 
4. The metastases must not have squamous cell features. 
In a study by Wadhera et al., the currently published rate of metastasis was found to be 
higher than the reported numbers seem to show.8 Using an incidence of 1 million cases per 
year in the United States and a metastasis rate of 0.0028%, there should be at least 30 cases of 
metastatic basal cell carcinoma (MBCC) per year. They report that this number conflicts with 
the number of cases reported to date. Dating back to 1894, when Beadles reported the first 
case of MBCC in a 56-year-old male, there have been around 300 reported cases, or an 
average of 3 cases of MBCC per year over 100 years. This discrepancy supports the idea that 
the current estimation of the rate of metastasis is incorrect and reporting of this disease in all 
cancer registries would be of great benefit.  
3. Risk factors 
3.1 Clinical 
Several studies have tried to elucidate the clinical risk factors for metastasis. It is thought 
that primary tumors in the head and neck region have a higher metastatic potential; up to 
85% of primary BCCs that metastasize originate from these regions.9 Primary tumors arising 
                                                 
6Christenson, L., Borrowman, T., Vachon, C., Tellefson, M., Otley, C., Weaver, A., & Roenigk, R. (2005). 
Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. Journal of 
the American Medical Association, Vol. 294, No. 6, (August 2005), pp. 681–690. 
7Lattes, R., & Kesser, RW. (1951). Metastasizing basal-cell epithelioma of the skin – Report of two cases. 
Cancer, Vol. 4, No. 4, (July 1951), pp. 866-878. 
8Wadhera, A., Fazio, M., Bricca, G., & Stanton, O. (2006). Metastatic basal cell carincoma: A case report 
and literature review. How accurate is our incidence data? Dermatology Online Journal, Vol. 12, No. 5, 
(September 2006), pp. 7. 
9Malone, JP., Fedok, FG., Belchis, DA., & Maloney, ME. (2000). Basal cell carcinoma metastatic to the 
parotid: report of a new case and review of the literature. Ear Nose & Throat Journal, Vol. 79, No. 7, (July 
2000), pp.511–515, 518–519. 
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from the face alone account for at least two-thirds of metastatic BCC.10 This may be related 
to the high concentration of blood vessels and thin skin around these areas.11  
Tumors with any of the following characteristics have been thought to be high risk for 
metastatic potential: long duration, location in the mid face or ear, diameter larger than 2cm, 
aggressive histological subtype, previous treatment, neglected, or history of radiation.12 
There is a 2% incidence of metastasis for tumors larger than 3cm in diameter. The incidence 
increases to 25% for tumors larger than 5cm in diameter and 50% for tumors larger than 
10cm in diameter.1 Increased of tissue invasion and extension of the tumor into adjacent 
anatomical structures also enhance metastatic potential.1 The male to female ratio is about 
2:1.13 Immunosuppression and evidence of perineural spread or invasion of blood vessels 
have also been implicated as risk factors for metastasis.14 
3.2 Histopathologic 
While clinical risk factors remain the most widely studied, others have tried to elucidate 
histopathologic risk factors associated with MBCC. BCC is made up of 5 major histological 
subtypes which include nodular, superficial, micronodular, infiltrating, and morpheaform. 
While nodular is thought to be the most common subtype,15 there is no evidence that 
supports a particular subtype predisposes to MBCC.16 
The concept of stromal dependence for primary tumor survival was first proposed in 1953 
by Pinkus.17 Several years later, this concept has proven to be applicable to metastatic 
tumors as well.18 In a study with nude mice, successful transplantation of tumors occurred 
                                                 
10Grimwood, RE., Glanz, SM., & Siegle, RJ. (1988). Transplantation of human basal cell carcinoma to 
C57/Balb/Cbg/bg-nu/nu (nude) mouse. The Journal of Dermatologic Surgery and Oncology, Vol. 14, No. 
1, (January 1988), pp. 59-62. 
10Snow, SN., Sahl, W., Lo, JS., Mohs, FE., Warner, T., Dekkinga, JA., & Feyzi, J. (1994). Metastatic basal 
cell carcinoma. Report of five cases. Cancer, Vol. 73, No. 2, (January 1994), pp. 328-335. 
11Cotran, RS. (1961). Metastasizing basal cell carcinomas. Cancer, Vol. 14., No. 5, (September-October 
1961), pp. 1036-1040. 
12Randle, HW. (1996). Basal cell carcinoma. Identification and treatment of the high-risk patient. 
Dermatologic Surgery, Vol. 22, No. 3, (March 1996), pp. 255-261. 
13von Domarus, H. & Stevens, PJ. (1984). Metastatic basal cell carcinoma. Report of five cases and review 
of 170 cases in the literature. Journal of the American Academy of Dermatology, Vol. 10, No. 6, ( June 1984), 
pp.1043-1060. 
14Robinson, JK. & Dahiya, M. (2003). Basal cell carcinoma with pulmonary and lymph node metastasis 
causing death. Archives of Dermatology, Vol. 139, No. 5, (May 2003), pp. 643-648. 
15Sexton, M., Jones, DB., & Maloney ME. (1990). Histologic pattern analysis of basal cell carcinoma. 
Study of a series of 1039 consecutive neoplasms. Journal of the American Academy of Dermatology, Vol. 23, 
No. 6.1, (December 1990), pp. 1118-1126. 
16Berlin, JM., Warner, MR., & Bailin, PL. (2002). Metastatic basal cell carcinoma presenting as unilateral 
axillary lymphadenopathy: report of a case and review of the literature. Dermatologic Surgery, Vol. 28, 
No. 11, (November 2002), pp. 1082-1084. 
17Pinkus, H. (1953). Premalignant fibroepithelioma tumors of the skin. Archives of Dermatology, Vol. 67, 
No. 6, (June 1953), pp. 598-615. 
18Van Scott, EJ. & Reinertson, RP. (1961). The modulating influence of the stromal environment on 
epithelial cells studied in human autotransplants. The Journal of Investigative Dermatology, Vol. 36, Issue 
2, (February 1961), pp. 109-131. 
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when accompanied with its surrounding stroma.19 Other studies have failed to achieve 
successful transplantation when the tumors’ stroma was not included.20 Stromal 
dependency thus implies that either metastatic tumor cells are required to carry along their 
stroma or develop ways to support independent stromal proliferation in order to survive in 
a new location – perhaps explaining the low rate of metastasis.17 
3.3 Cellular 
Cytogenic aberrations have also been described in MBCC. Chromosomal abnormalities, 
specifically Trisomy 6, originating in primary tumor cells have been implicated as a factor in 
giving BCC its metastatic potential. In a study by Nangia et al., Trisomy 6 was identified in 
metastatic tumors cells of all four cases reported.21 In addition, all twenty cases of 
nonaggressive BCCs showed no tumor cells with Trisomy 6 abnormalities. 
Immunohistochemical markers such as p53, Ki-67, and Bcl-2 can be helpful in differentiating 
aggressive versus non-aggressive BCCs.22,23 Unfortunately, they have not proven to be 
distinguishing factors between metastatic and non-metastatic BCCs.24 
4. Staging 
The American Joint Committee On Cancer (AJCC) staging manual groups non-melanoma, 
non-Merkel cell skin cancers, including BCC, along with over 80 different types of other 
tumors in the cutaneous Squamous Cell Carcinoma Staging System.25 As a result, the 
applicability of these guidelines to any individual cancer may be impaired. It is argued that 
some cutaneous tumors such as BCC do not require the staging needed for cutaneous 
squamous cell carcinomas, because of the infrequency of metastasis.26 Although full staging 
is unnecessary for the majority of BCCs, the identification of high-risk behaviors should 
indicate the need for more in depth evaluation and staging.  
                                                 
 
20Lyles, TW., Freeman, RG., & Knox, JM. (1960). Transplantation of basal cell epitheliomas. The Journal of 
Investigative Dermatology, Vol. 34, No. 6, (June 1960), pp. 353. 
21Nangia, R., Sait, SN., Block, AW., & Zhang, PJ. (2001). Trisomy 6 in basal cell carcinomas correlates 
with metastatic potential. Cancer, Vol. 91, No. 10, (May 2001), pp. 1927-1932. 
22Abdelsayed, RA., Guijarro-Rojas, M., Ibrahim, NA., & Sangueza, OP. (2000). Immunohistochemical 
evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and P53. Journal of 
Cutaneous Pathology, Vol. 27, No. 4, (April 2000), pp. 169–175. 
23Staibano, S., Lo Muzio, L., Pannone, G., Scalvenzi, M., Salvatore, G., Errico, ME., Fanali, S., De Rosa, 
G., & Piattelli, A. (2001). Interaction between bcl-2 and P53 in neoplastic progression of basal cell 
carcinoma of the head and neck. Anticancer Research, Vol. 21, No. 6A, (November-December 2001), pp. 
3757–3764. 
24Ionescu, DN., Arida, M., & Jukic, DM. (2006). Metastatic basal cell carcinoma: four case reports, review 
of literature, and immunohistochemical evaluation. Archives of Pathology and Laboratory Medicine, Vol. 130, 
No. 1, (January 2006), pp. 45-51. 
25Edge, SE., Byrd, DR., Compton, CC., Fritz, AG., Greene, FL., & Trotti, A., (Ed(s).). (2009) American Joint 
Committee On Cancer: Cancer Staging Manual, 7th edition, Springer, 978-0-387-88440-0, New York, NY, 
USA. 
26Warner, CL & Cockerell, CJ. (2011). The new 7th edition American Joint Committee On Cancer staging 
of cutaneous non-melanoma skin cancer: a critical review. American Journal of Clinical Dermatology, Vol. 
12, No. 3, (June 2011), pp. 147-154. 
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Based on current research, depth of invasion may be the most important tumor variable 
associated with prognosis (See Table 1). In a study by Rowe et al., the presence of either 
tumor thickness >4mm or depth of invasion ≥Clark level IV was found to be associated 
with an increased risk of recurrence by a factor of 2, as well as an increase in the risk of 
metastasis by a factor of 5.27 Similar to melanoma, there is evidence that Breslow thickness 
may be more important for determining prognosis in non-melanoma cutaneous carcinoma 
than Clark's level, although both are predictive of advanced disease. Additionally, while 
early studies identified Breslow thickness >4mm as predictive of aggressive behavior, 
subsequent studies have shown that a 2mm cutoff more appropriately stratifies low and 
high-risk lesions.26 
Primary tumor (T)*. 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Carcinoma less than 2cm in greatest dimension, with less than 2 high risk features** 
T2 Carcinoma greater than 2cm in greatest dimension, Or Tumor of any size with at least 2 high risk features** 
T3 Tumor invasion of the maxilla, mandible, orbit, or temporal bone 
T4 Tumor invasion of the skeleton (appendicular or axial) or with perineural involvement of the skull base 
*Excludes cutaneous squamous cell carcinoma of the eyelid. 
**High-risk features for the primary tumor (T) staging: Depth/invasion: >2mm thickness, Clark level 
≥IV, Perineural invasion. Anatomic location: Primary site ear, Primary site non-hair-bearing lip. 
Differentiation: Poorly differentiated or undifferentiated. From the American Joint Committee On 
Cancer 7th edition “Cutaneous Squamous Cell Carcinoma and Other Cutaneous Carcinomas.” 
Table 1. Primary Tumor (T) Staging. 
Perineural invasion has also been found to be a significant indicator of high-risk disease.1,28 
Although less commonly identified (only present in 5 percent of non-melanoma cutaneous 
carcinomas), there is some evidence that perineural invasion is associated with an increase 
in both the recurrence rate and the metastatic rate by a factor of 5.27 As perineural spread 
can be difficult to follow histologically and clinically, such tumors can spread much more 
prior to detection. The diagnosis of perineural invasion carries a generally dismal prognosis, 
as the 5-year mortality rate approaches 90%.28 
The 7th edition AJCC manual chose to include advanced tumor depth/invasion (defined as 
>2mm in thickness, ≥Clark level IV) among the high-risk features capable of upstaging a T1 
neoplasm. Overall, this represents an improvement over previous editions, as it allows for 
                                                 
27Rowe, DE., Carroll, RJ., & Day, CL Jr. (1992). Prognostic factors for local recurrence, metastasis, and 
survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality 
selection. Journal of the American Academy of Dermatology, Vol. 26, No. 6, (June 1992), pp. 976-990.  
28Garcia-Serra, A., Hinerman, RW., Mendenhall, WM., Amdur, RJ., Morris, CG., Williams, LS., & 
Mancuso, AA. (2003). Carcinoma of the skin with perineural invasion. Head & Neck, Vol. 25, No. 12, 
(December 2003), pp. 1027-1033. 
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the identification of a subset of lesions that, although small in size, nevertheless are likely to 
demonstrate aggressive clinical behavior.29,30 
The final high-risk feature identified in the 7th edition of the AJCC: Cancer Staging Manual 
guidelines is the location of the primary tumor on high-risk anatomic sites. This is based on 
evidence that lesions located on the lip and ear are more aggressive compared to tumors 
presenting on other locations throughout the body.31 These anatomic sites are associated 
with recurrence and metastatic rates between 10 to 25 percent. Similar to the previously 
mentioned high-risk variants, recognition of the increased risk associated with these sites. 
Warner and Cockerell feel that tumors located on the central face and dorsal hands and feet 
also should be considered high-risk sites.26 
Recurrent disease is a high-risk factor worth special discussion. Recurrent or persistent 
diseases are strong prognostic factors for metastasis.3,32 Recurrent or previously treated tumors 
tend to be more aggressive, less responsive to treatment, and associated with decreased 
survival (78% 5-year survival compared to 97% for primary lesions).33 Although rarely 
performed for Non-Melanoma Cutaneous Carcinoma, the current TNM staging system, 
denotes recurrent neoplasms with an “r” qualifier prior to TNM-specific designations For 
example, a locally recurrent tumor greater than 2cm in size, without evidence of lymph node 
involvement or metastasis would be staged as: rT2N0M0. As a result, a subset of high-risk 
lesions is clearly defined as such, and data collection for these tumors can be significantly 
enhanced. T3 tumors are now classified as those with bony extension to the mandible, maxilla, 
temple, or orbit whereas the T4 designation is reserved for perineural involvement of the skull 
base or bony extension to the axial or appendicular skeleton. 
Under the 7th edition of the AJCC Cancer Staging Manual guidelines (See table 2), 
metastasis to a single node less than 3cm in greatest dimension is defined as N1. The N2 
designation refers to either a single node 3–6cm in size, or multinodal disease where no 
individual node is greater than 6cm in size. Based on the specific pattern of nodal 
involvement, N2 is subcategorized into three separate groupings. Involvement of a single 
ipsilateral node is categorized as N2a, metastasis to multiple ipsilateral nodes as N2b, and 
involvement of contralateral or bilateral lymph nodes as N2c. The N3 designation is 
reserved for any lymph node greater than 6cm in greatest dimension, regardless of number 
of nodes involved. 
                                                 
29Lardaro, T., Shea, SM., Sarfman, W., Liegeois, N., & Sober, AJ. (2010). Improvements in the staging of 
cutaneous squamous-cell carcinoma in the 7th edition of the American Joint Committee On Cancer: 
Cancer Staging Manual. Annals of Surgical Oncology, Vol. 17, No. 8, (August 2010), pp. 1979–1980.  
30Buethe, D., Warner, C., Miedler, J., & Cockerell, CJ. (2011). Focus Issue on Squamous Cell Carcinoma: 
Practical Concerns Regarding the 7th Edition American Joint Committee On Cancer: Staging 
Guidelines. Journal of Skin Cancer, Vol. 2011, Article ID 156391, (2011), 9 pages. 
31Preston, DS. & Stern, RS. (1992). Nonmelanoma cancers of the skin. The New England Journal of 
Medicine, Vol. 327, No. 23, (December 1992), pp. 1649-1662. 
32Rowe, DE., Carroll, RJ., & Day, CL Jr. (1992). Prognostic factors for local recurrence, metastasis, and 
survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality 
selection. Journal of the American Academy of Dermatology, Vol. 26, No. 6, (June 1992), pp. 976-990.  
33Andruchow, JL., Veness, MJ., Morgan, GJ., Gao, K., Clifford, A., Shannon, KF., Poulsen, M., Kenny, L., 
Palme, CE., Gullane, P., Morris, C., Mendenhall, WM., Patel, KN., Shah, JP., & O'Brien, CJ. (2006). 
Implications for clinical staging of metastatic cutaneous squamous carcinoma of the head and neck based 
on a multicenter study of treatment outcomes. Cancer, Vol. 106, No. 5, (March 2006), pp. 1078-1083.  
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The distant metastasis designation of the 7th edition of the AJCC Cutaneous Squamous Cell 
Carcinoma staging system is unchanged from previous editions (See table 3). Importantly, 
there is no provision for classification of lymph node metastasis far removed from regional 
nodal basins as distant metastasis.26 
Regional lymph nodes (N). 
Nx Regional lymph nodes cannot be assessed.
N0 No regional lymph node metastases.
N1 Metastasis in a single ipsilateral lymph node, 3cm or less in greatest dimension. 
N2 Metastasis in a single ipsilateral lymph node, more than 3cm but not more than 6cm 
in greatest dimension; or in multiple ipsilateral lymphnodes, none more than 6cm in 
greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6cm 
in greatest dimension.
N2a Metastasis in a single ipsilateral lymph node, more than 3cm but not more than 6cm 
in greatest dimension.
N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6cm in greatest 
dimension.
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6cm in greatest 
dimension.
N3 Metastasis in a lymph node, more than 6cm in greatest dimension.
Table 2. Regional Lymph Node (N) Staging. 
                       Distant metastasis (M). 
M0 No distant metastasis
M1 Distant metastasis
Table 3. Metastasis (M) Staging. 
The staging groups offer reasonable stratification of patients based on prognosis (See table 
4). Briefly, T1 and T2 tumors are assigned Stage I and Stage II, respectively, Stage III 
includes all T3 or N1 tumors that do not meet criteria for Stage IV, and the presence of any 
T4, N2-3, or M1 designation is required for Stage IV classification.27 
                              Anatomic stage/prognostic groups. 
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage II T2 N0 M0




Stage IV T1 N2 M0
T2 N2 M0
T3 N2 M0
T Any N3 M0
T4 N Any M0
T Any N Any M1
Table 4. Staging Classification. 
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Cutaneous neoplasms that rarely metastasize, such as BCC, full staging is often unnecessary 
and perhaps should be mentioned in the staging guidelines as an exception.33 In other cases, 
although relevant, full initial evaluation of high-risk features may not be possible, as 
primary biopsies frequently involve only a small portion of the primary tumor, precluding 
accurate assessment. Moreover, surgeons and dermatologists need to alter their clinical 
practice and begin assessing for vertical depth of invasion. Other issues that need to be 
clarified include the definition of tumors of the lip and the histologic designation of “poorly 
differentiated” and “undifferentiated” neoplasms.30 However, the incorporation of these 
factors might be impractical for widespread use in clinical practice.1 
There is a single report of the use of sentinel lymph node biopsy in high-risk lesions.34 This 
approach would not detect any hematogenous spread, and so its role in the staging of the 
disease remains to be determined.  
5. Treatment 
Treatment for non-MBCC can be either surgical or nonsurgical. Surgical excision is generally 
curative with five-year cure rates of more than 99 percent for primary tumors not involving 
the head.35 For lesions involving the head, the five-year cure rate is 97 percent for lesions 
less than 6mm and 92 percent for lesions greater than 6mm. Other surgical options include 
Mohs micrographic surgery, curettage and electrodessication, and cryosurgery. In a 
Cochrane review of different treatment modalities, one study showed no significant 
difference between Mohs micrographic surgery and surgical excision in recurrence rates at 
30 months for high-risk facial BCCs.36  
Non-surgical options include radiotherapy, photodynamic therapy, and topical therapy. In 
one randomized control trial of surgery versus radiotherapy, surgery provided significantly 
better cure rates when compared to radiotherapy. 36 Radiotherapy has been shown to provide 
better cure rates when compared to cryosurgery. Imiquimod cream has shown promising 
early results but long-term data is lacking.36 With un-reviewed information available on the 
Internet and an un-regulated herbal therapeutic industry, patients will self-treat tumors with 
anecdotally supported alternative medicine.37 We discourage the use of these forms of 
treatment, especially within the current culture of practicing evidence-based medicine.38  
There are currently no established guidelines for the treatment of metastatic disease 
specifically because all forms of treatment thus far have provided dismal results in terms of 
morbidity and mortality. Primary BCC metastasizes usually via lymphatics, although it can 
also spread hematogenously. Metastasis most commonly occurs in regional lymph nodes, 
                                                 
34Harwood M, Wu H, Tanabe K, et al. Metastatic basal cell carcinoma diagnosed by sentinel lymph node 
biopsy. J Am Acad Dermatol 2005; 3:475-8. 
35Silverman, MK., Kopf, AW., Bart, RS., Grin, CM., & Levenstein, MS. (1992). Recurrence rates of treated 
basal cell carcinomas. Part 3: surgical excision. The Journal of Dermatologic Surgery and Oncology, Vol. 18, 
No. 6, (June 1992), pp. 471-476. 
36Bath-Hextall, FJ., Perkins, W., Bong, J., & Williams, HC. (2007). Interventions for basal cell carcinoma 
of the skin, In: Cochrane Database of Systematic Reviews, Issue 1, (January 2007), Art. No.: CD003412.  
37Laub, DR Jr. (2008). Death from metastatic basal cell carcinoma: herbal remedy or just unlucky? Journal 
of Plastic, Reconstructive, & Aesthetic Surgery, Vol. 61, No. 7, (July 2008), pp. 846-848. 
38McDaniel S, Goldman GD (2002) Consequences of using escharotic agents as primary treatment for 
nonmelanoma skin cancer. Archives of Dermatology Vol. 138, No.12, (December 2002), pp. 1593-6. 
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lung, and bone although there have been documented cases involving the spinal cord, 
parotid gland, skin, bone marrow, spleen, liver, adrenal glands, brain, dura mater, 
esophagus, heart, and kidney. The prognosis for these patients is poor with a mean survival 
time of only 8 months from the time at diagnosis.5 In cases where metastasis is only to 
lymph nodes, patients live up to an average of 3.6 years.39 There has been one reported case 
in which a patient lived 25 years after diagnosis.40 Median age at the first sign of metastasis 
is 59 years while the median interval between the onset of the primary tumor and the first 
sign of metastasis is 9 years.13 Systemic chemotherapy has been attempted with mixed 
results. Combinations of 5-fluorouracil, bleomycin, and methotrexate have been 
unsuccessful.41,42 However, there has been one case with a positive response to 
cyclophosphamide and cis-diamine dichloroplatinum in a patient with pulmonary 
metastasis.43 Cisplatin-based therapy has also been shown to be of benefit for patients with 
metastasis.44,45  
Surgical resection is recommended for isolated metastasis, as the results of systemic 
chemotheraputic treatment are generally not as promising. Ducic and Mara treated 
metastatic lesions to the parotid gland with parotidectomy with adjuvant radiation therapy 
with good results.46 Presentation with widely disseminated disease would not allow this 
approach, however. 
It has long been thought that treatment of primary cancers with radiotherapy can contribute 
to their metastatic potential, although there is no evidence to support this. In fact, the 
incidence of MBCC in patients treated primarily by radiotherapy is estimated to be 1 in 
25,000, which is much less than the incidence of MBCC in all patients with primary 
tumors.47 There have been, however, case reports in which radiotherapy has been found to 
be beneficial in the treatment of metastatic disease.48 In cases where clear surgical margins 
                                                 
39Raszewski, RL. & Guyuron, B. (1990). Long-term survival following nodal metastases from basal cell 
carcinoma. Annals of Plastic Surgery, Vol. 24, No. 2, (February 1990), pp. 170-175. 
40Lo, JS., Snow, SN., Reizner, GT., Mohs, FE., Larson, PO., & Hruza GJ. (1991). Metastatic basal cell 
carcinoma: report of twelve cases with a review of the literature. Journal of the American Academy of 
Dermatology, Vol. 24, No. 5.1, (May 1991), pp. 715-719. 
41Costanza, ME., Dayal, Y., Binder, S., Nathanson, L., Safai, B., & Good R.A. (1974). Metastatic basal cell 
carcinoma: Review, report of a case and chemotherapy. Cancer, Vol. 34, No. 1, (July 1974), pp. 230-235. 
42Bason, MM., Grant-Kels, JM., & Govil, CT. Metastatic basal cell carcinoma: response to chemotherapy. 
Journal of the American Academy of Dermatology, Vol. 22, No. 5, (May 1990), pp. 905-908. 
43Woods, RL. & Steward, JF. (1980). Metastatic basal cell carcinoma: report of a case responding to 
chemotherapy. Postgraduate Medical Journal, Vol. 56, No. 654, (May 1980), pp. 272-273. 
44Khandekar, J. (1990). Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: 
A report on two patients. Archives of Dermatology, Vol. 126, No. 12, (December 1990), pp. 1660. 
45Moeholt, K., Aagaard, H., Pfeiffer, P., & Hansen, O. (1996). Platinum-based cytotoxic therapy in basal 
cell carcinoma – a review of the literature. Acta Oncologica, Vol. 35, No. 6, (January 1996), pp. 677–682. 
46Ducic Y, Marra DE. Metastatic basal cell carcinoma Am J Otolaryngol. [Epub ahead of print] (October 
2010) 
47Christie, D. The benefit of radiotherapy in metastatic basal cell carcinoma. Australian and New Zealand 
Journal of Surgery, (July 1997), Vol. 67, No. 7, pp. 491–493. 
48Ozgediz, D., Smith, EB., Zheng, J., Otero, J., Tabatabai, Z., & Corvera, C. (2008). Basal cell carcinoma 
does metastasize. Dermatology Online Journal, Vol. 14, No. 8, August 2008, Article 5.  
Available at: http://dermatology-s10.cdlib.org/148/case_reports/bcc/corvera.html 
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may be difficult to obtain, radiotherapy can offer an advantage of tissue preservation in 
patients with large lesions through deep tissue penetration.  
More recently, a clinical trial with GDC-0449, a small-molecule inhibitor of smoothened 
homologue (SMO), has shown promising results. SMO is involved in activation of the 
hedgehog pathway that has been implicated in the development of BCC49 and various other 
cancers.50 In a phase 1 trial by Von Hoff et al., GDC-0449 was used to treat 33 patients with 
locally advanced or MBCC.51 Of the 15 patients with locally advanced disease, 60% of 
patients showed a good response. Of the 18 patients with metastatic disease, 50% of patients 
showed a good response. 
The management of patients with suspected metastasis often involves obtaining a CT or MRI 
scan to look for evidence of occult disease. Recently, a study using FDG-PET has proven to be 
effective in detecting subclinical disease in a man presenting with multiple primary cutaneous 
lesions.52 While further studies are required, FDG PET may prove to be more effective than 
both CT and MRI in the radiographic evaluation of suspected metastatic disease. 
6. Conclusion 
BCC generally follows a very predictable clinical course from the time of diagnosis to 
subsequent treatment. The standard of care is surgical excision, which provides excellent 
cure rates. Other methods of treatment include radiotherapy, photodynamic therapy, 
cryotherapy and topical chemotherapy.  
For patients with metastatic disease, morbidity and mortality remains exceedingly high. The 
biggest risk factors for metastasis are tumor size, depth, and recurrence. Primary tumors 
arising from the mid face and ears provide a majority of the cases of metastasis but this is 
also the case for non-metastasizing BCC. 
With the exception of platinum-based chemotherapeutic agents, combinations of most other 
forms of chemotherapy with radiation and/or surgery have not improved mortality rates. It 
is clear that the development of metastatic potential in BCC, like many cancers, is multi-
factorial in etiology. Research aimed at the clinical, histopathologic, and molecular 
characteristics of metastasis has helped us better understand the risk factors associated with 
such rare occurrences. As we further our understanding of the pathogenesis behind MBCC, 
more promising drugs such as GDC-0449 will be developed. 
                                                 
49Johnson, R., Rothman, A., Xie, J., Goodrich, L., Bare, J., Bonifas, J., Quinn, A., Myers, R., Cox, D., 
Epstein, E., & Scott M. (1996). Human homolog of patched, a candidate gene for the basal cell nevus 
syndrome. Science, Vol. 272, No. 5268, (June 1996), pp. 1668-1671. 
50Katoh, Y. & Katoh, M. (2009). Hedgehog target genes: mechanisms of carcinogenesis induced by 
aberrant hedgehog signaling activation. Current Molecular Medicine, Vol. 9, No. 7, (September 2009), pp. 
873-886. 
51Von Hoff, D., LoRusso, PM., Rudin, CM., Reddy, JC., Yauch, RL., Tibes, R., Weiss, GJ., Borad, MJ., 
Hann, CL., Brahmer, JR., Mackey, HM., Lum, BL., Darbonne, WC., Marsters, JC Jr., de Sauvage, FJ., & 
Low, JA. (2009). Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma. The New 
England Journal of Medicine, Vol. 361, No. 12, (September 2009), pp. 1164-1172. 
52Niederkohr, RD. & Gamie, SH. (2007). F-18 FDG PET as an imaging tool for detecting and staging 
metastatic basal-cell carcinoma. Clinical Nuclear Medicine, Vol. 32, No. 6, (June 2007), pp. 491-492. 
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The incidence of BCC will continue to increase over the years as the baby-boomer 
generation continues to age. Although the estimated rates of metastasis are low, there will 
still be a growing number of patients that will need treatment for this presently incurable 
disease. Physicians need to be aware of the poor prognosis that MBCC carries. Because 
adequate treatments are not available for metastasis, prevention should be practiced by all 
providers through vigilant monitoring of suspicious skin lesions and early surgical excision 
of primary tumor. 
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1. Introdcution 
Non-melanoma skin cancers, which include basal and squamous cell cancers, are the most 
common human cancers. Because of their relatively low metastatic rate and relatively slow 
growth these are frequently underreported. The high prevalence and the frequent 
occurrence of multiple primary tumours in affected individuals make non-melanoma skin 
cancers an important but underestimated public health problem. 
There has been a dramatic increase in the incidence of non-melanoma skin cancer in the past 
40 to 50 years, despite the awareness of the harmful effects of excessive sun exposure. A 
population-based study from Wales has shown that the crude incidence for non-melanoma 
skin cancer has increased from 173.5 to 265.4 per 100,000 population per annum between 
1988 and 1998 (Holme et al, 2000, Br J Dermatol).  
Although ultraviolet radiation is the most important risk factor in the genesis of both 
squamous cell carcinomas and basal cell carcinomas, there is a proportionately greater effect 
of increasing sun exposure on the risk of developing squamous cell carcinoma (Kricker et al, 
1995, Int J Cancer). The desirability of a tan, increased leisure time and the introduction of 
cheap package holidays have resulted in a marked increase in the levels and change of 
pattern of sun exposure in the last 4 to 5 decades and this is thought to have led to an 
increase in the incidence of NMSC. 
Basal cell carcinomas (BCC) which are the commonest cancer in Caucasians are slow 
growing tumour which, rarely metastasize. Their incidence is increasing by ~10%/year 
worldwide indicating that the prevalence of this tumour will soon equal that of all other 
cancers combined (Karagas et al, 1995, Skin cancer: Mechanisms and human relevance). 
Furthermore, 40-50% of patients will develop at least one more within 5 years.  
UV radiation is the major aetiological agent in the pathogenesis of BCC and an 
understanding of its effects on the skin is clearly critical. However, though exposure to UVR 
is essential, its relationship with risk is unclear and epidemiological studies suggest its 
quantitative effect is modest. For example, a large European case-control study has shown 
only a two-fold increase in risk with increased exposure (Rosso et al, 1996, Br J Can) while 
recent studies suggest that intermittent rather than cumulative exposure is more important 
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(Kricker, 1995, Int J Cancer). The relationship between tumour site and exposure to UVR is 
also unclear. The distribution of lesions does not correlate well with the area of maximum 
exposure to UVR in that BCC are common on the eyelids, at the inner canthus and behind 
the ear, but uncommon on the back of the hand and forearm. Indeed, compared with 
squamous cell cancer (SCC), BCC are relatively more common on less exposed sites such as 
the trunk. Thus, though exposure to UVR is critical, patients develop BCC at sites generally 
believed to suffer relatively less exposure. The basis of the different susceptibility of skin at 
different sites to BCC development is not known, but may be related to the association of 
BCC with intermittent UV exposure. 
Surgery remains the mainstay in the treatment of BCC. However, with a better 
understanding of the aetiopathogenesis and the relatively non- aggressive nature of these 
lesions, newer forms of destructive and non- destructive treatments are a focus of research. 
Induction of apoptosis, modulation of differentiation and immunomodualtion are some of 
the strategies by which some of the current pharmacotherapeutic agents exert their action. 
Unravelling the genetics of BCC will provide a basis for further research on the introduction 
of pharmacogenetics and development of newer agents targeting the specific genes 
implicated in the causation of BCC.  
Chronic irritation, inflammation and injury to the skin can predispose to malignant 
epithelial neoplasms, in particular squamous cell carcinomas (Kaplan, 1987, Adv Derm). 
Examples include complicated scars from frostbite, electrical injury, chronic sinuses or 
fistulas, chronic osteomyelitis, chronic stasis dermatitis, and scars following various 
cutaneous infections. 
The most often reported dermatoses complicated by cancer are discoid lupus 
erythematosus, scarring variants of epidermolysis bullosa, genital lichen sclerosus et 
atrophicus, its variant balanitis xerotica obliterans and lichen planus. 
Lupus vulgaris, a chronic form of cutaneous tuberculosis is complicated by squamous cell 
carcinoma or less commonly basal cell carcinomas in up to 8% of the patients (Betti et al 
2002, Hautarzt, Forstrum et al, 1969, Ann Clin Res ). Squamous cell cancers can also arise 
from lesions of erythema ab igne, a characteristic dermatosis resulting from repeated or 
prolonged exposure to infrared radiation, insufficient to produce a burn (Peterkin,  
1955, BMJ). 
There is strong evidence that Photochemotherapy (PUVA) increases the risk of developing 
squamous cell carcinoma and this correlates with the cumulative dose of ultraviolet A. High 
dose PUVA (more than 200 treatments) is associated with a 14- fold increase in the risk of 
NMSC compared to low dose PUVA (Stern et al, 1998 Arch Dermatol). Arsenic is an 
important chemical carcinogen implicated in the development of non-melanoma skin 
cancer. In the first half of the 20th century, this was caused by the ingestion of medicinal 
arsenic in the form of medications for asthma and psoriasis. Mining and well water which is 
high in arsenic are the main sources today.  
Patients who have received a renal transplant have a 50-250-fold increased risk of 
developing squamous cell carcinoma and a 5 -10 fold increase in the risk of developing basal 
cell carcinoma implicating anti-tumour immunity (McGregor et al, 1995, Lancet, Bouwes 
Bavinck , 1995, Hum Exp Toxicol). Moreover, there is a close association between the 
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development of non-melanoma skin cancer and premalignant lesions such as actinic 
keratoses and the presence of viral warts in these patients (Bouwes Bavinck , 1995, Hum Exp 
Toxicol). Actinic keratoses are hyperkeratotic lesions occurring on chronic light exposed 
adult skin, and carry a low risk of progression to invasive squamous cell carcinoma. Lesions 
are usually multiple and comprise of macules or papules with a rough scaly surface resulting 
from disorganised keratinisation and a variable degree of inflammation. Although the rate of 
progression of individual squamous cell carcinoma has been estimated to be less than 0.1%, 
the presence of actinic keratoses is an important marker of excessive UV exposure and 
increased risk of non-melanoma skin cancer (Salasche, 2000, J Am Acad Dermatol) 
Mucosal lesions such as leukoplakias are also known to be premalignant with 2-5 % 
becoming malignant in 10 years (Crispian, 2004, Rooks textbook of Dermatology, Blackwell 
publishing). Bowen’s disease is a form of intraepidermal squamous cell carcinoma, which 
presents as a persistent, non-elevated, red, scaly or crusted plaque and carries a small 
potential of invasive spread. Most studies suggest a risk of invasive cancer of about 3%. 
There is a significant frequency of multiple lesions and an association of Bowen’s disease 
with other skin cancers, which may reflect predominant solar aetiology or, in some cases 
exposure to arsenic. Genital, especially perianal Bowen’s disease has a higher risk of 
invasive malignancy.  
Various studies indicate that the risk of skin cancer may be related to the overall amount 
of immunosupression (Jensen , 1999, Science, Bouwes Bavinck ,1996, Transplantation, 
Dantal , 1998, Lancet). Skin cancers are the most common malignancies that occur in 
transplant patients and their frequency increases with time after transplantation (Penn, 
1993,Hematol Oncol Clin North Am). The normal SCC/BCC ratio as observed in normal 
population is reversed in transplant recipients, with an excess in SCC development (Ong 
et al, 1999, J Am Acad Dermatol, Barr et al, 1989, Lancet) Moreover, these tumours behave 
more aggressively with a higher risk of metastasis than in general population (Penn , 
1991,Transplant Proc). 
Patients receiving renal transplant from HLA –B antigen mismatched donors, are at a higher 
risk of developing SCC, which is thought to be related to more intense immunosupression 
which these patients receive (Bouwes Bavinck et al 1991,N Engl J Med.). SCC in transplant 
patients develop mostly on sun exposed sites (Bavinck et al 1993,Br J Dermatol.) and are 
more frequent in individuals with fair skin, blue eyes, and blonde and red hair (Bavinck et al 
1993,Br J Dermatol., Euvrard et al 1995, J Am Acad Dermatol, McLelland et al 
1998,Transplantation.); the standard risk factors for development of SCC. Early diagnosis 
and treatment of squamous cell cancers is important to avoid metastasis and tissue 
destruction as these cancers are more invasive and have a higher metastatic spread 
compared to basal cell cancers. 
2. SCC predisposing syndromes 
2.1 Xeroderma pigmentosum 
An autosomal recessive disease characterised by elevated sensitivity to sunlight, multiple 
epidermal skin cancers in childhood as a consequence of increased susceptibility to DNA 
damage and abnormal DNA repair. In vitro, cells from XP patients show a decreased ability 
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to conduct base excision repair in which single strand areas of DNA are excised and 
replaced with a new set of bases after sunlight induced damage. 
2.2 Albinism 
Partial or complete failure to produce melanin in the skin and the eyes. SCC and melanoma 
develop in sun exposed sites of most individuals at an early age. (Lookingbill et al 1995, J 
Am Acad Dermatol.) 
2.3 Muir Torre syndrome 
Germ line mutations in genes involved in DNA mismatch repair and microsatellite 
instability result in this autosomal dominant syndrome characterised by the presence of one 
or more sebaceous neoplasms in association with internal malignancy, most frequently of 
the colon. SCC have also been described in these patients. 
2.4 KID (Keratosis, Icthyosis, Deafness) 
Invasive SCC developing within dysplastic lesions have been reported in several patients 
suffering from this syndrome (Madariaga et al, 1986,Cancer).  
2.5 Dystrophic epidermolysis bullosa 
Recessive dystrophic epidermolysis bullosa (RDEB) is an autosomal recessive mechano-
bullous disorder caused by mutations in the human type VII collagen gene (COL7A1). 
Individuals with DEB lack type VII collagen and anchoring fibrils, structures that attach 
epidermis and dermis. The leading cause of death in RDEB is invasion and metastasis of 
cutaneous SCC. Although the SCC in RDEB are frequently well-differentiated by 
histopathology, they often have a poor prognosis due to multicentricity, rapid invasiveness, 
and development of distant metastases. Mutations in the p53 tumor suppressor gene and loss 
of p16ink4a through hypermethylation have been seen in cutaneous SCC from these patients 
(Arbiser et al, 2004, J Invest Dermatol). This suggests that alterations in both p53 and p16ink4a 
can contribute to SCC in RDEB. Patients with RDEB have also been found to have elevated 
levels of b fibroblast growth factor, which may contribute to increased fibroblast collagenase 
and the development of SCC (Arbiser et al, 1998, Mol Med). Reduced expression of IGFBP-3, as 
seen in SCC associated with RDEB, has been suggested as a likely reason for the aggressive 
behaviour and poor prognosis of these tumors (Mallipeddi et al, 2004, J Invest Dermatol). 
2.6 Fanconi anaemia 
Fanconi anemia is an autosomal recessive disorder characterized by congenital 
malformations, bone marrow failure, and the development of SCC and other cancers. 
Environmental factor such as human papillomavirus (HPV) may be involved in the 
pathogenesis of SCC in Fanconi anemia patients (Kutler et al 2003, J Natl Cancer Inst). HPV 
DNA was isolated in 84% of the SCC specimens from the patients with Fanconi anaemia and 
a large proportion of patients with Fanconi anemia and SCC were homozygous for Arg72, a 
p53 polymorphism that may be associated with increased risk for HPV-associated human 
malignancies (Kutler et al 2003,J Natl Cancer Inst). 
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2.7 Rothmund Thompson syndrome 
Rothmund-Thomson syndrome (RTS) is a rare autosomal recessive genodermatosis 
characterized by early onset of progressive poikiloderma including alopecia, dystrophic 
teeth and nails, juvenile cataracts, short stature, hypogonadism, bone defects and several 
other cutaneous and extracutaneous findings. Most (but apparently not all) cases of RTS are 
caused by null or hypomorphic mutations in the RECQL4 gene, a putative DNA helicase. A 
role for RECQL4 in the repair of DNA double-strand breaks by homologous recombination 
has been suggested (Petkovic et al, 2005 J Cell Sci). Several cases of skin malignancies 
including SCC have been described in RTS patients, indicating a higher incidence of 
cutaneous malignancies (Piquero-Casals et al 2002,Pediatr Dermatol).  
2.8 Werner syndrome 
Werner syndrome is a genetic disorder of early ageing, excess cancer risk, high incidence of 
type II diabetes mellitus, early atherosclerosis, ocular cataracts, and osteoporosis. The 
protein encoded by the defective gene, WRN (WRNp) associates with 3'-5'-exonuclease and 
ATPase activities. Werner syndrome protein (WRN) is a RecQ-type DNA helicase, which 
seems to participate in DNA replication, double-strand break (DSB) repair, and telomere 
maintenance. A deficiency in maintaining DNA integrity is thought to be a consequence of 
the defective DNA helicase. In vivo alterations of oxidative stress parameters in WS patients 
have been demonstrated which may cause oxidative damage to biomolecules, with multiple 
oxidative stress-related alterations, resulting in multi-faceted clinical consequences (Pagano 
et al, 2005, Biogerontology, Pagano et al, 2005, Free Radic Res). 
2.9 Other syndromes 
These include hereditary non-polyposis coli, dyskeratosis congenita, Huriez syndrome and 
chronic mucocutaneous candidiasis. 
3. Candidate susceptibility genes 
The concept of genetic susceptibility to BCC and SCC is complex as genes may influence 
susceptibility as well as tumour numbers, rate of appearance and site. Selection of putative 
susceptibility genes must be in part subjective though the varied effects of UVR suggest that 
candidate genes may be selected from those involved in DNA repair, defence against 
oxidative stress, immune modulation, tanning and other related biochemical activities. 
Although sunlight plays a crucial role in the development of SCC and to a lesser extent BCC, 
there is enough evidence that this is process is multifactorial with contributions from genetic 
and environmental factors. Several genes have been implicated in providing protection 
against and modifying the effects of UV radiation. It is also understood that UV is both 
mutagenic and locally immunosuppressant, thereby implying a huge pathogenic potential. 
3.1 DNA repair  
Signature UV-DNA lesions, cyclobutane dimers and 6-4 photoproducts, are repaired via the 
nucleotide excision repair pathway which may be subdivided into transcription-coupled 
repair and global genome repair. The XPC protein is specific to this latter repair pathway 
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recognizing helix distorting lesions and initiating their repair. Inactivating XPC mutations 
are associated with xeroderma pigmentosa and an extremely high risk of skin cancer. Most 
early research on DNA repair and skin cancer was performed in patients with xeroderma 
pigmentosum (XP), a rare autosomal recessive syndrome in which multiple skin tumours 
are seen. Reduced capacity to repair DNA was observed in XP cells (Cleaver et al, 1969, Proc 
Natl Acad Sci USA). Early in life, homozygote XP patients develop severe photosensitivity 
and a 2,000-fold increased risk of skin cancer.  
A common polymorphism in intron 9 of the XPC gene has been associated with both 
reduced repair of UV-DNA damage and increased risk of squamous cell head and neck 
cancer. It has been reported that PAT+ polymorphism may slightly modify the risk of SCC 
among individuals with a phenotype which results in low UV-DNA adduct burdens 
(Nelson et al, 2005, Cancer Lett). The XPD is another gene involved in the nucleotide 
excision repair pathway removing DNA photoproducts induced by UV radiation.  
Genetic variation in XPD may exert a subtle effect on DNA repair capacity with an  
inverse association between the Lys751Gln and Asp312Asn polymorphisms and the  
risks of melanoma and squamous cell carcinoma (Han et al, 2005, Cancer Epidemiol 
Biomarkers Prev).  
UVA-induced oxidative DNA damage and blocked DNA replication by UVB-induced 
photoproducts can lead to double-strand breaks (DSBs). DSB repair genes XRCC2, XRCC3, 
and LigaseIV were evaluated for their associations with skin cancer risk. (Han et al, 
2004,Cancer Res). XRCC3 18085T (241Met) allele and its associated haplotype were 
significantly inversely associated with the risks of SCC and BCC (Han et al, 2004, Br J 
Cancer) The XRCC1 gene is also involved in the base excision repair pathway.  
The 399Gln allele was inversely associated with SCC risk in those who had five or more 
lifetime sunburns, those with a family history of skin cancer, and those in the highest tertile 
of cumulative sun exposure in a bathing suit (Han et al 2004, Cancer Res.). There was  
also a significant association of the carriage of 194Trp allele with increased SCC risk,  
which was modified by family history of skin cancer (Han et al, 2004, Cancer Epidemiol 
Biomarkers Prev). 
In sporadic BCC, DNA repair capacity below the upper 30th percentile was associated with a 
2.3 fold increase in BCC relative risk. However, some studies have reported increased repair 
in BCC patients and so batch variability and the effects of age, family history of skin cancer 
and current sun exposure may confound results (Hall et al 1994, Int J Cancer). At least two 
types of XP are caused by defects in DNA helicases that are involved in nucleotide excision 
repair and in transcription. Werner and Bloom syndromes are hereditary skin cancer 
disorders that are associated with helicase defects but curiously not with the development of 
BCC’s (Yu Ce et al, 1996, Science, Ellis et al, 1995, Cell). Rothmund-Thomsen syndrome, which 
in some cases is caused by defects in a DNA helicase (Kitao et al, 1999, Nat Genet) does seem 
to predispose to BCC (Wang et al, 2001, Am J Med Genet). This tissue specific effect of 
helicases is poorly understood. Also, other forms of genomic instability disorders including 
the chromosome breakage disorders like ataxia telangiectasia and Nijmegen breakage 
syndrome and disorders with p53 gene mutations like Li Fraumeni syndrome (Malkin et al, 
1990, Science) or dyskeratosis congenita, a disorder associated with failure to maintain 
telomeres (Knight et al, 1999, Am J Hum Genet, Vulliamy T, 2001, Nature) are not causally 
associated with BCC. 
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3.2 Chemical detoxication 
While exposure to UVR is accepted as a critical causative factor in the pathogenesis of BCC, 
the magnitude of the risk associated with increased exposure appears to be insufficiently 
large to explain the considerable phenotypic diversity demonstrated by patients in terms of 
tumour numbers, site and patterns of presentation.  
UVA and UVB radiation cause indirect damage to DNA by inducing oxidative stress 
(Griffiths et al, 1998, Crit Rev Clin Lab Sci). Reactive oxygen species thus produced, interact 
with lipids, proteins and DNA to generate intermediates that combine with DNA to form 
adducts (Lear et al, 2000, Br J Dermatol). 
The authors have focused on the extensive clinical diversity following initial presentation, 
demonstrated by patients to identify subgroups that are associated with different risks of 
developing tumours. Two phenotypes are particularly important; firstly, presentation with 
clusters of BCC. These patients, termed multiple presentation phenotypes (MPP), had 2-5 
BCC at one presentation and comprised 15% of our study group of 1200 BCC patients. A 
minority of patients demonstrated multiple clustering events, a phenomenon that appears to 
be strongly associated with a genetic pre-disposition (Ramachandran et al, 1999, Cancer 
Epidemiol Biomarkers Prev; Ramachandran et al, 2000, Cancer).  
The second risk phenotype, characterized by tumours on the trunk, is also associated with 
a pre-disposition. These patients are important as there is evidence that different 
mechanisms mediate development of BCC on this, compared with other sites. For 
example, patients whose first tumour was truncal had more BCC than other patients 
(mean 2.4 vs. 2.0 tumours), were significantly younger at first presentation and developed 
more clusters of BCC than cases who did not develop truncal tumours. First presentation 
with a truncal tumour is associated with significantly more subsequent BCC on this site 
compared with cases with an initial head and neck lesion (Ramachandran et al, 2001, 
Cancer). These data suggest the development of a truncal BCC is not random but rather is 
associated with a pre-disposition. In contrast, the rate of increase of non-truncal 
BCC/year was similar in patients with and without initial truncal lesions suggesting 
different mechanisms determine the development of truncal and non-truncal BCC 
(Ramachandran et al, 2001, Cancer). 
Both the MPP and truncal phenotypes were characterized by a susceptibility to develop 
numerous BCC. All patients with more than 5 BCC had one or both of these phenotypes.  
The GST supergene family offers protection against cytotoxic and mutagenic effects of 
electrophiles generated by UV induced oxidative stress. This is achieved by conjugation of 
glutathione to electrophiles. GSTM1 catalyses the conjugation of 4-hydroxynonenal and 
linoleic acid hydroperoxide, products of lipid peroxidation (Kerb et al, 1997, J Invest 
Dermatol). It also catalyses the conjugation of DNA hydroperoxide (Kerb et al, 1997,J Invest 
Dermatol), a product of DNA oxidation, 5 hydroxymethyluracil , a mutagenic compound 
formed by either oxidative attack on the methyl group of the thymine base of DNA or from 
deamination of products formed by the oxidation of 5-methylcytosine (Boorstein at al 1989, 
Nucleic Acids Res. Lear JT et al 2000,Br J Dermatol). The GSTM1 and GSTT1 have been 
shown to be associated with the development and accrual of basal cell carcinoma (Lear et al 
1996, 1997, Carcinogenesis), raising the possibility of an association with SCC as well. Indeed, 
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GSTM1 gene has been shown to be associated with actinic keratoses, supporting the 
possibility of its implication in SCC (Carless et al, 2002, J Invest Dermatol.). 
The authors have examined the role of polymorphism in genes encoding detoxifying 
enzymes such as glutathione S-transferases (GST) and cytochrome P450s (CYP). The CYP 
supergene family comprise over 30 isoforms, which catalyse the biotransformation of a 
range of xenobiotics, often as the first of a two-phase detoxication. The resultant potentially 
highly reactive intermediate is then a substrate for phase two enzymes including members 
of the GST supergene family. The GSTs can also catalyse the detoxication of the products of 
oxidative stress (e.g. lipid and DNA hydroperoxides). Cytosolic GST activity in mammalian 
tissues is due to the presence of multiple GST isozymes, which can be assigned to 8 classes, 
e.g. α, θ, µ, π σ,, and  (Hayes et al, 1995, Crit Rev Biochem Mol). In human skin, the π class 
of GST is the predominant isozymes and is found predominantly in sebaceous glands (Raza 
et al, 1991, J Invest Dermatol). GST- π has been suggested to be an oncofetal protein that is 
expressed during carcinogenesis (Moscow et al, 1998, Proct Natl Acad Sci USA). Several 
polymorphisms in GST family members exist (Hayes et al, 1995, Crit Rev Biochem Mol Biol; 
Pemble , 1994,Biochem J) and have been associated with impaired detoxification, thus 
influencing the risk for several cancers, including non-melanoma skin cancer (Heagerty et al, 
1994, Lancet; Heagerty , 1996, Br J Cancer). 
A GSTT1 null genotype is associated with high UV sensitivity (Kerb et al, 1997 J Invest 
Dermatol) and we have shown that a GSTM1 null genotype also predisposes for BCC, 
probably due to its role in defence against UV induced oxidative stress (Learet al, 1997, 
Carcinogenesis; Lear, 1996,Carcinogenesis). Polymorphism of GSTM3 was also shown to 
increase the risk for multiple BCC (Yengi, 1996, Cancer Res). Polymorphism in cytochrome 
p450 CYP2D6 has also been associated with susceptibility as well as tumour numbers 
(together with vitamin D receptor and tumour necrosis factor alpha). In the case of multiple 
clustering, associations between the CYP2D6 EM genotype and risk demonstrated 
particularly large odds ratio (OR=15.5) (Ramachandran et al, 1999, Cancer Epidemiol Biomarkers 
Prev; Lear et al, 1996, Carcinogenesis). 
3.3 Immunological effects  
Though the role of UVR in the pathogenesis of skin tumours has been extensively studied, 
several reports have suggested that the resultant tumours are, at least in mice, highly 
immunogenic and regress on transfer to non-exposed hosts. This implies that the immune 
status of the UVR irradiated skin is compromised in those who develop tumours (Granstein, 
1996, Photochem Photobiol). These findings are explained by data showing that exposure to 
UVR results in a cascade of events including a T-lymphocyte-mediated immunosuppression 
(Kripke, 1994, Cancer Res; Streilein 1993, J Invest Dermatol). The extent of the 
immunosuppression appears, to some degree, dose-dependent. Studies on the mechanism 
of this effect have concentrated on two chromophores; DNA and urocanic acid, both of 
which can result in altered expression of several cytokines including tumour necrosis factor 
alpha (TNF-), interleukin (IL-)10, IL-1/, IL-3, IL-6, IL-8, IL-10, granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and nerve growth factor. This results in an alteration 
from a T helper 1 (Th1) to a suppressive T helper 2 (Th2) response (Granstein, 1996, 
Photochem Photobiol; Kripke, 1994, Cancer Res; Streilein 1993, J Invest Dermatol) thereby 
inhibiting the ability of antigen presenting cells to induce anti-tumour immunity. In a pilot 
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study, we found in 133 patients with multiple BCC, the TNF allele haplotype a2b4d5 
significantly influenced BCC number (mean BCC number; 8.1 vs. 3.7 in other allele 
combinations) (Hajeer et al, 2000, Br J Dermatol). Further support for the role of the immune 
system in the pathogenesis of skin cancer came from the finding that HLA-DR4 is associated 
with multiple BCC (Czarnecki et al, 1993, Dermatology) but this has been disputed (Rompel et 
al, 1995, Rec Res Canc Res). Interestingly, there is a possible link between GST and immune 
modulation in non-melanoma skin cancer with studies showing a link between contact 
hypersensitivity to dinitrochlorobenzene (a substrate for GST) and squamous cell carcinoma 
(and non-significantly with BCC) (de Berker , 1995, Lancet). Furthermore, GSTM1 and GSTT1 
genotypes have been shown to influence inflammatory response following UVR exposure, a 
finding possibly reflecting the link between oxidative stress and eicosanoid mobilisation. 
3.4 Immunosuppression 
The critical role of immunomodulation in skin cancer susceptibility is further supported by 
data showing immunosuppressed transplant patients are at considerably higher risk of both 
BCC and SCC than the general population. SCC of the skin is the most common malignancy 
occurring in the setting of solid organ transplantation and immunosuppression, and its 
incidence increases substantially with the extended survival after transplantation (Otley et al, 
2000, Liver Transpl). SCC occurs more frequently in transplant patients (Ondrus et al, 1999, Int 
Urol Nephrol) whereas in the general populations BCC is three to six times more frequent 
than SCC (Barrett et al, 1993, Cancer). It was shown in heart transplant recipients that the 
number of skin cancers is significantly correlated with both age at transplantation and 
duration of follow –up (Ong, 1999, J Am Acad Dermatol). In Europe, 40% of renal transplant 
recipients develop skin cancer within 20 years after grafting, (Hartevelt et al, 1990, 
Transplantation). Heart transplant recipients are at a higher risk than kidney transplant 
recipients, most probably due to the fact that they receive higher doses of 
immunosuppression agents (Euvrard et al, 1995, J Am Acad Dermatol) but it cannot be 
overlooked that the different types of immunosuppressive agents have different effects in 
this respect. Immunosupression as practised after organ transplantation does not increase 
the risk of developing BCC to the same extent as SCC. The incidence of BCC seems not to be 
affected by PUVA treatment. A diminished response to skin application of 
dinitrochlorobenzene was found in people with SCC but not in patients with BCC, again 
supporting the notion that the incidence of BCC is not affected by immune status to the 
same extent as SCC (de Berker et al, 1995, Lancet).  
3.5 Human Immunodeficiency Virus 
People suffering from aquired immunodeficiency syndrome (AIDS) have shown an elevated 
risk for the development of BCC (Franceschi et al, 1998, Br J Cancer; Ragni et al, 1993, Blood). 
Human Immunodeficieny virus (HIV) patients with BCC more frequently show blue eyes, 
blonde hair, family history and extensive prior sun-exposure (Lobo et al, 1992, Arch 
Dermatol). The pigmentation phenotype is probably an independent risk factor that adds to 
the increased risk of BCC conferred by the immunosuppression. There have been some 
reports of BCC’s metastasising in people suffering from AIDS, (Steigleder, 1987, Z Hautkr; 
Sitz, 1987, JAMA) suggesting that immune surveillance is one of the factors determining the 
normally metastatic nature of the BCC. Why immunosuppression by HIV increases the risk 
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of BCC, where as pharmaceutical immunosuppression does not is not clear. The depletion of 
CD4 lymphocytes by HIV may lead to a more pervasive defect in adaptive antitumour 
immunity that does mere functional suppression by commonly used immunosuppressive 
compounds. 
3.6 Human Leukocyte Antigen (HLA) haplotypes 
The major histocompatibility complex (MHC) genes code for membrane protein that play 
important roles in controlling immune responses (Benacerraf, 1981, Science). There are two 
classes of genes, class I (HLA-A, -B, -C) and class II (HLA-DR, -DP and DQ) which play a 
role in host defence against the development and spread of tumours (Dausset et al, 1982, 
Cancer Surv). For example, loss of class 1 antigens is related to tumour progression in 
melanomas (Ruiter, 1984, Cancer Res). Furthermore, abnormalities in cell- mediated 
immunity have been reported in patients with multiple BCC (Myskowsky et al, 1981, J Am 
Acad Dermatol) whereas normal skin shows high levels of class 1 molecules, BCC shows 
either complete absence or heterogeneous expression (Cabrera et al, 1992, Immunobiol). All 
class I –negative tumours were histologically proven to be aggressive, whereas all non-
aggressive BCC’s were class I positive. The low levels or absence of expression of class I 
antigens may result in escape from recognition by cytotoxic T cells, which then facilitates 
tumour growth. (Garcia- Plata, 1991, Inv Met). The presence of HLA – DR7 and decrease of 
HLA-DR4 are significantly associated with BCC (Bouwes Bavinck, 2000, Arch Dermatol). HLA 
–DR4 is decreased in BCC, especially in patients with multiple BCC’s located on the trunk 
(Rompel et al, 1995, Rec Res Canc Res,). HLA-DR1 is weakly associated with the development 
of multiple BCC’s at an early age (Czarnecki et al, 1992, J Am Acad Dermatol). A correlation 
between HLA-A11 expression and skin cancer in immunosuppressed renal transplant 
recipients has been shown (Bavnick, 1990, N Engl J Med; Bouwes Bavnick, 1997, Australia J 
Invest Dermatol). One study showed that HLA –A11 was associated with resistance to skin 
cancer in renal transplant recipients, (Bavnick, 1990, N Engl J Med) while another study 
shows that renal transplant recipients with HLA – A11 had an increased risk for developing 
skin cancer (Bouwes Bavnick, 1997, Australia J Invest Dermatol). The apparent discrepancy may 
be the result of different genetic backgrounds and differential environmental factors. 
3.7 Human Papilloma Virus 
The life cycle of these species-specific DNA tumour viruses is inseparably linked to 
differentiation processes in pluristratified epithelia (Stanley et al, 1994, Ciba Found Symp). 
Mucosal HPV types 16, 18, 31 and 33 are strongly associated with the genesis of anogenital 
and cervical carcinomas (Bosch et al, 2002, J Clin Pathol). Following viral genome integration, 
E6 and E7 oncoproteins are overexpressed, with inhibition of apoptosis via p53 dependent 
and independent mechanisms (Thomas et al, 1999, Oncogene). E6 protein from the cervical 
associated HPC-16 mediates degradation of p53 (Black et al, 2003,Clin Exp Immunol). A 
common p53 polymorphism at position 72 replacing proline with arginine renders p53 more 
susceptible to E6 mediated degradation. The arginine allele was found to be a risk factor in 
the development of cervical cancers and there was also a significant association with 
cutaneous SCC development in renal transplant patients (Storey et al, 1998, Nature). 
Cutaneous HPV types 5 and 8 are associated with warty lesions and SCC in the sun exposed 
sites of patients with the rare inherited condition epidermodysplasia verruciformis. This led 
 
Genomics of Basal and Squamous Cell Carcinomas 
 
103 
to the proposal that these EV types may also be oncogenic. (Majewski et al, 1995, Arch 
Dermatol ). The mechanism by which EV associated HPV might contribute to the 
development of SCC remains unclear. Unlike oncogenic mucosal HPV, EV-HPV DNA 
persist extrachromosomally in cancers and EV associated E6 proteins are unable to abrogate 
apoptosis via the degradation of p53. (Elbel et al, 1997,Virology) Instead, BAK protein, a 
member of the Bcl- 2 family may be abrogated resulting in inhibition of apoptosis (Jackson et 
al 2000, Genes Dev). 
HPV DNA has been identified in over 80% of immunosuppressed and 30% of 
immunocompetent SCC patients and EV-HPV types are consistently overexpressed in 
immunosuppressed patients. (Harwood et al, 2002, Curr Opin Infect Dis, Pfister et al 2003, J 
Natl Cancer Inst Monogr.) The association between prevalence of EV-HPV infection and 
SCC risk has been further strengthened by seroepidemiological studies (Bouwes Bavinck et al 
2000, Br J Dermatol., Feltkamp et al, 2003, Cancer Res. Masini et al 2003,Arch Dermatol.). 
Furthermore, localisation of HPV DNA to malignant keratinocytes in SCC as well as EV-
HPV gene transcription in almost 40% of tumours has been found by in situ hybridisation 
technique, thus providing further evidence of the role of HPV in pathogenesis of SCC 
(Purdie et al 2005, J Invest Dermatol.). The presence of UV induced p53 mutations in 
cutaneous SCC contrasts with tumours induced by high-risk HPV types, which contain wild 
type p53. It is postulated that arginine allele of p53, perhaps in combination with UV 
induced mutation, is more susceptible to interference from particular HPV types and 
subsequent malignant transformation (Black et al, 2003,Clin Exp Immunol). HPV 77 has so 
far been detected in cutaneous lesions of renal transplant patients and contains a p53 DNA 
binding site. Besides inducing p53 mutations, sunlight may also be indirectly involved in the 
pathogenesis of SCC by causing activation of p53 and subsequent stimulation of HPV 77 
promoter activity (Purdie et al, 1999, EMBO J.). Other viruses suggested to increase 
susceptibility to SCC include HPV 20, HPV 27 (Ruhland et al 2001,Int J Cancer.) and human 
herpes virus type 1 (Leite et al 2005, Cancer Lett.).Although HPV has been associated 
strongly with malignant progression of warts to SCC and with epidermodysplasia 
verruciformis, (Galloway et al, 1989, Adv Virus Res) different oncogenic subtypes of the virus 
were found in 60% of BCC’s from immunosuppressed patients in contrast to 36% of BCC’s 
from non-immunosuppressed patients, suggesting that these viruses may be involved in the 
development of BCC (Shamanin et al, 1996, J Natl Cancer Inst). In renal transplant recipients 
with skin cancer, HPV 5 /8 DNA could be detected, (Barr et al, 1989, Lancet) and Weinstock 
et al (Weinstock et al, 1995, Arch Dermatol) suggested immunosuppression to be a factor in 
BCC carcinogenesis by affecting HPV infection. 
3.8 Delayed hypersensitivity 
Patients with large SCC were found to have defective systemic cell-mediated immunity as 
shown by reduced reaction to intradermal antigen, and low rate of sensitization to 
dinitrochlorobenzene (DNCB) (Weimar et al 1980, J Am Acad Dermatol.). Because GST 
metabolises DNCB and polymorphisms of GST are associated with multiple skin tumours, 
variations in GST may underlie these differences (de Berker et al, 1995, Lancet). The T cell 
levels and leukocyte migration test in preoperative patients with SCC were also found to be 
significantly lower than in the noncancer control population. (Avgerinou et al, 1985, 
Dermatologica.) 
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4. Germline and somatic mutations  
Carcinogenesis involves a stepwise progression from a normal to a malignant phenotype 
through an accumulation of genetic alterations to cellular proto-oncogenes, that stimulate 
cell proliferation and tumour suppressor genes (TSG) that inhibit this process. In tumours, 
mutation of proto-oncogenes results in expression of constitutively active proteins, whereas 
mutational inactivation of TSG leads to loss of protein function.  
4.1 p53 
p53 is a TSE that normally functions in cell-cycle arrest, DNA repair and apoptosis. It 
functions as a critical regulator of the cell cycle progression and programmed cell death in 
response to insults that damage DNA, such as UVR exposure (Natraj, 1995, Photochem 
Photobiol.). The p-53 gene encodes a phosphoprotein that is involved in cell-cycle control 
and maintenance of chromosomal stability (Katayama 2004, Nat Genet; Hollstein M, 1991, 
Science). The most common genetic aberrations in human skin cancers are found at the level 
of p53 gene expression (Kastan, 1991, Cancer Res). DNA strand breaks results in expression of 
p-53, which in turn stimulates p21 Cip1 expression, which binds and inhibits cyclin-
dependent kinases 2 and 4 resulting in G1 blockade of cell cycle progression. This inhibition 
of cell cycle progression allows for DNA repair before it is replicated in S phase to prevent 
retention of introduced mutations. In severe DNA damage, p53 induces BAX, which binds 
to BCL-2 and inhibits its antiapoptotic activity, resulting in programmed cell death. Thus, 
mutations would be retained in genomic DNA if p53 gene becomes inactivated, leading to 
clonal expansion and tumourigenesis.  
p53 gets activated in response to cellular stress through phosphorylation (Siliciano et al, 1997, 
Genes Dev, Caspari, 2000, Curr Biol). MDM2 associates with p53 and regulated its level of 
activity depending on the phosphorylation status of p53. Upon dephosphorylation, p53 
binds to MDM2 and is degraded through the ubiquitin-proteasome pathway (Kubbutat et al, 
1997, Nature, Haupt et al, 1997, Nature)  
The response to DNA damage is growth, senescence or apoptosis (Vogt Sionov et al, 1999, 
Oncogene). The relative cellular content of p53 determines the response following DNA 
damage; when the content is low to moderate, cells will go into cell- cycle arrest to allow 
DNA repair, but when p53 levels are high, cells will progress to apoptosis (Ronen et al, 1996, 
Cell Growth Different). In response to DNA damage, p53 is phosphorylated by DNA damage- 
sensing proteins such as ATM and becomes detached from MDM2, resulting in stabilization 
and activation and of target genes regulated by p53 (Unger et al, 1999, EMBO J). In normal 
skin, wild type p53 is not detectable but appears within 2 hours after UV irradiation, with 
peak levels at 24 hours and again undetectable levels at 36 hours (Hall et al, 1993, Oncogene). 
Mutant p53 can accumulate in cells and p53 mutations have been detected in about half of 
all BCCs (Aeupemkiate et al, 2002, Histopathology, Demirkan et al, 2000, Pathol Oncol Res). 
Aggressive BCC are significantly associated with increased p53 expression, probably 
representing the mutated form. Despite the available evidence, the apparent limited 
contribution of DNA damage and chromosomal instability to the BCC phenotype means 
that the relevance of p53 mutations for BCC growth remains to be demonstrated as in the 
absence of genetic damage p53 activation does not occur. Moreover, one of the hallmarks of 
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p53 dysfunction, aberrant mitosis, has never been observed in BCC (Pritchard, 1993, Am J 
Dermatopathol). 
Patients with BCC, who were sunscreen users, had significantly lower level of p53 
mutations in their BCC as compared to non-sunscreen users (Rosenstein el al, 1999,Photochem 
Photobiol) suggesting that p53 mutations in BCC are secondary events. Inactivation of p53 
occurs predominantly by point mutation of one of the allele followed by loss of the 
remaining wild type allele (Knudson et al, 1985, Cancer Res). The p53 gene shows UV 
signature mutation, i.e. predominantly C(C) → T (T) conversions (Ziegler et al, 1993, Proct 
Natl Acad Sci USA, Wikonkal et al, 1999, J Invest Dermatol Symp Proc). In 33% of BCCs found in 
Korean patients, p53 mutations were detected (Kim, 2002, J Dermatol Sci) and up to 50% of 
the BCCs in Caucasian patients showed this mutation (Aeupemkiate et al, 2002, Histopathology, 
Demirkan, 2000, Pathol Oncol Res), suggesting that different ethnic factors play a role in BCC 
carcinogenesis, although differences in sun exposure may account for some of the observed 
differences. 
Thus, while it is known that p53 is involved in genome surveillance through the regulation 
of cell proliferation and death and is frequently inactivated in BCC (Rady et al, 1992 Cancer 
Res, Ziegler et al, 1993, Proct Natl Acad Sci USA), with up to 56% of tumours displaying 
mutation in the conserved region of one p53 allele, it has been suggested that p53 mutation is 
a crucial but late event in BCC progression (Van der Riet et al, 1994, Cancer Res). BCC also 
display a high level of LOH specifically at chromosome 9q22 suggesting the existence of a 
BCC TSG in this region (Quinn et al, 1994, Cancer Res). 
Up to 90% of cutaneous SCC lesions have UV induced signature mutations such as 
formation of thymidine dimers in the p53 gene, resulting in uncontrolled proliferation of 
keratinocytes (Brash et al, 1991, Proc Natl Acad Sci U S A, Ziegler, 1994, Nature). 
Overexpression of p53 co-relates with sun-exposure (Coulter et al 1995, Hum Pathol. Liang , 
1999, Virchows Arch.) and mutant p53 has been observed to accumulate in the cell 
cytoplasm, probably due to increased half-life of the protein (Dowell et al 1994, Cancer Res, 
Soussi , 2000, Ann N Y Acad Sci. ). Indeed, sunlight- induced mutations are found in p53 in 
actinic keratoses, the precancerous lesion of for SCC. In addition, it has been shown that 
mutations at particular p53 codons are present in sun exposed normal human skin and UV 
irradiated mouse skin (Ziegler et al, 1994, Nature. Nakazawa et al, 1994, Natl Acad Sci U SA, 
Jonason et al, 1996, Proc Natl Acad Sci U S A.) 
Sunlight has been shown to be a tumorigenic mutagen and tumour promoter by favouring 
the clonal expansion of p53 mutated cells. The role of UV in carcinogenesis is also supported 
by the observation that most human precancers (Marks et al, 1986, Br J Dermatol.) and UV 
induced clusters of p53 overexpressing cells in mouse skin (Berg et al 1996, Proc Natl Acad 
Sci U S A ) regress in the absence of continued exposure. The dermal-epidermal junction and 
hair follicles are the locations of the presumed stem cells in skin (Lavker et al 1993, Recent 
Results Cancer Res.) and appear to be the source of tumours in experimental animals (Miller 
et al,1993, J Invest Dermatol.). It is therefore thought that normal sun exposed skin carries a 
substantial burden of keratinocyes predisposed to cancer (Jonason et al, 1996, Proc Natl 
Acad Sci U S A.). The ubiquitin proteasome pathway rapidly degrades wild type p53 in 
normal tissue (Maki et al 1996, Cancer Res.). Thus, high level of p53 expression is seen in 
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cutaneous SCC and other tumours in contrast to the low levels found in non-malignant 
tissue.  
Clonal expansion of p53 mutated cell would be favoured if a p53 mutation confers 
resistance to apoptosis resulting from UV exposure (Ziegler A, 1994,Nature). Such 
resistance would allow sunlight to act as tumour promoter by killing normal cells and 
sparing the mutants (Ziegler A, 1994,Nature.). After surviving irradiation, these mutant 
cells could then clonally expand into vacated compartments (Jonason et al, 1996,Proc Natl 
Acad Sci U S A.). 
4.2 p63  
p63 is a p53 homologue that is mapped to chromosome 3q27. This gene encodes six different 
isoforms, which have either transactivating or dominant negative effects on p53-reporter 
genes. p63 is a reliable keratinocyte stem cell marker involved in the maintenance of the 
stem cell population . It is expressed in the nuclei of epidermal basal and suprabasal cells, 
cells of the germinative hair matrix and the external root sheath of hair follicles, basal cells of 
the sebaceous gland and in the myoepithelial /basal cells of the sweat glands. p63 has a 
nucleoplasmic distribution in the basal compartment of stratified epithelia such as skin, 
tonsil, bladder, and certain subpopulations of basal cells in prostate, breast, uterine cervix 
and bronchi (Wang et al, 2001, Hum Pathol; Quade et al, 2001, Gynaecol Onco; Di Como et al, 
2002, Clin Cancer Res). All terminally differentiated cells stain negative for p63. The p63 is 
restricted to cells with high proliferation and absent from cells undergoing terminal 
differentiation (Parsa et al, 1999, J Invest Dermatol). p63-deficient mice have striking 
developmental defects such as absence or truncation of limbs, absence of hair follicles, teeth 
and mammary glands, and the skin lacks stratification and differentiation (Mills et al, 1999, 
Nature). This indicates that p63 is essential for several aspects of differentiation during 
embryogenesis. Several isoforms of p63 can bind to p53 consensus sequences and activate 
p53 target genes. p63 is only rarely mutated in BCC ( Little et al. , 2002, Int J Biochem Cell Biol 
). p63 functions not only as a stem cell marker of keratinocytes but also maintain the stem 
cell phenotype. In keeping with its basal localisation in normal epidermis, BCC cells express 
p63 (Di Como et al, 2002, Clin Cancer Res, Dellavale et al, 2002, Exp Dermatol). It was shown 
that aberrant expression of p63 altered the UVB induced apoptotic pathway that down 
regulation of this protein in the response to UV irradiation is important in epidermal 
apoptosis (Liefer et al, 2000, Cancer Res). 
Although it has been described that in contrast to p53, p63 seems not to be associated with 
tumor predisposition, as neither p63 knockout mouse models nor germline p63 mutations 
are related to an increased risk of tumourigenesis; its role in the pathogenesis of SCC is 
becoming more convincing. Using immunohistochemistry techniques undifferentiated cells 
of grade III SCCs showed strong positivity for p63 (Reis-Filho et al 2002, J Cutan Pathol.). 
The SCCs in situ showed remarkable expression of p63 in all cell layers. Terminally 
differentiated squamous cells were either negative or showed only focal immunoreactivity 
in the carcinomas. p63 is consistently expressed in the basal cells of epidermis and 
cutaneous appendages, including the basal/myoepithelial cells of sweat glands. These 
probabilities favour that p63 might play a role in the pattern of differentiation and in the 
oncogenesis of usual carcinomas of the skin (Reis-Filho et al 2002, J Cutan Pathol.). 
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4.3 PTCH  
A major breakthrough in understanding BCC tumourigenesis came from the study of 
patients with Nevoid Basal Cell Carcinoma Syndrome (NBCCS) an autosomal dominant 
disease whose symptoms include developmental abnormalities and a predisposition to 
multiple BCC. The disease is linked to chromosome 9q22, which harbours the PTCH gene 
where inactivating germline mutations have been found in these patients (Hahn et al, 1996, 
Cell; Johnson et al, 1996, Science). Somatic PTCH mutation has also been described in sporadic 
BCC (Azsterbaum et al, 1998, J Invest Dermatol, Gailani et al. 1996, Nat Genet). In accordance 
with a tumour suppressor mechanism for PTCH, loss of the wild type allele has been 
demonstrated in BCC from both NBCCS patients and in up to 68% of sporadic BCC (Gailani 
et al. 1996, Nat Genet). 
Although most SCC carry a mutation in the p53 gene, they have also been shown to display 
PTCH mutations (Ping et al, 2001,J Invest Dermatol.) and allelic loss of PTCH gene 
(Ahmadian et al 1998,Oncogene.) and an increased incidence of SCC has been observed in 
UV irradiated heterogeneous PTCH knock out mice (Aszterbaum et al, 1999, Nat Med). The 
introduction of wild-type PTCH into human SCC lines that express mutant PTCH has been 
shown to suppress their oncogenic potential (Koike et al 2002, Oncogene). These finding 
implicate the role of PTCH in development of SCC in addition to its established association 
with the development of BCC (Asplund et al 2005, Br J Dermatol.) However, the association 
between PTCH and cutaneous SCC development remains controversial as a previous 
investigation of the PTCH status in cutaneous SCC failed to identify mutations on such 
cases (Eklund et al 1998, Mol Carcinog). Consistently, PTCH LOH has not been found to be 
as frequent in SCC, indicating a lesser importance of PTCH gene in SCC development 
(Asplund et al 2005, Br J Dermatol.) 
4.4 Hedegehog signalling and BCC development 
PTCH is the human homologue of the Drosophila patched (ptc) gene which encodes Ptc 
protein. Ptc a part of a receptor for the diffusible morphagen Hedgehog (Hh). In Drospophila 
Hh signalling is essential for the control of segment polarity during development. Hh is 
expressed in the Hensen node, the floorplate of the neural tube, the early gut endoderm, the 
posterior limb buds and throughout the notochord, and encodes a signal responsible for 
patterning the early embryo (Kim et al, 2002, J Dermatol Sci, Bodak et al, 1999, Proc Natl Acad 
Sci USA, Bale et al, 2001, Hum Mol Genet). 
Ptc negatively regulates Hh signalling through inhibition of a transmembrane signalling 
protein Smoothened (Smo). There is some evidence that Ptc may influence the localisation or 
intramembrane conformation of Smo (Sprong et al, 2001, Nat Rev Mol Cell Biol). Binding of 
Hh to Ptc releases Smo inhibition leading to intracellular signalling involving Costal-2, 
Fused and Suppressor of Fused proteins (Stone et al, 1999, J Cell Sci). This leads to activation 
of GSK3β which stimulated the release of a transcription factor Cubitus interrruptus (Ci) 
that regulates the expression of important genes involved in Drosophila cell proliferation 
including dpp, wingless and ptc. The Hh signalling pathway is highly conserved, where it is 
involved in determining cell fate and organogenesis in different species including humans 
(Wicking et al, 1999, Oncogene). 
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In humans, it is thought that signalling operates in a similar fashion to that described in 
Drosophila. To date, disrupted expression of the human homologues of Hh (sonic hedgehog; 
SHH), Ptc (PTCH and PTCH2), Smo (SMOH) and Ci (GLI) have been demonstrated in BCC 
tumourigenesis. Overexpression of SHH in transgenic human skin induces features of BCC 
in mice (Fan, 1997, Nat Med, Oro et al, 1997, Science). Furthermore, SHH activating mutations 
have also been described in sporadic BCC (Oreo et al, 1997, Science). SMOH and GLI 
transgenic activation in mice leads to BCC-like cutaneous growths (Xie et al, 1998, Nature, 
Nilsson et al 2000 Proc Natl Acad Sci. USA). SMOH, GLI-1 and GLI-2 are frequently over 
expressed in BCC and SMOH activating mutations have also been described in 20% of 
sporadic BCC’s (Xie et al 1998, Nature; Kallassy, 1997 Cancer Res; Dahmane 1997, Nature; 
Grachtchou, ,2000, Nature Genet ). The consequences of deregulated Hh signalling are 
widespread, as the downstream targets of GLI transcription factors include WNT signalling 
(human homologue of wingless), TGFß (homologue of dpp) BMP2B and BCL-2 (Fan, 1997, 
Nature Med) and may also influence cell cycle control genes including p21WAF1 the D-type 
cyclins and cyclin E (Fan, 1999, J Cell Biol; Duman-Scheel , 2002, Nature).  
4.5 Melanocortin-1 receptor genotype 
As pigmentation influences NMSC risk, the identification of gene variants at the 
melanocortin-1 receptor (MC1R), which control the production of red pigmentation in 
Caucasian individuals, suggest that the allelic variation within this gene should likewise be 
associated with skin cancer risk (Box et al 2001,J Invest Dermatol.) Indeed, gene variations at 
this locus are important in determining susceptibility to melanoma, BCC, SCC and solar 
keratoses (Box et al 2001, J Invest Dermatol.). The association between MC1R variants and 
the propensity to develop solar lesions is mediated largely through three variants, 
Arg151Cys, Arg160Trp, and Arg294His, which are also associated with red hair, fair skin 
colour and tanning ability (Box et al 2001,J Invest Dermatol.). 
4.6 RAS mutations 
Although the role of TSG in the development of SCC is well established, evidence relating to 
the role of dominantly transforming oncogenes in the development of skin cancers is slow to 
emerge. Activating RAS mutations are the most common genetic abnormalities in human 
cancers. Following RAS mutation, MAPK mediated signalling and other pathways are 
activated, resulting in cell proliferation (Shields, 2000, Trends Cell Biol.). Activation of RAS 
oncogenes usually occurs by point mutations within specific codons of the H-RAS, N-RAS, 
and K-RAS genes. Activating H-RAS mutations were observed in 35% to 46% of SCC 
(Kreimer-Erlacher, 2001, Photochem Photobiol., Pierceall, 1991,Mol Carcinog.) and 12% of 
actinic keratoses (Spencer et al , 1995,Arch Dermatol.). Incidences and numbers of skin 
tumors were much greater in Hras128 rats (a transgenic rat line carrying 3 copies of the 
human c-Ha-ras proto-oncogene with its own promoter region) than in their wild-type 
counterparts (Park el al, 2004, Cancer Sci.) 
These data suggest that RAS mutations play an important role in the pathogenesis of SCC. 
4.7 CDKN2A 
The p16(INK4a) and p14(ARF) TSGs are encoded within the CDKN2A locus on 
chromosome 9p21 and function as cell cycle regulatory proteins in the p53 and RB 
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pathways. Loss of heterozygosity of 9p21 markers has been seen in some cases of SCC 
(Brown et al 2004). Mutational analysis has confirmed point mutations that changed the 
amino acid sequence of p16 (INK4a) and p14 (ARF). Promoter methylation of p16 (INK4a) 
and p14 (ARF) has also been detected. Absent protein expression was has been confirmed 
by immunohistochemistry in SCC with biallelic inactivating events. Overall, promoter 
methylation is the commonest mechanism of gene inactivation. Alterations at this locus are 
significantly more common in tumors from immunocompetent compared with 
immunosuppressed individuals (Brown et al 2004, J Invest Dermatol.). UV radiation-
induced mutations in INK4a-ARF have been demonstrated in XP-associated skin 
carcinomas. The simultaneous inactivation of p53 and INK4a-ARF may be linked to the 
genetic instability caused by XP and could be advantageous for tumour progression. 
4.8 Progression and initiation of BCC  
Exposure to UVR is significant in BCC formation and this is reflected in the p53 mutations 
identified; C-T and CC-TT transitions at di-pyrimidine sites. A third of the BCC displaying 
LOH at 9q reveal mutations to PTCH indicative of UVR exposure. However, most mutations 
to PTCH are not typical of exposure. Further, inactivation of the second PTCH allele through 
LOH is unlikely to be due to UVB (Gailani et al, 1996, J Natl Cancer Inst). In addition, ptc 
heterozygous knockout mice (ptc/ptc-) display features of NBCCs syndrome, these mice 
develop microscopic follicular neoplasms similar to trichoblastoma and 40% subsequently 
develop BCC. If exposed to ionising or UVR irradiation these neoplasms occur at a much 
earlier stage and there is a clear shift in histological features to BCC (Aszterbaum et al, 1999, 
Nature Med). Thus, whilst UVR exposure is critical to SCC development, it appears that in 
BCC, UVR exposure may be more important in modifying tumour progression. Further 
characterisation of the role of the Hh signalling pathway should provide new insights into 
BCC carcinogenesis. Identifying the mutations to these BCC genes and the relationship of 
these mutations to environmental carcinogens may explain the variation in phenotype of 
sporadic BCC. It is possible that mutations manifest different phenotypic effects depending 
on the genetic background of the patient (e.g. skin type, hair colour, GST genotype). Whilst 
gene mutation influences tumour development, we can speculate that inter-individual 
variation in genes that protect against exposure to environmental carcinogens may modify 
the effects of exposure to mutation in these target genes. Thus, we have found an increase in 
the incidence of tumour specific p53 mutation and expression in ovarian cancer patients 
with GSTM1 null genotype (Sarhanis et al 1996, Br J Cancer). In addition, CYP3A and CYP2D6 
activities and the GSTM1 null genotype have been associated with mutations to p53 and RB 
and are associated with aggressiveness in bladder carcinoma (Romkes et al, 1996, 
Carcinogenesis).  
5. Pharmacogenomics  
As discussed above, UV radiation induced oxidative stress and mutagenic DNA lesions 
formed by reactive oxygen species (ROS) are pivotal in the pathogenesis of SCC. Clinical 
treatments inducing chronic oxidative stress may therefore carry a risk of therapy-related 
cancer. Immunosuppression by azathioprine (Aza) has been proposed as one such 
treatment. Biologically relevant doses of ultraviolet A (UVA) generate ROS in cultured cells 
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with 6-thioguanine substituted DNA and 6-thioguanine and UVA are synergistically 
mutagenic (O'Donovan et al, 2005, Science.). 
Kidney transplant recipients receiving cyclosporine, azathioprine, and prednisolone have a 
significantly (2.8 times) higher risk of cutaneous SCC relative to those receiving azathioprine 
and prednisolone alone (Jensen et al, 1999, Am Acad Dermatol) suggesting a tumourigenic 
role of cyclosporine based immunosuppressive therapy. Both cyclosporine and ascomycin 
inhibit removal of cyclobutane pyrimidine dimers, and UVB-induced apoptosis (Yarosh et 
al, 2005, J Invest Dermatol.). UVB induces nuclear localization of the transcription factor 
nuclear factor of activated T-cells (NFAT), a process blocked by cyclosporine and ascomycin 
(Yarosh et al, 2005, J Invest Dermatol. ) These data suggest that the increased risk of skin 
cancer observed in organ-transplant patients may be as a result of not only systemic 
immune suppression but also the local inhibition of DNA repair and apoptosis in skin by 
calcineurin inhibitors(Yarosh DB et al, 2005, J Invest Dermatol.) 
Thus, cancer is an increasingly recognized problem associated with immunosuppression. 
However, in contrast to cyclosporine which protects allografts from rejection but promotes 
cancer progression in transplant recipients, immunosuppressive agent rapamycin has been 
found to simultaneously protect allografts from rejection and attacks tumors in a complex 
transplant-tumor situation (Koehl et al, 2004,Transplantation.). In vitro experiments have 
shown that cyclosporine promotes angiogenesis by a transforming growth factor-beta-
related mechanism, and that this effect is abrogated by rapamycin (Koehl et al, 2004, 
Transplantation.). Various surgical and non- surgical therapies are available for the 
treatment of BCC (Albright et al, 1982, J Am Acad Dermatol). In spite of the fact that surgical 
excision is still the most prominent therapy used, non –invasive therapies such as 
photodynamic therapy (PDT) (Thissen et al, 2000, Br J Dermatol), or topical application of 5-
fluorouracil (5-FU) (Miller, 1997, J Am Acad Dermatol) are currently becoming more and 
more interesting in selective cases, especially because of the improved cosmetic outcome.  
5.1 Induction of apoptosis 
Many currently used antineoplastic agents exert their therapeutic effects through the 
induction of apoptosis. Different cell types vary profoundly in their susceptibility, 
suggesting the existence of distinct cellular thresholds for apoptosis induction (Fisher, 1994, 
Cell). For example, BCC cells overexpressing IL-6 are resistant to UV irradiation and PDT – 
induced apoptosis (Jee et al, 2001, Oncogene). de novo p53 synthesis or stabilisation of p-53 is 
essential to induce apoptosis in BCC ( Jee et al, 1998, J Invest Dermatol). Overexpression of the 
antiapoptotic bcl-2 has also been linked to resistance of cancers to various chemotherapeutic 
drugs (Huang, 2000, Oncogene). In BCC, interferon (IFN)-α induces apoptosis and is thus 
effective in the treatment (Rodriguez- Villanueva et al, 1995, Int J Cancer). Untreated BCC cells 
express FasL but not the receptor, but in IFN-α - treated BCC patients, the tumour cells 
express both FasL and receptor, whereas the peritumoural infiltrate mainly consists of Fas- 
receptor- positive cells (Buechner, et al, 1997, J Clin Invest). Therefore, with IFN- α treatment, 
BCC most likely regress through apoptosis. 
The regression of tumours treated with 5-FU is probably caused by enhancing apoptosis in 
the tumour cells (Brash, 1998, Cancer Surveys). Apoptosis is involved in the regression of 
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actinic keratoses after PDT (Nakaseko et al, 2003, Br J Dermatol).This therapy is also used for 
treatment of BCC, (Kalka, 2000, J Am Acad Dermatol), where tumour cells may also undergo 
apoptosis. 
Phytochemicals known to induce apoptosis are also being applied in cancer prevention and 
therapy (Hoffman et al, 1999, Cancer and the search for selective biochemical inhibitors, CRC Press). 
In mice bearing skin tumours, tumour growth was inhibited by 70% after treatment with 
black tea, which was established by inhibition of proliferation and enhanced apoptosis (Lu et 
al, 1997, Carcinogenesis). Ajone, an organosulphur compound of garlic (Apitz- Castro et al, 
1988, Arznei-Mittelforschung) has been shown to induce apoptosis in human 
promyeloleukaemic cells (Dirsch, 1998, Mol- Pharmacol). Recently, it was shown that ajone 
can induce apoptosis in the human keratinocyte cell line HaCat and has a diminishing on 
BCC in vivo by down–regulating the expression of the apoptosis- suppressing protein Bcl-2 
(Tilli et al, 2003, Arch Dermatol-Res). A SHH antagonist, the Veratrum alkaloid cyclopamine 
(11-deoxojervine) can be used to treat BCC (Taipale et al, 2000, Nature). Interestingly 
cyclopamine binds directly to Smoothened, which explains its activity in tumours 
characterised by activated SHH pathways (Chen et al, 2002, Proc Natl Acad Sci USA). 
Interestingly its application to the surface of the tumour resulted not only in the rapid 
induction of apoptosis but also influenced the differentiation status 7 of 7 tumours (Tas et al, 
2004, Eur J Dermatol) 
5.2 Modulation of differentiation 
Systemic retinoids are frequently used for chemoprevention of cutaneous malignancies in 
organ transplant recipients (Chen et al, 2005, Br J Dermatol.). Retinoids (vitamin A 
metabolites and analogues) have been shown to have suppressive effects on tumour 
promotion when administered in high doses, and the mechanism appears to be associated 
with modulation of growth, differentiation and apoptosis (Lotan et al, 1996, Faseb J). 
Retinoids are most effective in patients with multiple previous non-melanoma skin cancers 
(Kovach et al, 2005,Clin Transplant.) Low-dose systemic retinoids significantly reduce SCC 
development in organ transplant recipients for the first 3 years of treatment, and this effect 
may be sustained for at least 8 years (Harwood et al, 2005,Arch Dermatol.) It has been shown 
that retinoic acid is effective in inhibiting telomerase activity in HSC-1 human cutaneous 
squamous cell carcinoma cells (Kunisada et al, 2005,Br J Dermatol. ).  
5.3 Immunomodulation 
Because BCCs often elicit a strong inflammatory response, recent studies have sought to 
evaluate the effects of immunomodulatory compounds. On of the most promising is 
imiquimod, a Toll- like receptor 7/8 agonist that enhances the endogenous cytokine 
response (INF- α, IL-10, TNF-) among others stimulating the T- helper 1 – mediated 
inflammatory responses. 
6. Conclusions/ future directions 
In the past decade, significant progress has been made, in understanding the molecular 
genetics of NMSC and the molecular pathways involving tumour suppressor genes and 
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oncogenes. Research into immune response to p53 had led to promising therapeutic 
potential. p53-specific cytotoxic T lymphocytes capable of mediating protective immunity to 
tumours have been generated in murine models (Black et al, 2003,Clin Exp Immunol.). 
Adoptive transfer of p53 specific cytotoxic T lymphocytes generated in p53-/- mice confers 
immunity on the recipient to p53 overexpressing murine tumour (Vierboom et al, 1997,J Exp 
Med.). As p53 is over expressed in cutaneous SCC, vaccination against p53 is a logical 
approach to induce tumour reactive immunity (Black et al , 2003,Clin Exp Immunol.) 
Vaccines used to induce p53 specific immune responses in mice have included, Canary pox 
virus vectors (Roth et al, 1996,Proc Natl Acad Sci U S A.), peptide pulsed dendritic cells 
(Mayordomo et al, 1996, J Exp Med. ), recombinant adenovirus transduced dendritic cells 
(Ishida et al, 1999, Clin Exp Immunol., Nikitina , 2002,Gene Ther.), recombinant DNA, 
(Petersen et al, 1999,Cancer Lett.) recombinant vaccinia virus (Chen et al, 2000, Cancer Gene 
Ther. ) and pulsed human monocyte-derived dendritic cells (Tokunaga et al, 2005,Clin 
Cancer Res.). However, besides p53, many genes are involved in the pathogenesis of SCC 
and an understanding into the genomic of SCC is far from complete. It is very likely that 
new genetic and molecular pathways for SCC genesis will unravel in the future, hopefully 
leading to novel therapies. 
Clearly exposure to UVR is an important initiating factor in skin cancer, though the exact 
relationship between BCC risk and nature, extent and timing of exposure remains poorly 
understood. More recently, the influence of genetic factors influencing BCC susceptibility 
has been an area of intense interest with many genes having a similar impact as traditional 
risk factors such as skin type. Data so far suggests that risk of sporadic BCC is likely to 
result from the combined effect of many genes (defining distinct areas of biochemical 
activity) each with a relatively weak individual contribution, rather than a small number of 
highly influential genes. 
Presumably, the effect of disruption of these biochemical activities will result in 
dysregulation of expression of key TSG or oncogenes. In this regard, the function of the 
hedgehog signalling pathway appears critical in BCC development. Though the PTCH gene 
has been suggested to be the ‘gatekeeper’ for BCC development, future studies will need to 
address the role of other members of this pathway. There are no studies to date focusing on 
the interaction between susceptibility genes and mutational events in TSG in BCC; this may 
represent a way forward. 
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